Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.

Introduction

Hematologic malignancies are among the most common cancers and can involve all systems and organs. Hematologic malignancies mainly include leukemia, lymphoma, and multiple myeloma (MM), all of which are highly heterogenous in molecular characteristics, leading to severe difficulties in individualized treatment. Moreover, hematologic malignancies, especially MM, are often incurable and finally relapse or become refractory, appealing for innovative treatment strategies to increase treatment response and to improve their prognosis. Recent studies found that hematologic malignancies show recurrent methylation-related mutations, abnormal methylation profiles of DNA, and abnormal histone deacetylase expression, especially in leukemia and lymphoma. Furthermore, the hypomethylating agents and histone deacetylase inhibitors are effective to treat acute myeloid leukemia and T-cell lymphomas, indicating that epigenetic regulation is indispensable to hematologic oncogenesis. Thus, a comprehensive exploration of the change and the influence of each epigenetic mediators on hematologic oncogenesis assists to develop an innovative targeted treatment to improve the treatment response and prognosis of the patients.

Epigenetics originally referred to heritable features of a cellular phenotype that were independent of changes in DNA sequence. With the development of numerous studies and enlightened perspectives, epigenetics currently defines chromatin-based reactions that regulate DNA-templated processes. Chromatin consists of DNA and histones in a macromolecular complex that serves as a scaffold for genome packing. Histones are mainly divided into five categories. H2A, H2B, H3, and H4 are highly conserved, and an octamer consisting of two of each wrapped with 146 base pairs of DNA serves as the core of nucleosomes. H1 is variable among species and binds with internucleosome linear DNA to form a higher-level structure. According to the composition of chromatin, epigenetic regulation mainly includes alterations in DNA modifications, alterations in histone modifications, chromatin remodeling, and noncoding RNAs (ncRNAs) (Fig. 1 ). Epigenetic regulation plays an important role in various DNA-based processes, including DNA replication, repair, and transcription. With the development of epigenetic techniques, studies have explored the role of epigenetic regulation in hematopoiesis and have depicted the epigenome in hematologic malignancies. This review aims to highlight the influence of DNA modifications, histone modifications, and ncRNAs in hematopoiesis and their implications in targeted therapy of hematologic malignancies. Fig. 1 The overview of epigenetic regulation of hematologic malignancies. Epigenetic regulation of hematologic malignancies mainly includes DNA methylation, histone acetylation, histone methylation, and noncoding RNA. First, DNA methylation depends on writers, readers, and erasers. DNMTs are writers of DNA methylation, and targeted treatments focusing on DNMTs have been developed. Readers of DNA methylation include MBD-containing proteins, methyl-CpG binding zinc fingers, and SRA domain-containing proteins. Erasers of DNA methylation mainly consist of the TET family and the AID/APOBEC family. Second, histone acetylation depends on the writer KATs, the reader acetyl-lysine binding proteins, and the eraser HDACs. Correspondingly, innovative treatments targeting KATs, BETs, and HDACs are being developed. Third, histone methylation depends on the writer KMTs, the reader methyl-histone binding proteins, and the eraser KDMs. KMT inhibitors and KDM inhibitors are being explored in the treatment of hematologic malignancies. In addition, microRNAs and long noncoding RNAs also contribute to hematologic oncogenesis

DNA methylation alteration is common in hematologic malignancies

DNA methylation was first discovered from pneumococcal types when DNA was discovered as the hereditary material in mammals. 1 , 2 DNA methylation is characterized by the carbon-5 position of the cytosine adding with a methyl group to form 5-methylcytosine (5mC). 3 DNA methylation usually happens in the cytosine-guanine dinucleotides (CpG) sites by the DNA methyltransferase (DNMT) enzymes. 3

DNA methylation in the normal genome

In the human genome, CpG sites spread over the whole genome, and are highly methylated, except CpG islands in normal somatic cells. 4 – 7 Approximately 45% of the mammalian intergenic regions of the genome consist of transposable elements and viral elements, which are silenced by heavy methylation. 8 However, CpG islands, consisting of 500–2000 bps GC-rich sequences, are usually unmethylated in normal cells. 4 , 5 , 9 In addition, around 70% of gene promoters include CpG islands. 10 While most CpG islands are unmethylated, many oncogenes have methylated promoter CpG islands in normal cells, and the function of oncogenes were repressed. 11 In addition, distal regulatory regions, like enhancers, lack CpG islands and are regions with low methylation. 12

DNA methylation in the overall cancer cells

However, normal epigenetic processes are disrupted in multiple diseases, including inflammatory diseases, precancerous conditions, and cancers. 13 – 16 Generally, overall genome-wide hypomethylation or hypermethylation with regional DNA hypermethylation or hypomethylation of CpG islands can be observed in these diseases. 13 , 17 , 18 A loss of DNA methylation of transposable elements and repeat elements, accompanied by aberrant expression, results in the dysregulation of pathways. 19 The hypermethylation of unmethylated promoter CpG islands is related to the inhibition of tumor suppressor genes and functional genes. However, the hypomethylation of methylated promoter CpG islands is related to the activation of oncogenes, while CpG-poor regions in CpG island shores or enhancers tend to undergo methylation in cancer cells. 20 , 21

The change of DNA methylation in hematologic malignancies

Extensive studies have reported that DNA methylation patterns in regulatory regions play an important role in the development of cell proliferation and the function of leukemic stem cells (LSCs). The change of DNA methylation in hematologic malignancies is frequently observed in two aspects, the methylation level of methyltransferase genes themselves, and the mutations of methyltransferase genes or demethylase genes. Regarding the former aspect, studies have shown that the promoter of DNMT1 gene was unmethylated in all acute promyelocytic leukemia (APL) patients. 22 Tirdad et al. found that patients with B and T-acute lymphoblastic leukemia (ALL) had unmethylated promoters in the DNMT1 gene, whereas the control group showed a relatively methylated promoter. 23 Abnormal hypomethylation of the DNMT3A gene was also observed in 55.3% of acute myeloid leukemia (AML) patients, and was related to an adverse prognosis in cytogenetically normal (CN)-AML patients. 24 The hypomethylation of promoters or intragenic regions of methyltransferase genes probably led to DNMT hyperactivation, causing cancer cell hypermethylation in leukemia. In terms of the latter aspect, recurrent DNMT3A mutations and TET2 mutations were found in leukemia. For example, patients with DNMT3A mutations and IDH1/2 mutations exhibited a mixed DNA hydroxy-/methylation profile compared with samples from healthy controls. 25 AML patients with DNMT3A mutations displayed lower levels of DNA methylation as well as fewer concurrently hypermethylated genes. 26 A loss of DNMT3A caused enhancer hypomethylation in FLT3 -ITD-associated leukemias and was critical for the inhibition of leukemic transformation. 27 Studies identified somatic mutations by exome sequencing in AML-M5, and found that DNMT3A mutants caused decreased enzymatic activity and abnormal affinity to histone H3. 28 In chronic myelomonocytic leukemia (CMML) patients with TET2 mutations, AIM2 and SP140, the non-CpG island promoters, were hypermethylated. 29 TET2 was found to be transcriptionally repressed or silenced in 71% and 17% of T-ALL patients, respectively. 30 Apart from the frequently observed DNA methylation alterations, the change of other methylation mediators was also discovered. For example, the high expression of the methyltransferase DNMT3B was related to poor prognosis in AML patients. 31 Myelodysplastic syndrome (MDS) and AML-mesenchymal stem cells (MSCs) displayed global hypomethylation and underexpression of the methyltransferase DNMT1 and the methyl-binding protein UHRF1. 32 Changes in the methylation patterns of methyl-binding proteins, MBD2 and MeCP2, were observed in B-chronic lymphocytic leukemia (CLL). 33 The recurrent change in DNA methylation profile in AML and ALL could predict patients’ prognosis and treatment efficacy. 34

Enzymes of DNA methylation

Various enzymes participate in DNA methylation, and can be divided into three categories based on their function. The proteins that catalyze and cause a certain modification are referred to as writers. The proteins that eliminate an existing modification are referred to as erasers. The proteins that recognize an existing modification and recruit other macromolecular complexes to the template chain are referred to as readers.

Writers: DNA methyltransferases directly catalyze DNA methylation

The DNMT family can directly catalyze DNA methylation, including DNMT1, DNMT3A, and DNMT3B. 35 It has been known for many years that DNMT3A and DNMT3B, so-called de novo DNMTs, can develop a new methylation pattern in unmodified DNA. 36 , 37 The structure and function of DNMT3A and DNMT3B are extremely similar. On the other hand, DNMT1 primarily methylates hemimethylated DNA, 38 , 39 and can repair DNA methylation. 40 In addition, DNMT1 can maintain an established pattern of DNA methylation, copying the DNA methylation pattern when DNA replicates (Fig. 2 ). 41 – 43 The three DNMTs are necessary for embryonic or neonatal development. 37 , 44 DNMT3A is also critical for hematopoietic stem cell (HSC) differentiation. 45 DNMT2 and DNMT3L have no catalytic function. DNMT2 functions as an RNA methyltransferase. DNMT3L is associated with DNMT3A and DNMT3B, and promotes their methyltransferase activity. 46 – 48 Fig. 2 The methylation and demethylation pathways. DNMT3A and DNMT3B can methylate the cytosine (5mC) and set up a new methylation pattern to unmodified DNA. DNMT1 maintains an established pattern of DNA methylation during DNA replication. 5mC can be chemically modified at two sites: the amine group and the methyl group. The amine group of 5mC can be deaminated by AID/APOBEC to thymine (Thy). The methyl group of 5mC can be added a hydroxyl group by TET enzymes to generate 5-hydroxymethyl-cytosine (5hmC). Eventually, the products, Thy and 5hmU, can be recognized and removed by TDG

DNMT1 maintains the methylation

DNMT1 maintains an established pattern of DNA methylation. Upregulated DNMT1 could induce abnormal regional hypermethylation, and cause the pathogenesis of leukemia. The phenomena of DNMT1 alteration have been frequently observed in leukemia and lymphoma. Studies have shown that DNMT1 is overexpressed in APL, 22 AML, 49 , 50 ALL, 50 MDS, and chronic myelogenous leukemia (CML) patients. 49 , 51 The methylation of CpG islands in promoter regions is often observed in lymphomas. DNMT1 was overexpressed in Burkitt’s lymphoma (BL), 52 diffuse large B-cell lymphoma (DLBCL), 53 primary gastrointestinal diffuse large B-cell lymphoma (PGI-DLBCL) 54 and other lymphomas. 55 , 56 DNMT1 overexpression was identified as an independent risk factor in PGI-DLBCL. 54 Furthermore, DNMT1 overexpression was associated with advanced clinical stages and resistance to treatment in DLBCL. 53 DNMT1 could predict survival and Ki-67 expression in DLBCL patients received with the R-CHOP regimen. 57 In addition, the expression of DNMT1 in U266 myeloma cells was higher than that in normal control cells. 58

The function of DNMT1 in hematological malignancy progression has been reported in different pathways. In leukemia, conditional knockout of DNMT1 inhibited leukemia development, and DNMT1 haploinsufficiency delayed the progression of leukemogenesis and impaired LSC self-renewal without altering normal hematopoiesis. 59 In AML, Wang et al. discovered that the expression level of DNMT1 in AML patients was decreased compared with that in healthy controls, and was negatively regulated by miR-148a in AML cell lines. 60 In ALL, recent studies demonstrated that the level of exosomal DNMT1 mRNA transcripts was elevated in ALL patients, which might reprogram leukemia progression. 61 In CML, DNMT1 was upregulated by BCR-ABLp210, and promoted tumor stem cell priming, 62 and silencing the DNMT1 gene could inhibit the proliferation and promote the apoptosis of CML K562 cells. 63 Regarding lymphoma, DNMT1 played a critical role in the maintenance of MYC-induced T-cell lymphomas and BL and contributed to abnormal methylation. 64 , 65 In addition, DNMT1 was correlated with cell cycle and DNA replication gene sets in DLBCL. 66 In MM, DNMT1 also promoted the methylation of SOCS-1 67 and TJP1 68 in myeloma cells, thereby decreasing their expression and regulating MM development.

DNMT3A catalyzes de novo methylation

Among the different DNMTs, the DNMT3A has been investigated and reported the most frequently in hematologic malignancies, and its change is presented below in the order of leukemia, lymphoma, and MM, respectively.

In leukemia, mutations of DNMT3A , especially in R882H, are one of the most frequent recurrent genetic changes in AML. Mutations of DNMT3A also occur in clonal hematopoiesis, MDS, ALL, CMML, mixed phenotype acute leukemia (MPAL), and pediatric AML patients. 69 – 80 The prevalence of DNMT3A mutations was 7.4% in adult Thai AML patients, 81 25% in US patients, 82 19.7% in Korean patients, 83 4.0–13.9% in Chinese patients, 84 , 85 6% in Brazilian patients, 86 20.9% in German patients 87 and 17.9% in Egyptian AML patients. 88 The majority of DNMT3A mutations have been reported to be related to increased relapse 89 and poor survival in AML, 82 , 83 , 90 – 100 CMML, 101 ALL, 71 , 75 , 102 , 103 Chinese pediatric AML, 70 and Chinese pediatric ALL patients. 71 In addition, DNMT3A1 and DNMT3A2V have been reported as the main variants in AML. 104 In contrast to de novo AML, most mutations occurred in the methyltransferase domain other than arginine at position 882 in therapy-related and secondary AML. 105

Furthermore, DNMT3A mutations were associated with several clinical characteristics in leukemia. Studies showed that DNMT3A mutation was not only related to the intermediate-risk cytogenetic group in de novo AML 90 , 106 , 107 but also associated with age; the white blood cell (WBC) count, platelet (PLT) count, and blast percentage in peripheral blood; M4/M5 immunophenotype; FLT3 mutation; NPM1 mutation; IDH1/2 mutation; and CEBPA mutation in AML. 87 , 92 , 97 , 98 , 107 – 112 In T-ALL, DNMT3A mutation was also associated with increased age, high WBC, high BM blast cell percentage, and extramedullary disease. 103 Regarding cell of origin, the DNMT3A R882H mutation occurred more frequently in the T-ALL subtype than in the B-ALL subtype. 71 DNMT3A mutations also showed a marked predilection for T-lineage differentiation in MPAL. 93 Besides the genetic mutation of DNMT3A , overexpression of the DNMT3A protein was also reported in AML and the acute phase of CML. 49 , 113 The expression levels in AML patients were higher than ALL patients or healthy controls, 65 , 114 and DNMT3A expression acted as a potential prognostic biomarker. 113

In addition, DNMT3A mutations, together with other mutations, were related to the prognosis of leukemia patients. For example, FLT3 and/or NPM1 mutations contributed to survival differences in DNMT3A -mutant patients. 81 , 115 However, the IDH1/2 gene had little effect on patients’ survival with a DNMT3A mutation. 116 Dose escalation of anthracycline in the induction regimen was correlated with improved survival in AML patients with DNMT3A mutations. 117 Allogeneic hematopoietic stem cell transplantation (allo-HSCT) could increase the survival of CN-AML patients with DNMT3A mutations. 118 In patients with complete response (CR) after complete donor chimerism allo-HSCT, no DNMT3A R882H mutation was found. 119 DNMT3A mutant could always be detected during remission and did not predict prognosis in AML patients. 119 – 122 While, DNMT3A R882 / FLT3 -ITD had poor prognosis in AML patients after allo-HSCT. 123 – 125 DNMT3A variants were also associated with the progression of CML after tyrosine kinase inhibitor (TKI) therapy. 126

The relationship between the type of DNMT3A mutation and clinical outcomes remained controversial in leukemia patients. One study reported that outcomes of patients with R882 and non-R882 missense mutations were similar, while patients with truncation mutations had comparable outcomes to those of patients with wild-type DNMT3A . 99 However, in another study, patients with the R882 mutation and those with non-R882 mutations showed different clinical outcomes; patients with the R882 mutation had unfavorable relapse-free survival (RFS), while patients with non-R882 mutations had favorable overall survival (OS). 87 In addition, the DNMT3A R882 mutations were associated with adverse prognoses in older patients, while non-R882 mutations were related to worse prognoses in younger patients. 109 Mutations in DNMT3A exon 23 have also been reported to independently predict an unfavorable prognosis in older AML patients. 127

Though less frequently, DNMT3A mutations were also found in lymphomas. DNMT3A mutations occurred in 11% of T-cell lymphomas, 128 26.6–39% of peripheral T-cell lymphomas (PTCLs), 129 – 131 26.1–34% of angioimmunoblastic T-cell lymphomas (AITLs), 129 , 131 – 133 and were also found in NK/T-cell lymphoma/leukemia, 134 breast implant-associated anaplastic large cell lymphoma (ALCL) and BL. 135 However, DNMT3A mutations were infrequent in primary cutaneous CD4 + small/medium T-cell lymphoproliferative disorder (PCSMLPD), 136 monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) and enteropathy-associated T-cell lymphoma (EATL). 137 DNMT3A mutations were more commonly seen in patients of African ancestry compared than in those of European ancestry. 138 DNMT3A mutations or expression were related to prognosis in lymphoma patients. Study findings suggested that high expression of DNMT3A was significantly related to worse OS and progression-free survival (PFS) in patients with PGI-DLBCL patients treated with R-CHOP regimen. 54 DNMT3A mutation was found to be correlated with shorter PFS in AITL patients. 133 Since DNMT3A mutations were significantly decreased after therapy, 139 they could serve as sensitive indicators in circulating tumor DNA (ctDNA) and provide a noninvasive method of monitoring minimal residual disease in AITL. 140

The evidence for the effects of DNMT3A on MM is contradictory. Study findings indicated that DNMT3A mutations were present in newly diagnosed MM patients and those treated by autologous stem cell transplantation (ASCT). 141 , 142 Furthermore, DNMT3A overexpression was demonstrated in the cells of MM patients. 58 , 143 Different from lymphoma, studies showed that DNMT3A underexpression was associated with worse OS in MM patients. 144

DNMT3A potentiated hematologic oncogenesis in many ways. First, the DNMT3A R882 mutation stimulated the mTOR pathway 145 and reactivated the leukemic transcription factor MEIS1, 146 which initiated AML. DNMT3A R882 mutations also enhanced abnormal stem cell gene expression, which promoted leukemia progression. 147 Studies also found that DNMT3A R882 mutations reduced AML cell apoptosis by augmenting PRDX2, 148 and induced CML by disturbing DNA methylation. 149 In T-cell lymphomas, the DNMT3A mutation was found in both programmed cell death 1 (PD-1) + T cells and supportive cells, indicating its role in both tumor cells and microenvironment. 150 , 151 Second, DNMT3A was found to be a haploinsufficient tumor suppressor in various hematologic malignancies. The haploinsufficiency of DNMT3A could transform FLT3 -ITD myeloproliferative neoplasm (MPN) into AML, 152 and cooperate with oncogenic KRAS to promote the development of T-ALL. 153 The haploinsufficient tumor suppressor effect of DNMT3A was also reported in CLL, 154 CD8 + PTCL, 155 , and AITL. 156 – 159 Third, DNMT3A mutations were closely related to treatment response. Studies showed that DNMT3A mutations induced anthracycline resistance in AML by impairing nucleosome remodeling, 160 and evaded chemotherapy and infiltrated the central nervous system in a patient with AML. 161 DNMT3A R882H -dependent AML cells were sensitive to hypomethylating agents, such as azacytidine (AZA) 162 and decitabine. 163 In addition, DOT1L could be a therapeutic target, 164 and resistin may serve as an ancillary drug for AML patients with DNMT3A mutation. 165

DNMT3B also catalyzes de novo methylation

DNMT3B caused the generation of abnormal methylation during the development of hematologic malignancies. In leukemia, studies showed that DNMT3B was overexpressed in MDS, AML and CML patients. 49 , 51 , 65 The DNMT3A expression level in AML patients was higher compared with ALL patients. 65 However, another study found that DNMT3B expression was decreased in AML 113 and B-CLL. 33 Exploring the polymorphism C46359T in the DNMT3B promoter, Li et al. found different distributions of genotypes in different races and that the CT heterozygote was related to the pathogenesis of AL. 166 Furthermore, DNMT3B mutations, polymorphisms, and expression were related to AML prognosis. DNMT3B overexpression was related to adverse prognosis in older CN-AML patients. 167 The G allele of rs1569686 in DNMT3B represented poor outcomes for AML, while the C allele of rs2424908 was associated with favorable outcomes. 168 , 169

In lymphoma, DNMT3B expression was also increased in BL, 52 DLBCL 53 , and plasmablastic lymphoma (PBL), 170 and it was identified as an adverse prognostic factor. 53 DNMT3B overexpression was associated with advanced clinical stages and resistance to treatment in DLBCL. 53 However, studies also found that the expression of DNMT3B was lower in PGI-DLBCL patients. 54 In MM, the expression of DNMT3B was increased in in U266 and RPMI8226 myeloma cells. 58 , 171

DNMT3B mainly affected the progression of hematologic malignancies. Some studies found that the loss of DNMT3B accelerated MLL-AF9 leukemia progression. 172 Others showed that high expression of DNMT3B contributed to abnormal DNA methylation and MYC-driven tumor development in T-ALL and BL. 65

Readers: the methyl-binding proteins recognize DNA methylation and mediate subsequent reactions

DNA methylation can directly inhibit the binding of transcription factor and repress gene transcription when it occurred at the regulatory region of a gene. 173 In addition, the methylated site recruits methyl-binding proteins (MBPs), the readers, and then attracts the members of the chromatin remodeling complex, to activate or inhibit transcription. 174 , 175 MBPs mainly include three separate families of proteins: “methyl-CpG-binding domain (MBD)-containing proteins”, “methyl-CpG binding zinc fingers”, and “Set and RING-associated (SRA) domain-containing proteins”. 176

MBD-containing proteins

This is the first identified MBP family, of which all members have the conserved MBD domains. MeCP2 was the first MBP to be identified. 177 MeCP2 had an MBD domain, which comprises 70–85 amino acids, and recognizes and binds to methylated sites. 178 Then, this MBD domain could recognize other proteins with methyl-binding potentials. 179 According to the presence of domains excepted MBD, there were three groups of this family: (1) MeCP2-MBDs: MeCP2, MBD1, MBD2, MBD3, MBD4, MBD5, and MBD6; (2) histone methyltransferase-MBDs: SETDB1 and SETDB2; and (3) histone acetyltransferase-MBDs: BAZ2A and BAZ2B. However, the classification above is according to their structural characteristics other than methyl-binding abilities, thus not all proteins can bind to methylated DNA. The MBD domain of MeCP2, 180 MBD1, 181 MBD2 179 , and MBD4 182 can bind to methylated CpG. However, MBD3, 183 MBD5, MBD6, 184 BAZ2A, and BAZ2B 185 cannot bind to methylated DNA. Moreover, both SETDB1 and SETDB2 play a role as protein lysine methyltransferase activity. 186 , 187

The expression of MBD2 and MeCP2 was found to be increased in CML. 188 Studies found that deregulation of the epigenetic repertoire, including MBD2 and MeCP2 in B-CLL. 33 The homozygous CC genotype in MBD2 (rs603097, -2176C>T) was associated with favorable outcomes of non-Hodgkin lymphoma (NHL). 189 MeCP2 could epigenetically regulate SOCS5 expression in T-ALL and the SPAN-XB core promoter sequence in MM. 190 , 191 The MeCP2/SIN3a deacetylating complex could epigenetically silence the proapoptotic gene BIM in ALCL. 192 The knockdown of MBD2 inhibited apoptosis induced by B1 and overcame the resistance caused by Bcl-2 in HL60 cells. 193 MBD4 was found to be overexpressed in imatinib-resistant K562 cells, and the knockdown of MBD4 expression decreased cell survival after treatment with hydrogen peroxide and doxorubicin. 194

Methyl-CpG binding zinc fingers

The second family of MBPs is the “methyl-CpG binding zinc fingers” family, the members of which, including Kaiso, zinc-finger, and BTB domain containing 4 (ZBTB4), and ZBTB38. They can identify methylated and unmethylated DNA by zinc-finger motifs. 195 The first member of the family was Kaiso. 196 ZBTB4 and ZBTB38 are homologs of Kaiso proteins. 197 Kaiso is a transcription factor and the binding partner of p120-catenin in the cytoplasm. 198 It is encoded by the ZBTB33 gene which is located on the X chromosome. 199 Kaiso binds to a couple of methylated CpG dinucleotides. 196 ZTBT4 and ZBTB38 can bind to a single methylated CpG. 197

The knockdown of Kaiso increased cell proliferation and blocked granulocytic differentiation in CML blast crisis. 200 Kaiso protected human umbilical vein endothelial cells against apoptosis through the overexpression of BCL2 and decreased expression of BAX and BIK . 201 HBV preferential target genes, such as ZBTB38 , showed significantly altered expression levels in NHL. 202

SRA domain-containing proteins

The third family of MBPs is the “SRA domain-containing proteins” family, including UHRF1 and UHRF2. They contain the SRA domain, which can bind to methylated DNA. The SRA domain usually bind to the hemimethylated regions, 203 , 204 while the MBD/MeCP2 domains preferentially bind to the paired methylated DNA. UHRF1, also known as ICBP90 (human) or Np95 (mouse), binds to hemimethylated DNA and then attracts DNMT1 to methylate the sequence during replication. 205 , 206 UHRF2, also known as NIRF or Np97, is involved in the regulation of the cell cycle. 207

The UHRF1 level was found to be increased in aneuploid AML. 208 The UHRF1 promoter was found to be hypomethylated in leukemia patients. 209 UHRF1 was found to regulate the transcriptional repressor HBP1 through MIF in T-ALL, and UHRF1 -knockdown mice lived longer. 210 Furthermore, difluoromethylornithine (DFMO) and thymoquinone were found to downregulate UHRF1 in Jurkat cells. 211 , 212 UHRF1 promoted ubiquitination-mediated degradation of the tumor-suppressive promyelocytic leukemia protein. 213 Berberine was a novel drug for the treatment of MM via targeting UHRF1 . 202

Erasers: DNA demethylases remove the existing methylation

DNA demethylation is a dynamic process including passive or active pathways. Passive DNA demethylation happened in dividing cells, where newly incorporated cytosine remains unmethylated by DNMT1 inhibition or dysfunction. Active DNA demethylation can happen in both dividing and nondividing cells, which requires enzymes to remove 5mC to develop a permissive state for subsequent gene expression. 214 – 217 Enzymes in active DNA demethylation involve the ten-eleven translocation (TET) methylcytosine dioxygenases, activation-induced cytidine deaminase/apolipoprotein B mRNA-editing enzyme complex (AID/APOBEC), and thymine DNA glycosylase (TDG). 218 – 220 5mC can be modified at two sites, the amine group and the methyl group. The AID/APOBEC can deaminate an amine group of 5mC to thymine (Thy). 221 The TET enzymes can add a hydroxyl group to the methyl group of 5mC and generate 5-hydroxymethyl cytosine (5hmC). IDH enzymes converted isocitrate to α-ketoglutarate, which is critical for TET catalytic function. Eventually, the products, Thy and 5hmC, can be recognized and removed by TDG (Fig. 2 ). 221

TET1 : oxidation of 5mC to 5-hydroxymethyl cytosine (5hmC)

The disruption of normal DNA demethylation was identified to be associated with oncogenesis. Both genetic mutations and abnormal protein expression of the TET family were reported in hematologic malignancies. TET1 was found to act as oncogene in MLL-rearranged leukemia. 222 TET1 expression was decreased, whereas the expression of TET2 and TET3 was increased in AML. 223 , 224 In refractory AML, TET1 expression was increased compared to that in treatment-responsive patients. 225 Moreover, TET1 , TET2 , and TET3 overexpression was found to be related to poor prognosis in AML. 223 , 224 , 226 The expression of TET1 and TET3 decreased in CLL, and high TET2 expression was related to longer survival in CLL. 227 In addition, TET mutations could also be observed in hematological malignancies. The most frequently mutated gene was TET2 , with TET2 mutations happening in 32% (10/31) of patients with human T-cell lymphotropic virus type I (HTLV-I)-induced acute adult T-cell leukemia (ATL). 228 TET2 mutations also occurred in AML and T-ALL patients. 229 , 230 In the experimental study, TET1 promoted the growth of T-ALL and could be antagonized via PARP inhibition. 231

TET2 : oxidation of 5mC to 5-hydroxymethyl cytosine (5hmC)

TET2 mutations were found to happen in patients with hematological malignancies, and affected DNA hypermethylation. 232 In leukemia, studies found that 33% of patients had low levels of TET2 -specific differentially methylated CpG (DMC) methylation, and these patients had longer OS. 233 TET2 mutations occurred in 6–23% of CN-AMLs, 234 – 236 1.4% of childhood AMLs, 76 7.6% of younger adult AMLs, 237 and 11.8–27.4% of AMLs 82 , 235 , 238 – 245 and were unfavorable prognostic factors. 82 , 236 , 238 , 239 , 241 , 246 TET2 mutations occurred in 14% of adult T-cell leukemia/lymphomas (ATLLs) 247 and 32% of ATLs, 228 and lower TET2 expression was associated with adult T-cell leukemia aggressiveness. 248 Furthermore, TET2 mutations were also observed in 28% of chronic natural killer large granular lymphocyte (NK-LGL) leukemia cases. 249 In addition, TET2 mutations were also observed in advanced phase CML, 250 , 251 and the presence of TET2 SNP rs3442524 suggested disease progression. 251 However, some studies reported TET2 mutation did not affect prognosis. TET2 mutation alone was found to have no prognostic impact on event-free survival (EFS) or OS in one study. 245 Similarly, TET2 mutations were detected in 19.8–23.3% of secondary AMLs, and did not influence OS. 252 , 253 In addition, TET2 mutations occurred in 32–65% of CMML and were favorable prognostic factors, 29 , 254 – 260 but were associated with poor survival in the presence of ASXL1 mutations. 261 While in another study, TET2 mutations were correlated with poor survival. 262 There are different types of TET2 mutations, and patients have different clinical outcomes. Complete deletion of the TET_JBP domain (ΔJBP) of TET2 in AML patients had a lower CR rate and shorter EFS and OS. 263 TET2 I1762V acted as a favorable prognostic factor in AML. 264 TET2 SNP rs2454206 correlated with improved survival in childhood CN-AML. 265 TET2 exon 2 splicing status might improve survival in CN-AML patients. 266 TET2 mutations were reported to be associated with several clinical characteristics. TET2 was associated with a normal karyotype, high WBC count, low PLT count and high age. 238 , 255 , 267 Arginase 1 overexpression was related to DNMT3A and TET2 mutations in lower-grade MDS and CMML. 268 Besides the genetic alteration of TET2 , the expression of TET2 protein was also different between patients with hematological malignancies and healthy people. For example, the expression of TET2 was showed to be increased in B-CLL, 269 but decreased in AML 270 , 271 and childhood ALL, 272 , 273 and was related to poor survival. 270 , 271

TET2 is a well-established tumor suppressor in the context of lymphomas. Studies have detected TET2 mutations in mantle cell lymphoma (MCL), 274 DLBCL, 275 , and non-anaplastic PTCLs. 276 TET2 mutations occurred in 18–92% of AITLs, 129 , 132 , 247 , 277 5.7–12% of DLBCLs, 247 , 278 14% of ATLLs, 247 11% of PBLs, 279 38–64% of PTCLs, 280 , 281 75% of PTCLs with T-follicular helper phenotype (PTCL-TFH), 129 85% of mucosa-associated lymphoid tissue (MALT) lymphomas, 282 and 18% of T-cell lymphomas. 128 TET2 mutations were correlated with poor survival in AITL and PTCL, not otherwise specified (PTCL-NOS) patients. 281 , 283 Germline TET2 loss of function was found to cause childhood immunodeficiency and lymphomagenesis. 284 Besides the genetic alterations, TET expression was found to increase in NHL. 285 Moreover, TET2 mutations were correlated with advanced-stage disease, thrombocytopenia, and high International Prognostic Index (IPI) scores in AITL and PTCL-NOS. 281 TET2 mutations were related to positive B symptoms. 280 In MM, TET2 mutations were also detected, 141 , 142 , 286 – 288 and might be related to survival and resistance to therapy at relapse. 287

The recovery of TET2 function blocked abnormal self-renewal and progression of leukemia. 289 MEG3 promoter hypermethylation might result from decreased TET2 activity in AML. 290 TET2 mutations affected DNA methylation in non-CpG island of enhancers and transcription factor-binding sites in CMML. 291 Moreover, the expression of TET2 decreased, and promoter methylation of TET2 significantly increased the risk of ALL. 292 Cooperation between KDM6B overexpression and TET2 deficiency was found to initiate the pathogenesis of CMML. 293 RHOA mutations were correlated with a T-follicular helper (TFH) cell phenotype and TET2 and IDH2 mutations. 294 AID and TET2 cooperation modulated FANCA expression through active demethylation in DLBCL. 295 Reduced TET2 function led to T-cell lymphoma with TFH-like features in mice. 296

TET3 : oxidation of 5mC to 5-hydroxymethyl cytosine (5hmC)

TET3 mutations are infrequently observed in AML, but the expression of TET3 in HSCs and human peripheral blood T cells has been found to decrease with age. 297 , 298 The expression of TET3 was found to be increased in AML, which was associated with poor OS and disease-free survival (DFS). 223 , 224 , 227 TET3 mutation could be detected in newly diagnosed AML patients. 299

AID/APOBEC : deamination of 5mC to thymine (Thy)

The AID/APOBEC family of proteins was a group of cytidine deaminases, and played roles in multiple physiological functions. 300 , 301 The family consists of eleven members in humans: AID and APOBEC1, APOBEC2, seven APOBEC3 proteins (APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3D, APOBEC3F, APOBEC3G, APOBEC3H) and APOBEC4. 302 – 307 APOBEC1 is hardly expressed in CLL, while APOBEC3A and APOBEC3G are both present in CLL and normal B cells. 308 In a patient with two relapses, the interplay of aberrant AID/APOBEC activity was observed. 309 APOBEC overactivity was also observed in primary plasma cell leukemia (pPCL). 310

Furthermore, aberrant AID/APOBEC activity-associated mutations were enriched in early clonal hematopoiesis-associated mutations in AITL/PTCL-NOS. 311 AID/APOBEC overactivity was also observed in HBV-associated DLBCL. 312

APOBEC-associated mutations were enriched in patients with disease progression and were associated with a shorter time to progression in smoldering MM (SMM). 313 – 315 APOBEC mutations were detected in MM 316 – 319 and might be related to high risk, a shorter progression time, and therapy resistance. 287 , 317 , 320 The APOBEC mutation was observed in 3.8% of myeloma cases and was associated with the translocation-mediated deregulation of MAF and MAFB, which was associated with poor prognosis. 319 Dysregulated APOBEC3G was found to cause DNA damage and promoted genomic instability in MM. 321 APOBEC3B overexpression was found to constitutively generate DNA substitutions and deletions in myeloma cells. 322

TDG: demethylation of Thy and 5hmC to cytosine

TDG was a member of the uracil DNA glycosylase (UDG) superfamily. TDG is required for embryonic development. 323 DNA hypermethylation of TDG in MM cell lines was found to lead to low expression of genes, and inhibit DNA repair activity during hydrogen peroxide-induced DNA damage. 324 Moreover, SUMO-1 modification and colocalization with the promyelocytic leukemia protein were required in the noncovalent SUMO-1 binding activity of TDG. 325

IDH1/2 : conversion of isocitric acid to α-ketoglutaric acid

Isocitrate dehydrogenase (IDH) converted isocitrate to α-ketoglutarate (α-KG). The IDH family included IDH1 and IDH2, and their mutant forms transformed α-KG into 2-hydroxyglutarate (2-HG). 2-HG inhibited DNA demethylases and histone demethylases, thus increasing methylation of both DNA and histones. 326 There are three conserved mutational hotspots in the IDH enzymes. The mutational hotspot of IDH1 is R132, while the mutational hotspot of IDH2 were R140 and R172.

IDH1 mutations occurred in 6–9% of AML patients, especially in patients with normal karyotype AML (8–16%). 327 – 333 IDH1 mutations often co-occurred with normal karyotypes and NPM1 mutations, 328 – 331 , 333 and were associated with wild-type CEBPA and no FLT3 mutation. 331 Published results on the prognostic effects of IDH1 mutations failed to reach an agreement. Although some studies have shown that IDH mutations have no prognostic effect on OS in IDH -mutated ( IDH1 and IDH2 ) patients or in overall patients, 328 – 331 IDH1 mutations have a poor prognosis impact on low-risk or intermediate -risk subgroups of patients with normal karyotype AML. 328 , 331 , 333 In AML patients under 60 years old in the low-risk group, 5-year DFS (42% vs. 59%) and OS rates (50% vs. 63%) of IDH -mutated patients were significantly lower than those in IDH wild-type patients. In low-risk AML patients, IDH mutations (combined IDH1 and IDH2 ) were correlated with lower 5-year RFS and OS rates, respectively. 333 The same phenomenon was found in IDH1 or IDH2 mutations alone, although the number of patients in each subgroup was small and only the RFS analysis was statistically different. 333 IDH1 mutations were also correlated with poor EFS and OS in patients with intermediate-risk normal karyotype AML. 328 IDH2 mutations have been observed in 8–12% of AML patients, 327 – 329 , 333 , 334 with a higher mutation frequency of 19% in the normal karyotype. 331 In almost all cases, IDH2 and IDH1 mutations were mutually exclusive. 328 , 329 , 331 IDH2 mutation could occur at R172 or R140, while R140 mutation happened more frequently. 331 , 333 , 334 Interestingly, IDH2 R172 mutations appeared to repel NPM1 mutations and FLT3 -ITD. 331 , 333 , 334 The prognostic effects of IDH2 mutations were also inconsistent. Some studies reported no prognostic value of IDH2 mutations, 328 , 329 , 333 while others reported a good prognosis for IDH2 -mutated patients. 327 , 334 In one study, IDH2 mutations were associated with poor prognosis in a subpopulation of AML patients with normal karyotype and other low-risk factors. 333 However, IDH2 R140 mutations were correlated with increased survival in all patients as well as in a subgroup of patients with the low-risk group. 327 In the latter subgroup, patients with IDH1 or IDH2 mutations had a significant increase in OS at 3 years compared to patients with NPM1 mutations without FLT3 -ITD and patients without IDH1 or IDH2 mutations. These results suggested that in normal karyotype AML patients without FLT3 -ITD, NPM1 mutations conferred survival benefits only when IDH mutations were present simultaneously. 327 The conflicting results of these studies required further investigation.

Inhibition of IDH1 mutant promoted cycling of LSCs. 335 A genomic analysis was performed in R/R AML patients with IDH mutations who received ivosidenib (IDH1 inhibitor) treatment, and the results suggested that primary resistance to ivosidenib was correlated with RTK pathway mutations. 336 , 337 IDH2 mutation cooperated with a NUP98-HOXD13 fusion caused early immature thymocyte precursor ALL. 338

IDH2 R172 mutation defined a unique subgroup of patients with AITL. 158 Patients with IDH2 mutations had increased H3K27me3 and DNA hypermethylation of gene promoters. In a retrospective multicenter study, IDH2 R172 mutation was found in 19–45% AITL patients and was correlated with poor survival, 339 and different pathologic and clinical features. 132 , 133 , 340 – 342 When using plasma cell-free DNA as liquid biopsy for the diagnosis of AITL, IDH2 R172 hotspot mutations were detected in 15% of patients. 343 Studies found that IDH2 mutation was confined in the malignant T cell of AITL, and that 2-HG was elevated in tumor tissue and serum of patients. 344

IDH2 was observed overexpressed in CD138 + cells from MM, and it promoted progression and poor prognosis of MM by regulating m6A RNA methylation. 345 IDH2 inhibition increased efficacy of proteasome inhibitor in MM, MCL, and BL cells. 346

Histone modifications mainly include acetylation, methylation, and phosphorylation

Histone modifications in normal hematopoiesis

Posttranslational modifications of amino acids, especially lysines, at the N-terminal tail of the histone core change the chromatin configuration, ranging from the condensed repressive status to the open active status. There are at least sixteen types of histone modifications, including acetylation, methylation, phosphorylation, ubiquitylation, sumoylation, and ADP ribosylation. The histone modifications most essential for hematopoiesis and hematologic malignancy oncogenesis are acetylation, methylation, and phosphorylation.

HSCs are commonly recognized to arise from the endothelial-to-hematopoietic transition, which occurs at the early arterial endothelial cell, hemogenic endothelial cell, pre-HSC, and long-term HSC stages. Based on the results of low-input itChIP-seq and Hi-C assays, the stimulative histone modifications, H3K27-ac and H3K4me1, which regulate enhancer activation, already exist in the initiation stage of early arterial endothelial cells and hemogenic endothelial cells. During the differentiation of HSCs, the stimulative H3K27-ac gradually increases while the repressive H3K27me3 decreases, leading to the steady expression of HSC genes. 347 In lineage differentiation, histone modification also plays an important role. A crucial lineage-mediating protein, BAP1, regulates the balance between lymphopoiesis and myelopoiesis by altering the histone modifications of the promoters of pro-hematopoietic factors and myelopoiesis-promoting factors. Upon BAP1 deficiency, H2AK119-ub1 and H3K27me3 are strengthened on the promoter of the pro-hematopoietic factor Scf, leading to its downregulation. In addition, H3K4-me3 and H3K27-ac are strengthened on the promoter of the myelopoiesis-promoting factor Csf3, leading to its upregulation and steering the differentiation to myeloid lineage, which causes CMML-like disease. 348 , 349 The dynamic balance among the writers, readers, and erasers of histone modifications is essential to hematopoiesis and oncogenesis, which will be discussed below (Fig. 1 ).

The change of histone acetylation pattern in hematologic malignancies

Acetylation reduces the positive charge of lysines and in turn weakens the interaction between histones and negatively charged DNA, causing an open active euchromatin status, as evidenced by ChIP-seq, which reveals histone acetylation at promoters and enhancers of actively transcribed genes. 350 Histone deacetylase (HDAC) erases the acetyl group from lysines in the N-terminus, which amplifies the positive charge of lysines and in turn strengthens the interaction between histones and the negatively charged DNA, leading to the condensed repressive heterochromation status. 351 Histone lysine acetyltransferase (KAT, also named HAT) and HDAC counteract subtly to sustain the hematopoiesis balance. In normal erythropoiesis, erythroid-stimulating transcription factors, such as GATA-1, recruit KAT to the β-globin locus to increase the acetylation levels of H3 and H4, which in turn upregulates globin during erythropoiesis. 352 When the expression of wild-type or chromosomal-fused transcription factors is abnormal due to epigenetic dysregulation, the hematopoiesis balance is disturbed and malignancies occur. 353 For example, TAL1/SCL is a wild-type transcription factor steering differentiation to the erythroid and megakaryocytic lineage instead of the myeloid lineage. Upon association with the coactivating complex of p300 and PCAF, TAL1/SCL was found to be upregulated and propelled erythropoiesis leading to murine erythroleukemia. However, TAL1/SCL was found to be downregulated upon association with the corepressive complex of HDAC1 and mSin3A, impeding erythropoiesis. 354 Regarding fusion proteins caused by chromosome translocation, PML-RARα, RUNXI-MTG8 , and AML-ETO1 recruit abnormal histone-modifying enzymes to target genes, causing leukemogenesis. 355 In lymphoma, various oncogenic mutations which were related with histone acetylation were also discovered. 356

Writers: histone acetyltransferases directly catalyze histone acetylation

KATs are divided into two types. Type A KATs are mainly nuclear and consist of five families, the p300/CBP, MYST, GNAT, general transcription factor/orphan KAT, and SRC/NCoA families. Type B KATs, consisting of KAT1, are mainly cytoplasmic. 357 Of the many KAT families, the p300/CBP family, and MYST family are the most essential KATs in hematologic malignancy oncogenesis, and are presented below, respectively.

The p300/CBP family includes p300, also named KAT3B or EP300, and CBP, also named KAT3A or CREBBP. CBP has been found to bind to viral oncoprotein E1A, which is associated with oncogenesis. 358 CBP could also serve as a tumor suppressor, as various loss-of-function mutations have been found in lymphoma. For example, monoallelic mutations in CBP , which inactivated KAT and led to B-cell oncogenesis, were discovered in 40% of follicular lymphoma (FL) patients, up to 30% of DLBCL patients, and 26% of primary cutaneous DLBCL-leg type patients. 359 , 360 In addition, these inactivating mutations were found to cooperate with BCL2, BCL6, and MYC to promote lymphoma development, promoting the aggressiveness of lymphoma and indicating its indispensable role as tumor suppressors. 361 The chromosomal translocation of MLL-CBP, t(11;16)(q23;p13), was found to specifically drive the proliferation of granulocyte/macrophage progenitors (GMPs), leading to acute myelomonocytic leukemia (AMML) and CMML. 362 Furthermore, P300 mutations were also found in 10% of FL and DLBCL patients, 363 which disrupted the binding of transcription factors, such as CREB and c-Myb, and caused multilineage hematopoietic defects. 364 In DLBCL, mutations of CBP/p300 could repress acetylation of H3K27, stimulate the Notch pathway, which in turn upregulated CCL2/CSF1, leading to M2 polarization of the tumor-associated macrophages and lymphoma progression. 365

The MYST family includes MOZ, MORF, HBO1, TIP60, and HMOF. This family was frequently discovered to promote leukemogenesis by translocation, which consistently activated the downstream signaling pathway. For example, MOZ, also named KAT6A, was discovered to translocate with various genes. MOZ-CBP translocation, t(8;16)(p11;p13), led to consistent activation of KAT and was related to M4/M5 AML. 366 MOZ-TIF2 translocation, induced by inv(8)(p11;q13), simulated aggressive leukemia by introducing stem cell activity to progenitor cells, leading to persistent self-renewal and leukemogenesis. 367 MORF, also known as KAT6B, whose translocation with CBP induced by t(10;16)(q22;p13) caused a loss of monoacetylated H4K16, is a well-recognized indicator of AML transformation. 352 HBO1, also known as KAT7, is the acetyltransferase of H3K14, and its loss leads to abnormal consumption and exhaustion of HSCs; therefore, HBO1 is indispensable for HSC maintenance and self-renewal. 368

Readers: acetyl-lysine binding proteins recognize histone acetylation and mediate subsequent reactions

Readers of histone lysine acetylation include a highly conserved binding domain, the bromodomain. One of the most explored and targeted readers is the BET family, consisting of BRD2, BRD3, BRD4, and BRDt. However, few studies have revealed the contribution of BET family genetic alterations to the oncogenesis of hematologic malignancies. Most of the studies exploring its pathogenic influence have focused on solid tumors, for example, midline carcinoma. The translocation of the nuclear protein of testis (NUT) to BRD4, induced by t(15;19)(q14;p13.1), impeded the differentiation and promoted the proliferation of epithelial cells. On the one hand, the fusion protein stimulated p300 and amplified hyperacetylation, which recruited BRD4 and oncogenic transcription components. On the other hand, aberrant occupation of BRD4 inhibited c-fos transcription, which in turn inhibited epithelial differentiation. 369 A similar oncogenic translocation to NUT was also discovered in BRD3. 370 , 371 The evidence of histone acetylation readers contributing to hematologic malignancies are lacking and requires further investigation.

Erasers: histone deacetylases remove the existing acetylation of histones

HDACs are categorized into four classes, including the zinc-dependent classic HDACs (class I, II, and IV) and the NAD + -dependent nonclassic HDACs (class III). The three categories of classic HDACs can be divided based on sequence homology to yeast deacetylases. Class I HDACs, including HDAC1, HDAC2, HDAC3, and HDAC8, are homologous to reduced potassium dependency-3 (Rpd3) and localize mainly in the nucleus; these HDACs form multiprotein complexes and regulate transcription and proliferation. Class II HDACs are homologous to histone deacetylase-1 (Hda1). Class IIa HDACs, including HDAC4, HDAC5, HDAC7, and HDAC9, move between the nucleus and cytoplasm. Class IIa HDACs have only one catalytic domain and have weaker deacetylation capability than the nucleus-localizing class IIb HDACs, including HDAC6 and HDAC10, which contain two catalytic domains. Class IV HDACs share a homologous sequence to both Rpd3 and Hda1 and reside in the nucleus. Class IV HDACs include only HDAC11, which is the smallest among the various HDACs. The nonclassic class III HDACs consist of SIRT1 to 7.

The change of HDAC manifested itself mainly through altered protein expression, instead of genetic mutations, in hematologic malignancies. Impaired expression of H3K4ac1 and H3K4ac3 was commonly observed in lymphoma. 372 The overexpression of HDAC1 and HDAC2 was discovered in DLBCL compared to their expression in normal lymphoid tissues. 373 The inhibition of HDAC1 and HDAC2 was found to impede Eμ-myc B-cell lymphoma development via apoptosis stimulation and proliferation repression, indicating the oncogenic role of HDAC1 and HDAC2. 374 HDAC1 expression was found to be significantly related to worse prognosis in DLBCL patients and PTCL-NOS patients. 375 HDAC3 overexpression was pathogenic when CBP mutations were present. In normal differentiation, the BCL6-SMRT-HDAC3 complex counteracts CBP to regulate the acetylation balance of H3K27. However, upon CBP malfunction due to mutations, the BCL6-SMRT-HDAC3 complex overacts in enhancer deacetylation of the B-cell signaling pathway without opponents, leading to B-cell lymphomagenesis. 376 In contrast, HDAC4 was a tumor suppressor. It serves as a corepressor of BCL6 and represses oncogene expression upon recruitment, impeding B-cell lymphomagenesis. 377 DLBCL patients with high HDAC2 expression and low HDAC4 expression were found to display significantly worse prognosis than those with low HDAC2 expression and high HDAC4 expression, also indicating the pathogenic role of HDAC2 and the protective role of HDAC4 in DLBCL. 378 HDAC6 expression varies in different malignancies, and its role is controversial. In DLBCL, HDAC6 showed a tendency toward low or negative expression in most patients, and the minority of DLBCL patients who showed strong HDAC6 expression had a significantly better prognosis than the others. However, in PTCL, HDAC6 showed a tendency toward to be overexpressed, which was significantly related to worse prognosis. 373 Apart from PTCL, HDAC6 was also found to play a pathogenic role in MCL, and its inhibition exerted an antitumor influence. 379 HDAC6 could also regulate immunogenicity and downregulate PD-1/PD-L1 in cell subpopulations of CLL and MM. 380 , 381 HDAC6 inhibition could decrease Treg cells and myeloid-derived suppressor cells (MDSCs) and increase the cytotoxicity of T cells, strengthening immune response of the host to counteract myeloma cells. 381 In a CLL Eµ-TCL1 mice model, HDAC6 inhibition could reduce the immunosuppression caused by tumor T cells, and enhance immunomodulation of the supportive B cells, 380 indicating the potential combined treatment of HDAC inhibitors and immune treatment, which is presented in the Targeted Therapy section of this review. HDAC7 was crucial to committing pro-B cells to pre-B cells by interacting with MEF2C. Thus, HDAC7 downregulation was found in pro-B-ALL and BL, while its upregulation was found in pre-B-ALL and B-ALL t(8;14). 382 , 383 HDAC7 was also shown to be essential to the survival and TCR engagement of thymic T cells during differentiation, whose overexpression was discovered in T-ALL patients. 384

The class III HDACs are the SIRT family, which has been found less associated with HDAC function. The SIRT family showed a tendency to regulate HSC aging through various pathways. For example, SIRT1 preserved aged HSCs by stimulating FOXP3 and inhibiting the mTOR pathway. Moreover, SIRT1 rendered HSCs vulnerable to stepwise mutation development in CML, while SIRT1 inhibition strengthened DNA repair and improved the sensitivity of leukemic stem cells (LSCs) to imatinib. 385 The evidence of the SIRT family affecting hematologic malignancies is relatively limited. Further investigation is needed to better reveal their relationship.

The change of histone methylation pattern in hematologic malignancies

The methylation of histones mainly occurs on lysines and arginines. Lysine methylation manifests itself as mono-, di-, and trimethylation. Arginine methylation can be symmetrical or asymmetrical. Unlike acetylation, which alters chromatin status and regulates transcription by changing the charge of the lysine, methylation does not change the charge of lysine or arginine. Whether lysine methylation stimulates or inhibits transcription depends on the position and features of methylation. For example, methylation on H3K4, H3K36, and H3K79 is more often related to active euchromatin status, while methylation on H3K9, H3K27, and H4K20 usually causes repressive heterochromatin. 386 Moreover, H3K9me1 is commonly seen in actively transcribed genes, while H3K9me3 is frequently discovered in repressed genes. 387 Arginine methylation is commonly related to gene activation. 388

Writers: histone methyltransferases directly catalyze methylation of the histone

Histone methyltransferases are mainly divided into lysine methyltransferases (KMTs) and protein arginine methyltransferases (PRMTs). KMTs mainly consist of KMT2, KMT6, NSD, and KMT1 families. Members of the KMT2 family, including KMT2A (also known as MLL1), KMT2B (also known as MLL2), KMT2C (also known as MLL3), KMT2D (also known as MLL4), KMT2F (also known as SETD1A), and KMT2G (also known as SETD1B), catalyze the methylation of H3K4. MLL is essential for proliferation and lineage differentiation during hematopoiesis. MLL can not only activate genes by methylating H3K4 and recruiting KAT but also inhibit genes by recruiting HDACs and polycomb group (PcG) proteins. 389 Recurrent mutations and fusion proteins related to MLL have been reported in various hematologic malignancies. On the one hand, KMT2A mutations have been reported in AML (2.5%), T-ALL (5.6%), and high-grade B-cell lymphoma (14%). 390 Recurrent KMT2B mutations were discovered in more than 90% of FLs. 391 KMT2C mutations were revealed in 45.5% of posttransplant plasmablastic lymphomas. 392 KMT2D mutations were reported in more than 70% of FL patients and nearly 30% of DLBCL patients, which impaired its methylation capability and steered the transformation of cancer stem cells. 391 , 393 , 394 On the other hand, MLL fusion proteins caused by the translocation of chromosome 11q23 and more than 60 counterparts have been discovered in leukemia, such as the t(9;11) translocation and the t(4;11) translocation identified in de novo AML and ALL, and the t(11;16) translocation discovered in therapy-related AMML and CMML. 362 In MLL fusion proteins, DNA binding domains were found to be preserved, and HOX genes were overexpressed and promoted leukemogenesis. 395 Moreover, partial tandem duplication (PTD) of MLL was also found in AML patients with normal karyotypes, which occurred after DNA methylation-related mutations ( TET2 , DNMT3A , IDH1 / 2 ) but before kinase mutations ( FLT3 , RAS ). 396 MLL -PTD was found to be significantly related to worse prognoses in AML patients. 327

The KMT6 family includes KMT6A, also named EZH2, which catalyzes the trimethylation of H3K27. EZH2 serves as an important part of the polycomb repressive complex (PRC), which negatively regulates transcription. EZH2 has a dual role, as evidenced by its oncogenic role and tumor-suppressive role in different hematologic malignancies. As oncogenes, EZH2 gain-of-function mutations (Y641, A682, and A692) in catalytic SET domains amplified H3K27 methylation, which in turn inhibited the differentiation of plasma cells, promoting oncogenesis in B-cell lymphoma. 363 , 397 These mutations were discovered in 22% of DLBCLs, 10% of BLs, and 4% of primary mediastinal B-cell lymphomas. Excessive EZH2 expression was also found to exist in NK/T-cell lymphoma and CLL. 398 , 399 As tumor suppressors, loss-of-function mutations of EZH2 were found in T-ALL, MDS, and MPN. 400 – 402

Members of the NSD family, including KMT3A (also known as SETD2), KMT3B (also known as NSD1), KMT3G (also known as NSD2), and KMT3F (also known as NSD3), catalyze the methylation of H3K36 and H4K20. NSD1 was found to be fused to NUP98 , a part of the nuclear core complex, caused by the translocation of t(5;11)(q35;p15.5), in 16.1% of pediatric AML with normal cytogenetics. 403 The NUP98 / NSD1 translocation was significantly related to FLT3 -ITD variations and worse prognoses, which could be attenuated only through bone marrow transplantation. 404 , 405 NUP98/NSD1 protein was shown to influence CD34 + CD133 + hematopoietic precursor cells in MDS, AML, and T-ALL patients; transform bone marrow cells; and trigger AML in mouse models. 406 , 407 NSD2 was found to be fused to FGFR3 , caused by the translocation of t(4;14)(p16.3;q32), in 15% of MM patients. The NSD2 / FGFR3 translocation was significantly related to 13q- and worse prognoses, which could not be overcome even by a high-dose regimen and ASCT. 408 , 409 NSD3 was also found to fuse to NUP98 , caused by the t(8;11)(p11.2;p15) translocation, in AML and radiation-related MDS patients. 410 , 411

PRMT, catalyzing the mono- and demethylation of histone arginine, participates in the epigenetic regulation of leukemogenesis. PRMT4 was found to be indispensable to the onset of MLL - AF9 -driven AML. 412 PRMT4 could also negatively regulate CBP/p300 coactivation by methylating CBP. 413 PRMT5 stimulated the self-renewal and viability of LSCs by triggering the Wnt/β-catenin pathway in CML. 414 PRMT7 was shown to regulate glycine metabolism to preserve LSCs in CML, and the loss of PRMT7 downregulated glycine decarboxylase and propelled glycine metabolism to produce toxic methylglyoxal in LSCs without influencing normal hematopoiesis. PRMT7 inhibition impeded leukemogenesis based on CML mouse models and primary CD34 + cells from CML patients. 415

Readers: methyl-histone binding proteins recognize histone methylation and mediate subsequent reactions

Since the methylation of lysines occurs in various sites in different forms, the readers of methylated lysines are diverse. Methyllysine readers are mainly divided into two groups based on recognition domains, the Royal domain (chromodomains, MBT domains, and Tudor domains) and PHD fingers. In NUP98 - PHD ( PHF23 or JARID1A ) fusion AML, the PHD finger was found to read H3K4me2/3 and inhibit its removal at various lineage differentiation transcription factors, which caused persistent activation of Hox, Pbx1, and Gata3 transcription factors and led to leukemogenesis. Mutations in PHD fingers, which prevented H3K4me2/3 reading, were shown to impede leukemogenesis, indicating the essential role of methyl reading in leukemogenesis. 416 In addition to hematologic malignancies, abnormal methyllysine reading was more commonly seen in solid cancers. HP1 belongs to the chromodomain family, and decreased HP1 expression was reported in breast cancer, colon cancer, ovarian cancer, and papillary thyroid carcinoma. 417 ING belongs to the PHD finger family, and its mutations were discovered in melanoma. 418 Further research is required to explore the influence of altered methylation readers on hematologic malignancies.

Erasers: histone demethylases remove the existing methylation of histones

The most explored lysine demethylases (KDMs) can be divided into two groups. The first group requires an amine oxidation reaction relying on flavin adenine dinucleotide (FAD) as cofactor, which can only demethylate mono- or dimethyllysine. The second group, the Jumonji demethylase, relies on oxidation and radical attack, such as a-ketoglutarate, and can methylate mono-, di-, and trimethyllysine.

LSD1, also named KDM1A, belongs to the first group. LSD1 has a dual role, as evidenced by its transcription-activating and repressing ability. On the one hand, LSD1 was found to demethylate H3K9me1/2 and repress transcription when related to androgen or estrogen receptors. 419 , 420 On the other hand, LSD1 was shown to promote transcription after demethylating H3K4me1/2 in promoter regions. LSD1 has also been shown to serve as an essential member of transcription repressing complexes, such as CoREST, HDAC2, and ZNF217. 421 Moreover, LSD1 was found to demethylate H3K4 after HDAC deacetylation, which in turn assisted in and amplified transcription inhibition, as evidenced by the impaired LSD1 function caused by HDAC inhibitors. 422 , 423 In hematopoiesis, LSD1 was found to mediate the function of the TAL1, GATA-1, and C/EBPa transcription factors; steer erythroid differentiation, 424 , 425 and promote erythroleukemia by inhibiting GFI1 superenhancers. 426 LSD1 inhibition was demonstrated to reactivate PU.1-dependent enhancers and eradicate AML in mouse models. 427

The KDM5 family, which demethylates H3K4, belongs to the second group and consists of KDM5A, KDM5B, KDM5C, and KDM5D. KDM5A translocation with NUP98 was frequently found to be pathogenic in AML patients, and KMD5A downregulation suppressed proliferation and induced the apoptosis of AML cells. 428 , 429 The loss or inhibition of KDM5D promoted cell differentiation, impeded the growth of APL cells, and improved sensitivity to all-trans retinoic acid treatment. 430 KDM5B was overexpressed in CML, and mediated myeloid differentiation and Toll-like receptors via GATA and AP-1 transcription factors. KDM5B knockdown impaired colony formation in CML cells. 431 KDM5D , located on chromosome Y, encodes a demethylase of H3K4. KDM5D downregulation was associated with human and mouse AML. The contribution of mosaic loss of chromosome Y to leukemogenesis might be attributable to KDM5D loss.

KDM6A, also named UTX, plays various roles in hematopoiesis and hematologic malignancies. UTX is essential for protecting young hematopoietic stem progenitor cells (HSPCs) from aging. UTX deficiency was associated with the aggregation of reactive oxygen species, reduced DNA damage repair, and aging in HSPCs. 432 Regarding hematologic malignancies, UTX mutations were found in 8% of CMML patients. 74 UTX has been demonstrated to be a tumor suppressor that represses myeloid leukemogenesis and preserves drug sensitivity in MDS, AML, APL, and even T-ALL. 433 – 437 However, studies also discovered that UTX served as a pro-oncogenic cofactor indispensable to leukemia development in TAL1-positive T-ALL, and UTX inhibition significantly impeded TAL1-positive leukemia. 438

Because methylation is essential to both DNA modification and histone modification, the 2-HG caused by IDH mutants inhibited demethylases of both DNA and histones, especially the Jumonji family. Recurrent IDH1 / 2 mutations were found in 20% of AML patients, and these mutations transformed isocitrate into 2-HG instead of the original a-KG in the tricarboxylic acid cycle, leading to the accumulation of 2-HG and a decrease in a-KG. However, the Jumonji family relies on a-KG to exert a demethylating function, and 2-HG displays a similar orientation in the catalytic core of the JmjC domain, leading to the repression of Jumonji family function, which in turn increases the histone methylation level. The phenomena and influence of IDH mutations on hematologic malignancies have been discussed in the DNA methylation section of this review. IDH inhibitors have been approved by the Food and Drug Administration (FDA) for AML treatment and are presented in the Targeted therapy section below. 439

The change of histone phosphorylation is less frequently reported in hematologic malignancies

Histone phosphorylation displays less evidence than histone acetylation and methylation in hematologic malignancies. Histone phosphorylation plays a role in crucial cellular reactions, including apoptosis, transcription, DNA repair and replication, and usually occurs on threonine, tyrosine, and serine residues. Kinases not only stimulate signal transduction but also phosphorylate histones. For example, JAK2 mutations are frequently discovered in MPN, ALL, and AML. H3Y41 phosphorylated by JAK2 was found to disturb the binding of the chromatin repressor HP1a and to stimulate the Lmo2 oncogene to promote leukemogenesis. 355 In primary mediastinal B-cell lymphoma and Hodgkin lymphoma (HL), excessive IL-13 and the amplification of chromosome 9p24 were found to stimulate JAK2, which in turn phosphorylated H3Y41 and activated various oncoproteins, including MYC and JAK2 itself. Moreover, JAK2 was found to stimulate PD-L1/2 expression, which conferred immune escape of cancer cells. 440 – 442 Furthermore, in activated B-cell-like (ABC) DLBCL, JAK1 was discovered to phosphorylate H3Y41, which in turn stimulated MYC, MYD88, and IRF4. MYD88 overexpression was shown to produce excessive IL-6 and IL-10 which in turn activated JAK1 in a positive feedback loop. 443 In CML, H2AX phosphorylation was found to be stimulated by imatinib and resveratrol, which in turn triggered apoptosis via the caspase-3/Mst1 pathway. 444 – 446

Noncoding RNAs mainly include micrornas and long noncoding RNAs to exert epigenetic regulation function

Traditionally, ncRNAs refer to RNA transcripts that do not encode proteins. 447 , 448 Although around 75% of the human genome can be transcribed, only about 2% of it is translated into mRNAs that encode proteins. 449 – 451 A substantial percentage of the human genome is translated into regulatory, catalytic, and structural RNAs. 447 , 451 – 453 Recent studies have demonstrated that some ncRNA transcripts can also encode small peptides within 100 amino acids. 454 NcRNAs participate in a variety of cellular activities, regulate gene expression and protein function, and are functionally involved in normal development, physiological functions, and the pathogenesis of illness. On the basis of RNA length, many kinds of ncRNAs can be distinguished. Currently, the most extensively researched ncRNAs are microRNAs (miRNAs) and long noncoding RNAs (lncRNAs).It has been revealed that the dysregulation of miRNAs and lncRNAs is involved in all hallmarks of cancer initiation and progression, 455 – 457 including hematologic malignancies (Fig. 1 ). 458 Table 1 shows the selected miRNAs and lncRNAs implicated in hematologic malignancies. Table 1 Selected microRNAs and long noncoding RNAs involved in hematologic malignancies Name NcRNA Class Implicated hematologic malignances Function roles in tumorigeneses References miR-155 miRNA DLBCL(ABC), CLL, HL, PMBL, PTLD, pediatric BL, CTCL, AML Oncogene 484 , 731 – 736 miR-150 miRNA CLL, MDS, MLL-associated leukemia Oncogene 737 – 739 miR-21 miRNA CLL, DLBCL(ABC) Oncogene 491 , 733 miR-221 miRNA DLBCL(ABC) Oncogene 740 miR130b miRNA DLBCL Oncogene 499 miR-29 miRNA CLL Oncogene 508 , 741 miR-181 miRNA CLL, AML, APL Oncogene/tumor suppressor 508 , 742 – 745 miR-15a/16–1 miRNA CLL, APL, MM Tumor suppressor 475 , 476 , 733 , 746 miR-143/145 miRNA CLL, DLBCL, MALT, BL Tumor suppressor 747 miRNA-193b-3p miRNA T-ALL Tumor suppressor 748 miR-497/195 miRNA ALL Tumor suppressor 749 miR-22 miRNA AML Oncogene 750 , 751 miR-9 miRNA MLL-rearranged AML/t(8;21), EVI1 + AML Oncogene/tumor suppressor 752 – 754 miR-17–92 cluster miRNA MLL-rearranged AML Oncogene 755 , 756 miR-146a miRNA del(5q) MDS/MDS-derived AML Tumor suppressor 757 – 760 miR-125b miRNA AML, B-ALL Oncogene 761 , 762 miR-126 miRNA AML Oncogene 763 – 765 miR-155 miRNA FLT3-ITD-induced AML Oncogene 735 , 736 193a miRNA AML Tumor suppressor 766 , 767 miR-193b miRNA AML Oncogene/tumor suppressor 768 – 770 miR-223 miRNA AML Tumor suppressor 771 , 772 miR-495 miRNA MLL-rearranged AML Tumor suppressor 773 miR-30–5p miRNA MM Tumor suppressor 774 miR-137 and miR-197 miRNA MM Tumor suppressor 775 miR-214 miRNA MM Tumor suppressor 776 miR-26a miRNA MM Tumor suppressor 777 LUNAR1 lncRNA T-ALL Oncogene 564 TCLlnc1 lncRNA T-ALL Oncogene 566 DANCR lncRNA AML Oncogene 565 HOXBLINC lncRNA NPM1-mutant AML Oncogene 778 HOXB-AS3 lncRNA NPM1-mutated AML Oncogene 779 BlackMamba lncRNA ALK − anaplastic large cell lymphoma Oncogene 780 HOXB-AS3 lncRNA NPM1-mutated AML Oncogene 779 MEG3 lncRNA AML Tumor suppressor 567 H19 lncRNA CML Tumor suppressor 781 BGL3 lncRNA BCR-ABL-positive CML Tumor suppressor 568 NEAT1 lncRNA MM Oncogene 782 CRNDE lncRNA MM Oncogene 783 MALAT1 lncRNA MM Oncogene 784 ABC activated B-cell-like, ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, APL acute promyelocytic leukemia, BL Burkitt’s lymphoma, CLL chronic lymphocytic leukemia, CTCL cutaneous T-cell lymphoma/leukemia, DLBCL diffuse large B-cell lymphoma, EVI1 Ecotropic viral integration site 1, FLT3 FMS-like tyrosine kinase 3 receptor, HL Hodgkin lymphoma, ITD internal tandem duplication, lncRNA long noncoding RNA, MALT mucosa-associated lymphoid tissue, MDS myelodysplastic syndrome, miRNA microRNA, MLL mixed lineage leukemia, MM multiple myeloma, ncRNA noncoding RNA, NPM1 Nnucleophosmin 1, PMBL primary mediastinal B-cell lymphoma, PTLD posttransplant lymphoproliferative disorder

The physiologic role of microRNAs

MiRNAs are small single-stranded ncRNAs that are usually approximately 22 nucleotides (nt) in length, 459 and they were first identified in 1993 in studies on the development of C. elegans . 460 , 461 MiRNAs regulate posttranscriptional gene expression predominantly via sequence-complementary binding to the 3' untranslated region (3' UTR) of target messenger RNA (mRNA), resulting in the degradation of the associated mRNA or the suppression of protein expression. 462 , 463 Moreover, miRNAs can also interact with other targets, such as loci of the protein-coding region of mRNAs, 464 – 466 5’ UTRs of mRNAs, 467 intronic and intergenic transcripts, 468 , 469 and other ncRNAs. 470 , 471

The synthesis of miRNAs involves multiple processes. RNA polymerase II (Pol II) first transcribes miRNA-encoding genes in the nucleus, producing a lengthy primary transcript called pri-miRNA. The pri-miRNAs fold back on themselves to create a distinctive hairpin structure, which is recognized and cleaved by the heterotrimeric complex of Drosha endonuclease and its companion protein, DGCR8, resulting in the release of a 60-nt pre-miRNA. The pre-miRNAs are then exported to the cytoplasm by Exportin 5 and the Ran-GTP complex, where Dicer cleaves both pre-miRNA strands near the loop to form a miRNA duplex. One of the miRNA strands is chosen to serve as the guide strand, which is then loaded into an Argonaute protein to form the RNA-induced silencing complex (RISC). 463 , 472 , 473 After the RISC is formed, the miRNA within the RISC pairs with the target mRNA to direct posttranscriptional repression. 463 A single miRNA can target various genes, while multiple miRNAs can target a single gene. 463 According to the latest miRbase (v22) data, the total number of human miRNAs identified to date includes 2654 mature miRNA molecules, 474 and these miRNAs play extensive fundamental roles in normal physiologic processes and disease states.

In 2002, miRNAs' role in cancer was established for the first time, upon discovering frequent deletions and downregulation of the miR15 and miR16 genes in CLL. 475 miR-15/16 have been identified as negative regulators of the BCL2 oncogene and the receptor kinase-like orphan receptor 1 (ROR1) gene. 476 , 477 Subsequently, miRNA dysregulation has been found in almost all studied cancers, including solid tumors and hematologic malignancies. 478 – 481 In cancer, miRNAs function mainly in two ways: as tumor suppressors or as oncogenes. 482 Changes in miRNA function in cancer cells are mainly due to changed expression levels of mature or precursor miRNAs compared to related normal tissues. 457 The underlying processes of miRNA expression pattern deregulation are diverse, and include miRNA locus deletions or amplifications, miRNA gene mutations, epigenetic and transcriptional regulation, posttranscriptional modification, and dysregulation of miRNA processing. 473

MiRNAs can function as oncogenes in hematologic malignancies

MiRNAs can function as oncogenes in hematologic malignancies, thereby contributing to leukemia and lymphoma tumorigenesis. These microRNAs can directly suppress the activity of tumor suppressors or indirectly limit the activity of oncogene-negative regulators. 482 A typical example is miR155, which is mainly involved in B-cell malignances. 483 – 485 The copy number of miR-155 is 10- to 30-fold more in B-cell lymphomas, including DLBCL, than in normal B cells. 484 Transgenic mice carrying a miR-155 transgene expressed selectively in B cells were found to exhibit a gradual process of an initiation and progression of B-cell malignancy. 483 Overexpression of miR-155 in lymphoid organs resulting in disseminated lymphoma in a mouse model, whereas withdrawal of miR-155 in tumor-established mice resulted in rapid lymphoma remission. 484 Furthermore, delivery of anti-miR-155 therapy as the sole treatment intervention was found to effectively suppress tumor growth. 486 A negative regulator of the kinase AKT, Src homology-2 domain-containing inositol 5-phosphatase 1 (SHIP1) was targeted by MiR-155 and its expression was suppressed. Decreased SHIP1 expression was found to enhance AKT signaling, subsequently promoting cell proliferation and survival and ultimately leading to lymphoma. 485 Cobomarsen, a miR-155 inhibitor, has been evaluated in multiple types of lymphoma ( NCT 02580552 ). Another example is miR-21, which has been identified as being overexpressed in a variety of solid tumors and hematologic malignancies. 478 , 487 – 489 Overexpression of MiR-21 was observed in CLL, 490 DLBCL, 491 AML, and HL. 492 , 493 Overexpression of miR-21 in a mouse model was capable of the initiation, maintenance and survival of tumors, ultimately leading to a pre-B-cell lymphoma. Strikingly, the inactivation of miRNA-21 resulted in rapid and completed tumor regression in a few days, induced by the apoptosis and rapid proliferative arrest of tumor cells. 494 The miR-17–92 cluster has also been demonstrated to be an oncogene. The human miR-17–92 cluster is located on chromosome 13q31.3 and comprises six miRNAs: miR-17, miR-18a, miR-19a, miR-19b-1, miR-20a, and miR-92-1. 495 The transcript C13orf25, which included the miR-17–92 cluster, was first observed to have elevated expression in malignant lymphoma. 496 The overexpression of the miR-17–92 cluster, in concert with the expression of the c-myc oncogene, accelerated the formation of B-cell lymphoma tumors in a mouse model, according to a subsequent study. 497 C-myc might directly bind to the miR17–92 cluster locus and stimulate the miR17–92 cluster’s expression. 498 However, this cluster of microRNAs inhibited E2F1, a transcription factor that promotes cell cycle progression and is also targeted by c-myc. 498 In an analysis of a large cohort of 532 newly diagnosed cases of DLBCL, serum levels of the miR130b were correlated with shorter PFS and OS. 499 Comprehensive research revealed a correlation between serum miR130b and tumor miR130b. In DLBCL, the activity of miR130b on the IFNAR1/p-STAT1 axis reduced lymphoma cell OX40L expression. Through the interaction of OX40L/OX40 lymphoma cells and Th17 cells, the downregulation of tumor cell OX40L expression leads to the increase of Th17 cells at the tumor site. 499 MiR130b overexpression also promoted the function of Th17 cells by increasing IL17 production. Thus, miR130b contributed to the progression of DLBCL by fostering a tumor microenvironment that is immunosuppressive and hostile. Therapeutic targeting miR130b with OX40 agoniztic antibody and lipid nanoparticles (LNP)-miR130b antagomir significantly inhibited Th17 cells and miR130b-overexpressing tumor growth in vitro and in vivo, and could be candidates for immunotherapeutic strategies for treating OX40-deficient B-cell lymphoma. 499

MiRNAs could also function as tumor suppressors in hematologic malignancies

MiRNAs can also function as tumor suppressors, and the prototypical examples are miR-15 and miR-16 in CLL. 475 The deletion of 13q14 was the most prevalent genomic aberration detected in more than half of CLL cases. 500 MiR15 and miR16 genes located within a 30-kb region of 13q14 that was lost in approximately 65% of cases of CLL. In 68 percent of CLL cases, allelic loss of this region was related with the deletion or downregulation of miR15 and miR16. 475 This was the first time miRNA genes were found to be involved in cancer. The expression of miR-15 and miR-16 was then shown to be inversely associated to the expression of antiapoptotic Bcl-2, and both miR-15 and miR-16 targeted the 3' end of the BCL2 cDNA, thus adversely regulating BCL2 at the posttranscriptional stage. The loss of miR-15a and miR-16-1 caused BCL2 overexpression, which then worked as a driver of malignant transformation. 476 Furthermore, miR-15 and miR-16 were also found to target the receptor tyrosine kinase-like orphan receptor 1 (ROR1) gene, 477 which encodes an onco-embryonic antigen expressed on the surface of CLL cells. 501 – 503 ROR1 is a receptor for Wnt5a, 504 which could accelerate the development/progression of leukemia in a mouse model, 505 and could be targeted by anti-ROR1 monoclonal antibodies for the treatment of CLL. 506 , 507 Overall, miR-15/16 depletion enhanced the overexpression of ROR1 and BCL2, two important genes in the initiation and progression of CLL, acting as tumor suppressors in CLL.

Some controversial miRNAs function as either oncogenes or tumor suppressors

Some miRNAs can function as either oncogenes or tumor suppressors, depending on the different contexts they encounter. The previously stated miR-17–92 cluster could be both oncogenic and tumor suppressive by targeting E2F1, which induces apoptosis in some cancers. c-MYC promoted the expression of the E2F1 gene, 507 whereas E2F1 was able to induce c-MYC expression through positive feedback. miR-17-5p and miR-20a are capable of targeting E2F1, reducing the reciprocal activation of MYC/E2F1, and inhibiting c-MYC-mediated cell proliferation and carcinogenesis. MiR-29 works as a tumor suppressor by targeting the expression of TCL1, an oncogene in aggressive CLL, 508 but transgenic mice that overexpressed miR-29 in B cells developed indolent CLL, suggesting that miR-29 plays an oncogenic role. 509

The physiologic role of long noncoding RNAs

LncRNAs are noncoding RNA transcripts longer than 200 nt that do not encode proteins. 510 , 511 Pol II predominantly transcribes LncRNAs. Similar to mRNAs, they are frequently capped with 7-methyl guanosine (m7G) at their 5' ends, polyadenylated at their 3' ends, and posttranslationally spliced. 512 LncRNAs are expressed at lower levels, are shorter, often lack an open reading frame (ORF), and are less evolutionarily conserved than protein-coding RNAs. 513 – 517 Low expression of lncRNAs is associated with repressive histone modifications at their gene promoters, 518 , 519 and they are also processed less efficiently than mRNAs. 518 , 520 The majority of lncRNAs synthesized are retained in the nucleus. 514 , 516 The remaining genes are spliced and transported to the cytoplasm. 521 LncRNAs regulate gene expression at multiple levels, including epigenetic, transcriptional, and posttranscriptional levels. 512 They exert biologic activity by interacting with DNA, RNA, and proteins through their functional modules which incorporate sequence motifs and secondary structures. 522 They can act in cis or trans manners, and they can not only modulate their nearby chromatin state and gene expression but also leave their local transcription site and execute functions at distant cellular locations. 523 LncRNAs can regulate chromatin by recruiting chromatin modifiers to the promoters of target genes, resulting in transcriptional repression or activation. 524 – 526 Certain lncRNAs serve as decoys for chromatin modifiers by sequestering them from target gene promoters or interacting directly with chromatin. 527 lncRNAs may also interact directly with DNA to produce RNA-DNA hybrids, such as triplexes 528 , 529 or R-loops, 530 – 533 which coordinate with chromatin modifiers or transcription factors to activate or repress the transcription of targeted genes. 530 – 532 , 534 LncRNAs play a pivotal role in transcriptional regulation. By interacting with the transcription machinery, they modify recruited transcription factors or RNA polymeras, 535 histone modification stations 535 , 536 and chromatin accessibility 537 , 538 to inhibit target gene expression. Some enhancer loci can be translated into lncRNAs, which are known as enhancer-associated lncRNAs (elncRNAs). 539 , 540 ElncRNAs can promote target gene expression through the action of preexisting chromatin conformations 541 or through the recruitment of chromatin-activating complexes to the promoters of target genes. 542 They can recruit looping factors, thereby directly stimulating chromatin looping and distant gene expression. 543 – 545 Multiple lncRNAs can form complex regulatory units to regulate the expression of target genes in concert. 546 Specifically, regulatory DNA elements are just embedded in lncRNA loci and can stimulate the expression of neighboring genes. 547 , 548 At the posttranscriptional level, lncRNAs also play important regulatory roles. They interact with proteins through their sequence motifs or structural motifs, subsequently interfering with mRNA splicing, 549 , 550 regulating mRNA turnover, 551 , 552 and modulating signaling pathways. 553 In addition to binding with proteins, lncRNAs interact with RNAs through base pairing and then recruit proteins that regulate mRNA degradation. 554 – 556 Furthermore, some lncRNAs are complementarily base paired with miRNAs and thus can competitively bind with miRNAs or “sponging” miRNAs, and modulate corresponding miRNA-targeted gene expression. 471 , 557 Finally, lncRNAs are components of nuclear paraspeckle, and paraspeckles act as scaffolds for regulatory molecules. 558 – 561

As described above, lncRNAs act extensively to regulate gene expression, and play important roles in development and various biological and disease contexts, including cancer. Accumulating evidence shows that lncRNAs are differentially expressed in tumors and are involved in malignant transformation and cancer progression. 456 , 562 , 563 Similar to miRNAs, lncRNAs function as tumor suppressers and oncogenes or have dual effects. 482 In hematologic malignancies, lncRNAs may influence cell proliferation, cell cycle regulation, and drug resistance, acting as tumor suppressors or oncogenes.

LncRNA could function as an oncogene in hematologic malignancies

LUNAR1 (leukemia-induced noncoding activator RNA), a NOTCH-regulated lncRNA transcript in human T-ALL, is an example of a lncRNA functioning as an oncogene in hematologic malignancies. 564 LUNRAR1 is controlled by the Notch1/Rpbj activator complex and has the ability to boost IGF1R mRNA expression and maintain IGF1 signaling, hence being essential for effective in vitro and in vivo T-ALL proliferation. LncRNA DANCR has been identified as a lncRNA related with LSCs in AML. DANCR is increased in functionally validated LSC-enriched populations and maintains the self-renewal and quiescence of LSCs. In vivo knockdown of Dancr in a primary murine model of AML slowed disease progression and increased mouse survival, confirming its oncogenic function in acute leukemia. 565 TCLlnc1 was a newly identified lncRNA that acted as an oncogenic driver in the progression of PTCL. 566 Serum TCLlnc1 level was correlated with tumor TCLlnc1 level. TCLlnc1 could be exploited as a possible biomarker for PTCL prognosis as it aws associated with high-risk clinical characteristics and poor prognosis. 566 Overexpression of TCL1nc1 enhanced PTCL cell proliferation and migration in vitro and in vivo. 566 TCLlnc1 interacted with the transcription activator heterogeneous nuclear ribonucleoprotein D (HNRNPD) and the Y-box binding protein-1 (YBX1) as a modular scaffold, thereby upregulating the transcription of the TGFB2 and TGFBR1 genes and activating the tumor growth factor-β signaling pathway, leading to lymphoma progression. 566

LncRNAs could also function as tumor suppressors in hematologic malignancies

LncRNAs may also function as tumor suppressors in hematologic malignancies, as illustrated by the downregulation of the lncRNA MEG3 in AML. MEG3 has been shown to inhibit leukemia cell growth via p53-dependent and p53-independent pathways, and WT1 and TET2 cooperate to upregulate MEG3 expression. MEG3 lowers cell proliferation, causes G0/G1 cell cycle arrest, and decreases AML leukemogenesis in animal models of AML. 567 CML-specific LncRNA BGL3 is a critical regulator of cellular transformation mediated by Bcr-Abl. It was found that BGL3 overexpression makes leukemic cells more susceptible to apoptosis and suppresses Bcr-Abl-induced carcinogenesis. Transgenic animals expressing BGL3 were resistant to the Bcr-Abl-induced transformation of primary bone marrow, indicating that BGL3 is a tumor suppressor in CML. 568

Targeted therapy based on epigenetic regulation

Targeting DNA methylation

DNA hypomethylating agents (HMAs)

Targeting abnormal DNA methylation has been explored, and DNA hypomethylating agents (HMAs) have been proposed. Two cytidine analogs, 5-azacytidine/vidaza (5-aza-CR, azacitidine) and 5-aza-2’-deoxycytidine/dacogen (5-aza-dCR, decitabine), have been approved to treat MDS by the FDA. 569 , 570 The uridine-cytidine kinase phosphorylated azacitidine to a monophosphate derivative and then diphosphate and triphosphate forms. The triphosphate form (5-AZA-CTP) is primarily incorporated into RNA (∼80–90%) but also some into DNA (10–20%). 569 , 571 , 572 Decitabine is a prodrug that undergoes a 3- step phosphorylation process intracellularly to be converted to the active moiety, decitabine triphosphate (5-AZA-dCTP), which is then incorporated into DNA by DNA polymerases. 5-AZA-dCTP forms a covalent complex with DNMTs, which leads to the trapping and degradation of the enzyme. 573 , 574 It has been shown that cytidine deaminase (CDA) can deaminate azacytidine and decitabine to inactive aza-uradine nucleosides. 575 Cedazuridine is a CDA inhibitor that prevents the degradation of decitabine when taken orally and increases the oral bioavailability of the drug. ASTX727 (decitabine/cedazuridine) has been approval by the USA and Canada for the treatment of MDS and CMML in July 2020. 576 The details are shown in Fig. 3 . Guadecitabine (SGI-110) is a second-generation HMA consists of a dinucleotide of decitabine and deoxyguanosine, 577 which is an active metabolite of decitabine that prevents drug clearance by deamination by CDA has a longer half-life, bioavailability and greater safety. 578 It is being tested in clinical trials for MDS and AML. OR-1200 and OR-2100, orally available single-compound prodrugs of decitabine, targeted aberrant DNA hypermethylation and repressed the development of CML and ATL. 579 , 580 Myelosuppression was found to be the most common toxicity of azacitidine and decitabine, and adverse events (AEs) were generally transient, resolving during therapy. 581 – 583 Zebularine is a DNMT-inhibiting cytosine nucleoside analog with stability in acidic environments and in aqueous solutions. 584 Zebularine was shown to efficiently decrease AhR gene methylation in childhood ALL cells. 585 However, zebularine required a near millimolar dose and had limited bioavailability in rodents (<7%) and primates (<1%); thus, it did not show good performance in a clinical trial. 586 Although the TET family plays an essential role in DNA demethylation, TET protein inhibitors have yet to be tested for cancer treatment. The intracellular metabolism of azanucleosides is shown in Fig. 2 . The completed clinical trials with results of targeting DNA methylation are concluded in Table 2 . Fig. 3 Intracellular metabolism of azacytidine and decitabine. Azacytidine (5-AZA-CR) and decitabine (5-AZA-dCR) are modified in a 3-step phosphorylation process by different metabolic pathways. 5-AZA-CTP/5-AZA-dCTP is incorporated into RNA or DNA by RNA/DNA polymerases, respectively. CDA can deaminate azacytidine and decitabine to inactive aza-uradine nucleosides. CDA cytidine deaminase, 5-AZA-CR 5-azacitidine, 5-AZA-CMP 5-azacitidine monophosphate, 5-AZA-CDP 5-azacitidine diphosphate, 5-AZA-CTP 5-azacitidine triphosphate, 5-AZA-U aza-uridine nucleosides, 5-AZA-dCR 5-aza-2’-deoxycytidine, 5-AZA-dCMP 5-aza-2’-deoxycytidine monophosphate, 5-AZA-dCDP 5-aza-2’-deoxycytidine diphosphate, 5-AZA-dCTP 5-aza-2’-deoxycytidine triphosphate, 5-AZA-dU deoxyuridine Table 2 The completed clinical trials with results of targeting DNA methylation therapy Conditions Interventions Phases Patients NCT number Azacitidine AML/ALL/JMML/MDS Azacitidine 2 17 NCT02458235 High-risk MDS Azacitidine 2 72 NCT01599325 AL/MDS Azacitidine+Sorafenib 1/2 60 NCT01254890 High-risk MDS/AML Azacitidine+Sorafenib 2 16 NCT02196857 High-risk MDS/AML Azacytidine+Lenalidomide 1/2 94 NCT01038635 R/R AML/AML with11q23 rearrangement Azacitidine+Pinometostat 1/2 1 NCT03701295 CMML Azacitidine 2 11 NCT01350947 High-risk MDS Azacitidine 2 16 NCT00721214 AML Azacitidine 2 24 NCT00387647 MDS/AML/MPN/CMML Azacitidine/APR-246 1/2 55 NCT03072043 High-risk MDS Azacitidine NA 25 NCT00660400 Myelofibrosis Azacitidine 2 34 NCT00569660 MDS/CMML Azacitidine+Volasertib 1 5 NCT02201329 MDS Azacitidine 3 40 NCT01186939 High-risk MDS/CMML/AML Azacitidine+Pevonedistat 2 120 NCT02610777 MDS/AML/MM/NHL/HL Azacitidine 1 31 NCT00652626 Low and intermediate-1 risk MDS Azacitidine/Decitabine 2 113 NCT01720225 High-risk MDS Azacitidine 4 44 NCT01201811 Advanced MDS Azacytidine+Lenalidomide 1/2 37 NCT00352001 Relapsed AML Azacitidine+Gemtuzumab ozogamicin 1/2 50 NCT00766116 Leukemia/AML/MDS Azacitidine 3 187 NCT00887068 MM Azacitidine NA 17 NCT01050790 MDS Azacitidine 2 25 NCT00384956 AML Azacitidine/Conventional Care Regimen 3 488 NCT01074047 Poor-risk AML/MDS Azacitidine+Sargramostim 2 25 NCT01700673 AML Azacitidine/Lenalidomide/Best Supportive Care 2 88 NCT01358734 Leukemia Azacytidine/PKC412 1/2 54 NCT01202877 AML Azacitidine+Lenalidomide 1/2 45 NCT00890929 AML/MDS Azacitidine+Vorinostat 2 110 NCT00948064 AML Azacitidine+MLN4924 1 64 NCT01814826 AML/MDS/CMML Azacitidine 2 43 NCT01083706 R/R AML Azacitidine+Lenalidomide 2 37 NCT01743859 MDS/AML/CMML Azacitidine+PF-04449913 (Glasdegib) 1 73 NCT02367456 AML/MDS Azacytidine 2 40 NCT02497404 AML Azacitidine+Lenalidomide 1/2 31 NCT01016600 MDS/CMML/AML Azacytidine+Panobinostat (LBH589) 1/2 113 NCT00946647 MDS/AML Azacytidine+Valproic Acid+ATRA 2 34 NCT00326170 Refractory MM Azacitidine Lenalidomide+Dexamethasone 1/2 45 NCT01155583 MDS Azacytidine 2 151 NCT00102687 MDS Azacytidine+Etanercept 1/2 32 NCT00118287 AML/CMML/MDS Azacitidine/+Entinostat 2 197 NCT00313586 AML Azacitidine+Midostaurin 1/2 34 NCT01093573 R/R AML/high-risk MDS Azacytidine+Ara-C 1/2 36 NCT00569010 AML/MDS Azacytidine+Valproic Acid+Ara-C 2 11 NCT00382590 CML Azacitidine 2 24 NCT00813124 Childhood R/R ALL/AML Azacytidine+Chemotherapy 1 15 NCT01861002 High-risk MDS Azacitidine/Conventional Care 3 358 NCT00071799 R/R DLBCL Azacitidine Vorinostat 1/2 17 NCT01120834 High-risk MDS Azacytidine+Valproic Acid+ATRA 2 62 NCT00439673 R/R AML Azacitidine+Vorinostat+Gemtuzumab Ozogamicin 1/2 52 NCT00895934 DLBCL Azacytidine+R-CHOP 1/2 14 NCT01004991 Refractory lymphoma Azacytidine -SAHA-GBM 1/2 61 NCT01983969 AML Intensive Chemotherapy/+Glasdegib/+Azacitidine/+Glasdegib 3 730 NCT03416179 AML Azacitadine+Pracinostat 2 50 NCT01912274 AML/MDS Azacitidine (CC-486) 1/2 31 NCT01835587 MDS Eltrombopag/+Hypomethylating Agent 2 29 NCT01893372 Decitabine Relapsed AML Decitabine+Pembrolizumab 1/2 10 NCT02996474 AML/high-risk MDS Decitabine+Vosaroxin 1/2 66 NCT01893320 AML/MDS Decitabine 2 114 NCT01687400 AML Decitabine 2 74 NCT01786343 AML Decitabine+Talacotuzumab (JNJ-56022473; anti CD123) v.s. Decitabine 2/3 326 NCT02472145 MDS Decitabine 2 37 NCT00744757 AML/MDS Decitabine 2 10 NCT00760084 MDS/AML Decitabine/+Valproic Acid 2 153 NCT00414310 Low and intermediate-1 risk MDS Decitabine v.s. Azacitidine 2 113 NCT01720225 High-risk MDS Decitabine+Clofarabine 2 42 NCT00903760 AML/high-risk MDS Decitabine+Gemtuzumab Ozogamicin 2 43 NCT00882102 MDS Decitabine+Arsenic Trioxide+Ascorbic Acid 2 7 NCT00621023 AML/high-risk MDS Decitabine+Gemtuzumab Ozogamicin 2 71 NCT00968071 R/R AML/high-risk MDS Decitabine+Mitoxantrone Hydrochloride+Etoposide+Cytarabine 1/2 52 NCT01729845 Low or intermediate-1 risk MDS Decitabine 2 67 NCT00619099 MDS Decitabine 3 135 NCT01751867 AML/MDS Decitabine 1 16 NCT01378416 AML Decitabine 2/3 50 NCT00398983 AML/high-risk MDS/MPN Decitabine+Cytarabine NA 12 NCT02121418 AML/MDS Decitabine+Vorinostat 1 71 NCT00479232 AML/high-risk MDS Decitabine+GCLAM 1/2 28 NCT02921061 MDS Decitabine 1 39 NCT00796003 MDS/AML Decitabine+LBH589 1/2 52 NCT00691938 Advanced MDS Decitabine 2 99 NCT00260065 AL Decitabine+Clofarabine+Idarubicin+Cytarabine 1/2 65 NCT01794702 AML Decitabine 3 485 NCT00260832 AML/high-risk MDS Decitabine+Clofarabine+Cytarabine 2 122 NCT00778375 MDS Decitabine 2 128 NCT00067808 AML Decitabine+Cytarabine 2 44 NCT01829503 AML Decitabine 2 55 NCT00358644 High-risk MDS Decitabine+Vorinostat+Natural killer (NK) cells 2 9 NCT01593670 AML Decitabine 2 546 NCT00416598 AML Decitabine 2 55 NCT00492401 R/R AML Decitabine+total body irradiation 2 20 NCT01707004 MDS Decitabine 1/2 25 NCT01165996 AML/MDS PF-04449913+Ara-C+Decitabine+Daunorubicin+Cytarabine 2 255 NCT01546038 Guadecitabine MDS SGI-110 (guadecitabine) 2 22 NCT03075826 AML SGI-110 (guadecitabine) 3 815 NCT02348489 AML SGI-110 (guadecitabine)/+Idarubicin or Cladribine 2 44 NCT02096055 AML SGI-110 (guadecitabine) 1 21 NCT02293993 ASTX727 (Cedazuridine/Decitabine) MDS/CMML Decitabine/Cedazuridine 1/2 130 NCT02103478 AL acute leukemia, ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, Ara-C cytosine arabinoside, ATRA all-trans retinoic acid, CMML chronic myelomonocytic leukemia, DLBCL diffuse large B-cell lymphoma, HL Hodgkin lymphoma, JMML juvenile myelomonocytic leukemia, MDS myelodysplastic syndrome, MM multiple myeloma, MPN myeloproliferative neoplasm, NHL non-Hodgkin lymphoma, R/R relapsed/refractory

Furthermore, many non-nucleoside analogs have been reported as DNA HMAs, which are usually small-molecule inhibitors and directly target catalytic sites rather than being incorporated into DNA. GSK3685032 was a DNMT1-selective inhibitor that could inhibit DNA methylation, transcriptional activation and cancer cell proliferation inhibition in vitro. 587 Epigallocatechin gallate (EGCG) was the most effective polyphenol in green tea and inhibited the proliferation of APL, AML, and CML cells by inhibiting the expression of DNMTs. 588 – 592 EGCG also induced the demethylation and transcription of the p16 gene in the MM cell line CA46. 593 Thymoquinone (TQ) was a major component of Nigella sativa seeds, inducing DNMT1 dysfunction, 594 and could enhance demethylation in AML. 595 TQ could also mediate apoptosis by targeting UHRF1 in Jurkat cells. 212 The combination of DFMO and TQ decreased the expression of the UHRF1 , DNMT1 and HDAC1 genes in Jurkat cells. 211 Quercetin, an important dietary flavonoid, eliminated DNMT1 and DNMT3a expression and enhanced the apoptosis of leukemia cells. 596 Harmine, a beta-carboline alkaloid derivative of Peganum harmala, could inhibit DNMT1 expression in leukemia cells. 597 Curcumin, a component of the popular Indian spice turmeric, could decrease DNMT1 expression and played an anti-leukemic role in AML. 598 Novel curcumin liposomes modified with hyaluronan was found to downregulate DNMT1 expression and played an anti-leukemic role in AML. 599 NT1721, a novel epidithiodiketopiperazine, was shown to deplete DNMT1 protein levels, causing the re-activation of silenced tumor suppressor genes. 600 Furthermore, parthenolide, a major component of the feverfew medicinal plant, reduced the expression of DNMT1 in primary effusion lymphoma models. 601 Oridonin was an ent-kaurene diterpenoid extracted from the Chinese herb Rabdosia rubescens, and was shown to inhibit DNMT3A R882 mutation-driven clonal hematopoiesis and leukemia. 602 RG108, a DNA methyltransferase inhibitor, could inhibit the activity of DNMT enzymes and cause demethylation. 603 Emodin, an active component in the roots and rhizomes of numerous Chinese medicinal herbs, was demonstrated to inhibit human lymphoma Raji cell proliferation by UHRF1-DNMT3A-∆Np73 pathways. 604 Berberine was a main constituent of optidis rhizome and an isoquinoline alkaloid, and it was reported to repress the expression of DNMT1 and DNMT3B, and to induce apoptosis in the human MM cell line U266 through p53 promoter hypomethylation. 605 MG98, oligonucleotide antisense to DNMT1, displayed no pharmacodynamic or clinical activity when administered to patients with high-risk MDS. 606

Combination treatment of HMAs with immune treatment

HMAs in combination with immune checkpoint inhibitors were widely used. 607 CD47 was a macrophage checkpoint and can be targeted for AML and MDS, 608 and its inhibitor in combination with azacitidine had increased efficacy of AML and higher-risk MDS, especially in patients with TP53 mutation. 609 T-cell immunoglobulin domain and mucin domain-3 (TIM-3) was a T-cell immune checkpoint, and highly expressed in LSCs. Sabatolimab (an anti-TIM-3 monoclonal antibody) in combination with HMAs had durable responses in HR-MDS and AML patients. 607 In a phase 1b trial, ipilimumab (CTLA-4) showed limited efficacy in HR-MDS patients after failing from HMAs. 610 HMAs could increase the expression level of PD-1, PD-L1, PD-L2, and CTLA-4 in patients with AML and MDS, which caused HMA resistance. 610 Therefore, there are clinical trials combining PD-1/PD-L1 inhibitors with HMAs in AML and MDS patients. The ORR rate and median OS were higher in azacitidine plus nivolumab plus ipilimumab than azacitidine plus nivolumab group. 611 While, high-risk MDS patients after the failure of HMAs did not benefit from pembrolizumab. 612 Decitabine in combinatipn with PD-1 inhibitors was also used in classical HL (cHL) treatment. Decitabine increased the efficacy of anti-PD-1 antibody in refractory cHL, even in patients with anti-PD-1 monotherapy resistance. 613 , 614 The completed clinical trials with HMAs plus other treatments, including chemotherapy, PD-1 inhibitor, are listed in Table 2 .

IDH inhibitors

The IDH1 inhibitors ivosidenib, olutasidenib, and IDH2 inhibitor enasidenib have been approved by FDA for patients with relapsed/refractory IDH1 mutant AML. In a phase I study, the ORR of ivosidenib was 41.6%, the CR and CRi was 30.4%. 615 In a phase 1 clinical trial, the ORR of olutasidenib was 41% and 46% in combination with azacitidine in relapsed/refractory AML. 616 The ORR of enasidenib in relapsed/refractory AML patients with IDH2 mutations was 40.3%, and the CR was 19.3% in a phase I/II study. 617 The median OS for all pateints was 9.3 months, but 19.7 months for patients who achieved CR.

Furthermore, the IDH1 inhibitor ivosidenib combined with azacytoside as a first-line treatment for AML patients carrying an IDH1 mutation has been approved by the FDA. In a phase Ib clinical trial, the ORR was 78.3% and the CR was 60.9%. 618 In a phase 3 study, the EFS was longer in the combination group than in the placebo-and-azacitidine group (HR = 0.33, P = 0.002). The median OS in ivosidenib and azacitidine group (24.0 months) was longer than the placebo and azacitidine group (7.9 months) (HR = 0.44, P = 0.001). 619

The ongoing clinical trials are listed in Table 3 . The clinical trials mainly focus on AML, and MDS. The IDH inhibitor combined with other treatments, including chemotherapys, PD-1 inhibitor, MEK inhibitor, and FLT3/AXL inhibitors, are listed in Supplementary Table 1 . Table 3 The clinical trials of IDH inhibitors NCT number Conditions Interventions Phase Number enrolled NCT04176393 R/R AML Ivosidenib Phase 1 30 NCT03564821 IDH1-mutated myeloid neoplasms Ivosidenib Phase 1 18 NCT03245424 AML Ivosidenib NA NA NCT02074839 R/R AML/MDS/other IDH1-mutated positive hematologic malignancies Ivosidenib Phase 1 291 NCT03839771 AML/MDS Ivosidenib Phase 3 968 NCT03503409 AML/MDS Ivosidenib Phase 2 68 NCT05282459 AML Enasidenib Phase 1/2 48 NCT04203316 R/R AML Enasidenib Phase 2 10 NCT03515512 AML/CML Enasidenib Phase 1 23 NCT01915498 Hematologic neoplasms Enasidenib Phase 1 345 NCT03720366 AML Enasidenib Phase 1 40 NCT03728335 AML Enasidenib Phase 1 15 NCT03881735 R/R AML Enasidenib Phase 2 0 NCT03744390 AML/MDS Enasidenib Phase 2 68 NCT03723057 AML Enasidenib NA NA NCT04522895 AML/MDS/CML Enasidenib Phase 2 50 AML acute myeloid leukemia, CML chronic myeloid leukemia, MDS myelodysplastic syndrome, NA not applicable, R/R relapsed/refractory

Targeting HDAC

HDAC inhibitors not only trigger cell differentiation, apoptosis, autophagy, and cell cycle arrest but also modulate immune reactions and inhibit angiogenesis in various hematologic malignancies and some solid tumors. 620 It has been hypothesized that malignant cells are more vulnerable to epigenetic treatment, rendering the specificity and selectivity of malignant cells over normal cells. 351 A number of HDAC inhibitors have been developed and demonstrated effective in treating hematologic malignancies. The U.S FDA and China National Medical Products Administration (NMPA) have approved five HDAC inhibitors for the treatment of T-cell lymphoma, MM, and breast cancer. The classical inhibitors, dual-target inhibitors, and PROTAC for HDAC are discussed below (Fig. 4 ). Fig. 4 Classic HDAC inhibitors, dual-target HDAC inhibitors, and RPOTAC for HDAC. HDAC inhibitors not only inhibit angiogenesis, cell migration, resistance to treatment, and cell proliferation but also stimulate cell differentiation, apoptosis, and tumor antigenicity. The development of HDAC-targeting treatment ranges from classic HDAC inhibitors, dual-target HDAC inhibitors, and PROTAC for HDACs. Classic HDAC inhibitors are divided into four groups based on structures. The first group is aliphatic carboxylic acid group. None of the HDAC inhibitors of this group have been approved for hematologic malignancy treatment. The second group is hydroxamic acid group and includes vorinostat, belinostat, and panobinostat, which has been approved for treatment of CTCL, PTCL, and MM, respectively. The third group is benzamide group and includes chidamide, which has been approved for the treatment of PTCL. The last group is the cyclic peptide group and includes romidepsin, which has been approved for the treatment of CTCL and PTCL. Furthermore, dual-target HDAC inhibitors have been explored in hematologic malignancy treatment, which also target RTK, JAK2, and PI3K. In additions, PROTAC for HDACs has been developed recently

Classic HDAC inhibitors

Classic HDAC inhibitors can be divided into four groups based on their zinc-binding group: the aliphatic carboxylic acid group, hydroxamic acid group, benzamide group, and cyclic peptide group. In general, the aliphatic carboxylic acid group displays weak deacetylation ability and mild selectivity for class I HDACs. The hydroxamic acid group displays strong pan-deacetylation ability with an IC 50 value of nM level. The benzamide group and cyclic peptide group have strong selectivity for class I HDAC.

In the aliphatic carboxylic acid group, which inhibits class I HDACs, sodium butyrate has been investigated in the chemoprevention of breast cancer and colon cancer. Valproic acid has been approved for seizure treatment, and several clinical trials are investigating its combination with chemotherapy to treat CLL, AML, MDS, and lymphoma. AR-42 resembles phenylbutyrate in structure and inhibits HDACs with an IC 50 of 30 nM. In AML, AR-42 was shown to repress the NF-κB pathway, downregulate oncogenic Kit through HSP90 disturbance, and specifically trigger the apoptosis of LSCs without affecting normal HSCs. 621 In MM, AR-42 could trigger cell cycle arrest and the apoptosis of MM cells, and downregulated CD44, which represents resistance to immunomodulating agents (IMiDs) and dexamethasone. 622 , 623 However, in clinical trials, AR-42 demonstrated only mild disease control of MM and a relatively low overall response rate (ORR) (23.1%) when combined with decitabine in AML, impeding its further application in hematologic malignancy treatment. 624 , 625

In the hydroxamic acid group, vorinostat, belinostat, and panobinostat have been approved by the FDA, while ricolinostat and citarinostat are being investigated in clinical trials. Vorinostat, also named SAHA, inhibits class I, II, and IV HDACs, and in 2006 was the first HDAC inhibitor approved by the U.S. FDA to treat cutaneous T-cell lymphoma/leukemia (CTCL). For CTCL patients who had previously received two lines of systemic treatment, the ORR of vorinostat treatment was 30%, and the median time to progression was 202 days. Serious adverse events (sAEs) of grade 3 or above included pulmonary embolism (5%) and fatigue (4%). 626 , 627 Combination treatment of vorinostat with rituximab, proteasome inhibitors (PIs), and HMA is under investigation in lymphoma. In MM, the combination of vorinostat, PIs and IMiDs is being explored in clinical trials. Furthermore, various clinical trials exploring vorinostat combined with chemotherapy to treat AML, MDS, ALL, CML, and CLL and to prevent graft-versus-host disease (GVHD) have been completed or are ongoing (Table 4 ). In 2014, belinostat, also known as PXD101, which inhibits class I and II HDACs with nanomolar IC 50 values, was the third HDAC inhibitor approved by the U.S. FDA to treat relapsed/refractory (RR) PTCL. For R/R PTCL patients, the ORR of belinostat was 25.8%, and the median duration of response (DoR) was 8.4 months. The sAEs of grade 3 or above were hematologic AEs (6.2–10.9%), pneumonia (5.4%), dyspnea (6.2%), and fatigue (5.4%). 628 In addition to PTCL, belinostat has been investigated alone or in combination with rituximab, idarubicin, HMA, NEDD8 activating enzyme inhibitors, and PIs in the treatment of R/R aggressive B-cell lymphoma, AML, MDS, and MM in various clinical trials (Table 4 ). In 2015, panobinostat (also named LBH589), which inhibits class I, II, and IV HDACs, was the fourth HDAC inhibitor approved by the U.S. FDA to treat MM. In the PANORAMA1 trial, R/R MM patients received bortezomib and dexamethasone combined with panobinostat or a placebo. The panobinostat group displayed significantly longer PFS (median 11.99 months) and higher CR or near CR rate (27.6%) than the placebo group, although no significant benefit in OS was discovered. 629 , 630 In the PANORAMA2 trial, heavily pretreated bortezomib-refractory MM patients received treatment with panobinostat, bortezomib, and dexamethasone, and the ORR was 34.5%. 631 In the MUK-six trial, R/R MM patients received treatment with panobinostat, bortezomib, thalidomide and dexamethasone, and the ORR was 91%. 632 However, the U.S. FDA has issued a warning regarding an increased risk of diarrhea, cardiac toxicity, and abnormal electrocardiogram manifestations with the use of panobinostat. Various clinical trials have examined panobinostat alone or combined with PIs, IMiDs, and everolimus in MM and lymphoma. In addition, AML, MDS, myelofibrosis (MF), and GVHD were also explored to confirm the safety and efficacy of panobinostat combined with corresponding standard therapy (Table 4 ). Apart from the approved HDAC inhibitors, various not-yet-approved inhibitors have been explored in clinical trials. Givinostat, also named ITF2357, inhibits HDAC1 and HDAC3 and has been demonstrated to regulate NFE2 and C-MYB hematopoietic transcription factors and trigger the apoptosis in JAK2 V617F -positive MPN. 633 , 634 It was also shown to trigger apoptosis, regulate the cell cycle, and promote differentiation in T-ALL and B-ALL. 635 – 637 Several clinical trials investigated its efficacy in MPN and HL, and the ORR of givinostat in the treatment of polycythemia vera was more than 80%, accompanied by a favorable safety profile. 638 – 640 Quisinostat, also named JNJ-26481585, inhibits HDAC1, HDAC2, and HDAC3 with nanomolar IC 50 value. In MM cells, quisinostat stimulated the caspase cascade and upregulated p21, which in turn triggered apoptosis and cell cycle arrest in vitro. Quisinostat alone could also inhibit angiogenesis and significantly reduce the tumor burden in MM mouse models. 641 , 642 Quisinostat combined with bortezomib significantly remodeled bone structure and reduced bone disease. 643 When combined with bortezomib and dexamethasone, quisinostat exerted an ORR of 88.2% in R/R MM patients. 644 The cutaneous response rate to quisinostat in previously treated CTCL patients was 24%. 645 Tefinostat, also named CHR-2845, is a pan-HDAC inhibitor that exerts anti-leukemic activity in monocytoid-lineage leukemia in vitro. 646 In a phase I trial including 18 patients with R/R hematologic malignancies, tefinostat displayed a good tolerance profile and showed early signs of response in a CMML patient and an AML-M2 patient. 647 Resminostat, also named 4SC-201, inhibits HDAC1, HDAC3, and HDAC6. Resminostat repressed proliferation and induced the apoptosis and G0/G1 cell cycle arrest of MM cells in vitro. Resminostat also disturbed the Akt signaling pathway by reducing 4E-BP1 and p70S6k phosphorylation. 648 In addition, resminostat exerted an antitumor effect when combined with ruxolitinib in CTCL models. 649 In the phase II SAPHIRE trial, resminostat showed an ORR of 34% in R/R HL patients. 650 Abexinostat, also named PCI-24781, is a pan-HDAC inhibitor that mainly targets HDAC1. Abexinostat can stimulate apoptosis via the NFκB pathway and remodel chromatin in lymphoma cells. 651 , 652 Various clinical trials have examined abexinostat in FL, MCL, and DLBCL. The ORR of abexinostat in R/R FL patients was 64.3%, and that in R/R MCL patients was 27.3%. 653 Alteminostat, also named CKD-581, is a pan-HDAC inhibitor that inhibits proliferation; downregulates c-Myc, BCL-2, BCL-6, and MCL-1; and upregulates p53, p21, and H2AX phosphorylation in MM cells and double-hit/double-expressor DLBCL cells. 654 , 655 In a phase I trial including MM and lymphoma patients who were refractory to standard treatment, alteminostat exhibited a favorable safety profile with a relatively low PR rate of 5.6%. 656 Citarinostat, also named ACY-241, inhibits HDAC6 and HDAC3 and exerts synergistic antimyeloma effects combined with pomalidomide in vitro and in MM mouse models. 657 Several clinical trials have explored its safety and efficacy in MM patients. Remetinostat, also named SHP-141, inhibits HDAC1, HDAC3, and HDAC6 and was designed to exert efficacy specifically and locally in the skin. 658 Clinical trials have examined remetinostat in early stage CTCL. Pracinostat, also named SB939, is a pan-HDAC inhibitor that showed synergism with JAK2 inhibitors in AML models and increased sensitivity to BCR-ABL kinase inhibitors in CML. 659 , 660 Several clinical trials have investigated its efficacy in MDS and MF. Pracinostat showed only modest or mild efficacy in MF and showed an even lower ORR when combined with HMAs compared with HMA alone, preventing its further application to the two diseases. 661 – 664 Ricolinostat, also named ACY-1215, is a first-in-class HDAC6 inhibitor. Ricolinostat combined with bortezomib caused sustained endoplasmic reticulum stress and apoptosis by stimulating caspase-3, caspase8, caspase 9, and poly (ADP) ribosome polymerase in MM cells in vitro. In a plasmacytoma MM model and disseminated MM model, ricolinostat combined with bortezomib significantly inhibited tumor growth and extended OS. 665 It also increased sensitivity to daratumumab by upregulating CD38 expression in MM cells. 666 A similar antitumor effect was also found in lymphoma. 667 A combination treatment of ricolinostat with an immune checkpoint inhibitor and ibrutinib was effective in CLL and FL, respectively, in vitro and in vivo. 668 , 669 Several clinical trials are examining its effect in R/R MM, CLL, and lymphoma. For R/R MM patients, ricolinostat combined with bortezomib and dexamethasone showed an ORR of 37%. 670 and ricolinostat combined with lenalidomide and dexamethasone displayed an ORR of 55%. 671 Purinostat, an HDAC I/IIb inhibitor, has demonstrated promising antitumor effects in B-ALL and DLBCL mouse models and is being explored in B-cell lymphoma and MM in China. 672 , 673 Table 4 The clinical trials of approved HDAC inhibitors Conditions Interventions Phase N NCT number Status Vorinostat CTCL Vorinostat 1 10 NCT00771472 Completed Advanced CTCL Vorinostat 2 74 NCT00091559 Completed ND T-cell lymphoma Vorinostat+CHOP 1/2 14 NCT00787527 Completed ND T-cell lymphoma, MCL, R/R other types of lymphoma Vorinostat+Rituximab+Ifosfamide+Carboplatin+Etoposide 1/2 29 NCT00601718 Completed ENKT Vorinostat+Azacitidine 1 18 NCT00336063 Active, not recruiting Low-grade NHL Vorinostat 2 37 NCT00253630 Completed Indolent NHL Vorinostat+Rituximab 2 30 NCT00720876 Completed R/R NHL, AML, ALL, CML Vorinostat+Decitabine 1 80 NCT00275080 Completed Relapsed NHL Vorinostat+Combination Chemotherapy 2 30 NCT04220008 Not yet recruiting Indolent B-cell NHL, MCL Vorinostat 2 56 NCT00875056 Completed R/R MCL, DLBCL Vorinostat+Bortezomib 2 65 NCT00703664 Completed MCL, R/R B-NHL, R/R CLL Vorinostat+Cladribine+Rituximab 2 57 NCT00764517 Completed ND stage II-IV DLBCL Vorinostat+Rituximab+Combination Chemotherapy 1/2 83 NCT00972478 Active, not recruiting R/R DLBCL, FL, HL Vorinostat+Pembrolizumab 1 52 NCT03150329 Completed R/R DLBCL Vorinostat+Azacitidine 1/2 17 NCT01120834 Completed Relapsed DLBCL Vorinostat 2 18 NCT00097929 Completed Elderly relapsed DLBCL Vorinostat+Cyclophosphamide, Etoposide, Prednisone and Rituximab 1/2 30 NCT00667615 Completed R/R B-cell lymphoma Vorinostat+Carfilzomib 1 20 NCT01276717 Completed R/R advanced HL Vorinostat 2 27 NCT00132028 Completed HIV-related DLBCL, other aggressive B-cell lymphoma Vorinostat+Rituximab+Combination Chemotherapy 1/2 107 NCT01193842 Completed Lymphoma Vorinostat+Niacinamide+Etoposide 1 40 NCT00691210 Completed High-risk lymphoma Vorinostat after stem cell transplantation 1 23 NCT00561418 Completed Relapsed lymphoma Vorinostat 1 10 NCT00127140 Completed R/R lymphoma Vorinostat+Gemcitabine+Busulfan+ Melphalan+Stem Cell Transplant 1 78 NCT01421173 Completed R/R lymphoma Vorinostat+Alisertib 1 34 NCT01567709 Completed NHL after ASCT Vorinostat+Bortezomib 2 27 NCT00992446 Completed ND MM Vorinostat+Bortezomib+Lenalidomide+Dexamethasone 1 30 NCT01038388 Completed ND MM in maintenance treatment Vorinostat+Lenalinomide 3 4420 NCT01554852 Active, not recruiting R-resistant MM Vorinostat+Lenalinomide+Dexamethasone 1/2 25 NCT01502085 Completed R/R MM Vorinostat+Bortezomib 1 34 NCT00111813 Completed R/R MM Vorinostat+Bortezomib 1 9 NCT00858234 Completed R/R MM Vorinostat+Bortezomib 1 40 NCT00310024 Completed R/R MM Vorinostat+Bortezomib 2 143 NCT00773838 Completed R/R MM Vorinostat+Lenalinomide+Dexamethasone 1 31 NCT00642954 Completed R/R MM Vorinostat+Bortezomib+Doxorubicin+Dexamethasone 1/2 34 NCT01394354 Completed R/R MM Vorinostat+Carfilzomib+Lenalidomide+Dexamethasone 1/2 17 NCT01297764 Active, not recruiting MM after ASCT Vorinostat+Lenalinomide 1 19 NCT00729118 Completed MM after ASCT Vorinostat+Bortezomib 2 31 NCT00839956 Completed MM Vorinostat+Bortezomib 3 637 NCT00773747 Completed MM Vorinostat+Bortezomib+ Dexamethasone 2 16 NCT01720875 Completed Young ND AML Vorinostat/+Idarubicin and Cytarabine v.s. Cytarabine+Daunorubicin Hydrochloride 3 754 NCT01802333 Completed ND AML, MDS Vorinostat+Azacitidine 2 110 NCT00948064 Completed R/R AML Vorinostat+Temozolomide 2 23 NCT01550224 Completed R/R AML, MDS Vorinostat+Decitabine+Cytarabine 1 17 NCT01130506 Completed R/R AML, ALL, CML Vorinostat+Flavopiridol 1 24 NCT00278330 Completed R/R AML Vorinostat+Decitabine+Fludarabine+Cytarabine+Filgrastim (G-CSF) 1 37 NCT03263936 Completed R/R or poor prognosis AML, MDS, CML, ALL Vorinostat+Decitabine 1 50 NCT00357708 Completed R/R AML Vorinostat+venetocla+azacitidine+Cytarabine+Fludarabine+Filgrastim 1 40 NCT05317403 Not yet recruiting Elder R/R AML Vorinostat+Azacitidine+Gemtuzumab Ozogamicin 1/2 52 NCT00895934 Completed Poor-risk AML, high-risk MDS Vorinostat+Sorafenib 1 15 NCT00875745 Completed Pediatric or young adult AML, MDS Vorinostat+Azacytidine after alloSCT 1 15 NCT03843528 Recruiting Complex/poor-risk cytogenetics AML or FLT3-ITD Vorinostat+Sorafenib+Bortezomib 1/2 37 NCT01534260 Completed AML Vorinostat 2 37 NCT00305773 Completed AML, MDS Vorinostat+Decitabine 1 71 NCT00479232 Completed AML, MDS Vorinostat+Azacitidine 1/2 135 NCT00392353 Active, not recruiting AML, high-risk MDS Vorinostat/+Azacitidine 2 260 NCT01617226 Completed AML, high-risk MDS Vorinostat+Idarubicin+Cytarabine 2 106 NCT00656617 Completed R/R leukemia, MDS Vorinostat+Idarubicin 1 40 NCT00331513 Completed AML before alloSCT Vorinostat+Fludarabine Phosphate+Clofarabine+Busulfan 1 70 NCT02083250 Completed High-risk MDS Vorinostat+Low Dose Cytarabine 1/2 52 NCT00776503 Completed High-risk MDS before CD3-/CD19- NK Cells Infusion Vorinostat+Decitabine 2 9 NCT01593670 Completed High-risk MDS, CMML Vorinostat/Lenalidomide/- +Zzacitidine 2 282 NCT01522976 Completed Acute leukemia, MDS, MPN Vorinostat+Cytarabine+Etoposide 1 25 NCT00357305 Completed Infant ALL Vorinostat+Bortezomib+Chemotherapy 1/2 50 NCT02553460 Active, not recruiting Accelerated phase or blastic phase CML, ALL Vorinostat+Dasatinib 1 5 NCT00816283 Completed ND CLL/SLL Vorinostat+Fludarabine+Cyclophosphamide+Rituximab 1/2 40 NCT00918723 Completed Reduced intensity, related donor stem cell transplant Vorinostat+Tacrolimus+Mycophenolate 1/2 61 NCT00810602 Completed Unrelated stem cell transplant Vorinostat+Tacrolimus+Methotrexate 2 26 NCT01790568 Completed AlloSCT Vorinostat+Tacrolimus+Methotrexate+Mycophenolate Mofetil+Cyclophosphamide 1/2 49 NCT03842696 Recruiting Stem cell transplant Vorinostat+Tacrolimus+Methotrexate 2 12 NCT01789255 Completed Belinostat PTCL Belinostat+CHOP 1 23 NCT01839097 Completed R/R PTCL Belinostat 2 129 NCT00865969 Completed R/R BL, DLBCL Belinostat 2 22 NCT00303953 Completed R/R NHL Belinostat+Carfilzomib 1 19 NCT02142530 Completed Relapsed aggressive high-risk lymphoma Belinostat+Rituximab+Yttrium Y 90 Ibritumomab Tiuxetan 2 5 NCT01686165 Completed Adult T-cell leukemia/lymphoma Belinostat+Zidovudine 2 20 NCT02737046 Recruiting R/R AML Belinostat+Pevonedistat 1 30 NCT03772925 Recruiting AML unsuitable for standard intensive therapy Belinostat+Idarubicin 1/2 41 NCT00878722 Completed AML Belinostat 2 12 NCT00357032 Completed R/R acute leukemia, MDS Belinostat+Bortezomib 1 41 NCT01075425 Completed AML, ALL, CML, MDS Belinostat+Azacitidine 1 56 NCT00351975 Completed MDS Belinostat 2 21 NCT00357162 Completed Advanced MM Belinostat+Dexamethsone 2 25 NCT00131261 Completed Panobinostat R/R MM Panobinostat+Bortezomib+Dexamethasone 3 767 NCT01023308 Completed R/R MM Panobinostat+Bortezomib+Dexamethasone 2 249 NCT02654990 Active, not recruiting R/R MM Panobinostat+Bortezomib+Dexamethasone 2 31 NCT02290431 Completed Relapsed and bortezomib-refractory MM Panobinostat+Bortezomib+Dexamethasone 2 55 NCT01083602 Completed R/R MM Panobinostat+Bortezomib 1 62 NCT00532389 Completed R/R MM Panobinostat+Carfilzomib 1/2 80 NCT01496118 Completed R/R MM Panobinostat+Carfilzomib 1 32 NCT01549431 Completed R/R MM Panobinostat+Carfilzomib 1 46 NCT01301807 Active, not recruiting R/R MM Panobinostat+Lenalidomide+Dexamethasone 2 32 NCT01651039 Completed R/R MM Panobinostat+Bortezomib+Lenalidomide+Dexamethasone 1 21 NCT01965353 Completed R/R MM Panobinostat+Daratumumab+Bortezomib+Dexamethasone 1 27 NCT04956302 Recruiting Relapsed MM Panobinostat+Melphalan 1/2 40 NCT00743288 Completed Adult MM Panobinostat+Lenalidomide+Dexamethasone 1 46 NCT00532675 Completed ND transplant-eligible MM Panobinostat+Bortezomib+Lenalidomide+Dexamethasone 1 77 NCT01440582 Completed R/R MM before autoSCT Panobinostat+Gemcitabine+Busulfan+Melphalan 2 83 NCT02506959 Active, not recruiting MM after autoSCT Panobinostat 2 30 NCT02722941 Active, not recruiting Recurrent MM, lymphoma Panobinostat+Everolimus 1/2 124 NCT00918333 Completed R/R MM, lymphoma Panobinostat+Everolimus 1 11 NCT00962507 Completed Refractory CTCL Panobinostat 2 139 NCT00425555 Completed R/R PTCL, ENKT Panobinostat+Bortezomib 2 25 NCT00901147 Completed R/R MCL Panobinostat+Bortezomib 1 3 NCT01504776 Completed R/R DLBCL Panobinostat 2 35 NCT01523834 Completed R/R WM Panobinostat 2 39 NCT00936611 Completed R/R NHL Panobinostat 2 41 NCT01261247 Completed R/R classical HL Panobinostat 2 129 NCT00742027 Completed R/R HL Panobinostat+Lenalidomide 2 24 NCT01460940 Completed Relapsed HL Panobinostat/+Ifosfamide+Carboplatin+Etoposide 1/2 62 NCT01169636 Completed HL maintenance Panobinostat 3 41 NCT01034163 Completed R/R lymphoma Panobinostat+Everolimus 1/2 31 NCT00967044 Completed Pediatric lymphoma, AML, ALL Panobinostat for lymphoma, Panobinostat+Cytarabine for Leukemia 1 30 NCT01321346 Completed High-risk AML, MDS after HSCT Panobinostat 3 52 NCT04326764 Active, not recruiting AML younger than 65 years old Panobinostat+Chemotherapy 1 40 NCT01242774 Completed ND AML older than 65 years old Panobinostat+Idarubicin+Cytarabine 1/2 46 NCT00840346 Completed ND AML, advanced MDS Panobinostat+Daunorubicin+Cytarabine 1 29 NCT01463046 Completed Refractory AML Panobinostat 2 59 NCT00880269 Completed R/R AML Panobinostat+Azacitidine+Mitoxantrone 1 59 NCT01055483 Completed AML, MDS Panobinostat+Decitabine 1/2 52 NCT00691938 Completed AML, MDS, CMML Panobinostat+Azacitidine 1 10 NCT01613976 Completed AML, MDS, CMML Panobinostat+Azacitidine 1/2 113 NCT00946647 Completed Previously treated chronic phase CML Panobinostat+Imatinib 1 9 NCT00686218 Completed MF Panobinostat+Ruxolitinib 1 61 NCT01433445 Completed MF Panobinostat+Ruxolitinib 1/2 20 NCT01693601 Completed MF, PV, GVHD, AML Panobinostat/+Ruxolitinib 4 298 NCT02386800 Recruiting Advanced hematologic malignancies Panobinostat 1/2 175 NCT00621244 Completed AlloSCT Panobinostat+Sirolimus+Tacrolimus 2 42 NCT02588339 Completed AlloSCT Panobinostat+Corticosteroids 1/2 22 NCT01111526 Completed Chidamide ND PTCL Chidamide+CHOP 1 30 NCT02809573 Completed ND PTCL Chidamide+CHOEP 1/2 100 NCT02987244 Recruiting ND PTCL Chidamide+Azacitidine/+CHOP 3 107 NCT05075460 Not yet recruiting ND PTCL unfit for conventional chemotherapy Chidamide+Azacitidine 2 28 NCT04480125 Recruiting R/R PTCL Chidamide+Parsaclisib 1/2 28 NCT05083208 Not yet recruiting R/R PTCL Chidamide+Lenalidomide 2 44 NCT04329130 Recruiting R/R PTCL Chidamide+Sintilimab 2 51 NCT04512534 Recruiting R/R PTCL Chidamide+Sintilimab+Azacitidine 2 30 NCT04052659 Not yet recruiting R/R PTCL Chidamide v.s. Mitoxantrone Hydrochloride Liposome Injection 3 190 NCT04668690 Not yet recruiting ND AITL Chidamide+CHOP 2 23 NCT03853044 Active, not recruiting R/R ATIL Chidamide+Azacitidine 2 20 NCT05179213 Not yet recruiting R/R AITL Chidamide+Sintilimab 2 83 NCT04831710 Not yet recruiting R/R AITL Chidamide+Rituximab+Lenalidomide NA 26 NCT04319601 Recruiting ND ENKT Chidamide+Sintilimab 2 30 NCT04994210 Recruiting R/R ENKT Chidamide+Sintilimab 1/2 40 NCT03820596 Completed Stage I/II ENKT Chidamide/+Gemcitabine+Cisplatin+Dexamethasone+Radiotherapy NA 76 NCT04511351 Recruiting R/R CTCL Chidamide+Sintilimab 2 52 NCT04296786 Recruiting T-NHL before autoSCT Chidamide+Carmustine+Etoposide+Cytarabine+Melphalan 2 23 NCT05367856 Not yet recruiting ND double-expressor DLBCL Chidamide/+RCHOP 3 418 NCT04231448 Recruiting R/R DLBCL Chidamide+Rituximab+Anti-PD-1 Antibody 2 27 NCT05115409 Not yet recruiting R/R transplant-ineligible DLBCL Chidamide+Rituximab+Gemcitabine+Oxaliplatin 2 54 NCT04022005 Recruiting R/R B-NHL Chidamide 2 100 NCT03245905 Recruiting R/R B-NHL before CAR-T Chidamide/+Fludarabine+Cyclophosphamide 1/2 120 NCT05370547 Recruiting Aggressive R/R B-NHL undergoing decitabine-primed tandem CD19/CD20 CAR-T Chidamide v.s. Decitabine v.s. Chidamide+Decitabine 1/2 80 NCT04553393 Recruiting R/R NHL Chidamide+Chiauranib 1/2 9 NCT03974243 Completed R/R NHL Chidamide+Decitabine+Immune checkpoint inhibitors 1/2 100 NCT05320640 Recruiting NHL who relapsed after CAR-T Chidamide+Decitabine 1/2 100 NCT04337606 Recruiting NHL Chidamide 1 13 NCT02697552 Completed ND primary central nervous system lymphoma Chidamide+Rituximab+Methotrexate 2 51 NCT04516655 Not yet recruiting R/R classical HL Chidamide+Decitabine+Camrelizumab 2 100 NCT04233294 Recruiting Anti-PD-1 antibody-resistant classical HL Chidamide/+Decitabine+Camrelizumab 2 200 NCT04514081 Recruiting Aggressive lymphoma Chidamide+BEAC+autoSCT 2 69 NCT03629873 Active, not recruiting R/R MM Chidamide+Lenalidomide+Dexamethasone 2 25 NCT03605056 Not yet recruiting Primary high-risk MM Chidamide/+Bortezomib+Lenalidomide+Dexamethasone 1/2 50 NCT04025450 Recruiting CBF AML Chidamide v.s. Cytarabine 1/2 250 NCT03031262 Recruiting R/R AML Chidamide+Azacitidine+Venetoclax 2 30 NCT05305859 Not yet recruiting R/R AML Chidamide+Cladribine 2 31 NCT05330364 Recruiting R/R AML Chidamide+Decitabine+Priming IAG 2 40 NCT03985007 Completed R/R AML Chidamide/+Azacitidine+HAG 2 210 NCT05029141 Recruiting AML after transplant Chidamide+Azacitidine 1/2 20 NCT05270200 Recruiting T-ALL Chidamide+Ruxolitinib 1/2 50 NCT05075681 Recruiting B-ALL undergoing haploidentical alloSCT Chidamide+Ruxolitinib 2 50 NCT05088226 Recruiting Adult Ph-like ALL Chidamide v.s. Dasatinib 2/3 120 NCT03564470 Recruiting HLH Chidamide+VP-16+Methylprednisolone NA 20 NCT05137522 Recruiting ENKT-HLH Chidamide+Sintilimab v.s Azacitidine+Sintilimab v.s. L-DEP 2 37 NCT05008666 Not yet recruiting Steroid-resistant/steroid-dependent Severe cGVHD Chidamide 1/2 20 NCT05140616 Recruiting Romidepsin Conditions Interventions Phase Patients NCT number Status ND PTCL Romidepsin/+CHOP 3 421 NCT01796002 Active, not recruiting ND PTCL Romidepsin+Lenalidomide 2 35 NCT02232516 Active, not recruiting ND PTCL Romidepsin+CHOP 1/2 37 NCT01280526 Completed ND young nodal PTCL before HSCT Romidepsin+CHOEP 1/2 89 NCT02223208 Active, not recruiting R/R PTCL Romidepsin+Ixazomib 1/2 11 NCT03547700 Active, not recruiting R/R PTCL Romidepsin+Carfilzomib 1/2 50 NCT03141203 Completed R/R PTCL Romidepsin+Gemcitabine 2 20 NCT01822886 Completed R/R PTCL Romidepsin+Pembrolizumab 1/2 39 NCT03278782 Recruiting R/R PTCL Romidepsin+Ifosfamide+Carboplatin+Etoposide 1 22 NCT01590732 Completed Progressive or relapsed PTCL Romidepsin 2 131 NCT00426764 Completed Progressive or relapsed PTCL Romidepsin 1/2 51 NCT01456039 Completed PTCL, CTCL Romidepsin 2 131 NCT00007345 Completed R/R mature TCL Romidepsin+Venetoclax 2 9 NCT03534180 Active, not recruiting R/R TCL Romidepsin+Tenalisib 1/2 33 NCT03770000 Completed R/R TCL Romidepsin+Parsaclisib 1 20 NCT04774068 Recruiting R/R TCL Romidepsin+Duvelisib v.s. Bortezomib+Duvelisib 1 114 NCT02783625 Active, not recruiting R/R TCL Romidepsin+Azacitidine+Lenalidomide+Dexamethasone 1 30 NCT04447027 Recruiting R/R AITL Romidepsin+Sintilimab 2 83 NCT04831710 Not yet recruiting R/R ENKT Romidepsin 1 16 NCT01913119 Completed TCL Romidepsin+Azacitidine+Duvelisib 1 60 NCT04639843 Not yet recruiting TCL, T-ALL after alloSCT Romidepsin 1 10 NCT02512497 Recruiting Previously treated PTCL, DLBCL Romidepsin+Gemcitabine+Dexamethasone+Cisplatin 1 21 NCT01846390 Completed CTCL Romidepsin+Brentuximab Vedotin 1 27 NCT02616965 Recruiting R/R CTCL Romidepsin+doxorubicin HCl liposomal 1 24 NCT01902225 Completed R/R CTCL Romidepsin 2 102 NCT00106431 Completed T-NHL after autoSCT Romidepsin maintenance 2 47 NCT01908777 Active, not recruiting R/R NHL Romidepsin 2 35 NCT00077194 Completed R/R NHL Romidepsin+Alisertib 1 26 NCT01897012 Completed R/R NHL Romidepsin+Carfilzomib+Lenalidomide 1/2 31 NCT02341014 Active, not recruiting R/R aggressive lymphoma Romidepsin+Gemcitabine+Oxaliplatin+Dexamethasone 1 24 NCT02181218 Completed R/R lymphoma, myeloma Romidepsin+Lenalidomide 1/2 62 NCT01755975 Active, not recruiting R/R MM Romidepsin 2 50 NCT00066638 Completed R/R AML Romidepsin 2 47 NCT00062075 Completed R/R leukemia, MDS, MPN Romidepsin+Decitabine 1 36 NCT00114257 Completed R/R CLL/SLL Romidepsin+Bortezomib 1 18 NCT00963274 Completed AITL angioimmunoblastic T-cell lymphoma, ALL acute lymphoblastic leukemia, alloSCT allogenic stem cell transplantation, AML acute myeloid leukemia, ASCT autologous stem cell transplantation, BL Burkitt’s lymphoma, CLL chronic lymphocytic leukemia, CML chronic myeloid leukemia, CTCL cutaneous T-cell lymphoma/leukemia, DLBCL diffuse large B-cell lymphoma, ENKT extranodal NK/T-cell lymphoma, FL follicular lymphoma, GVHD graft-versus-host disease, HL Hodgkin lymphoma, ITD internal tandem duplication, MCL mantle cell lymphoma, MDS myelodysplastic syndrome, MF myelofibrosis, MM multiple myeloma, ND newly diagnosed, NHL non-Hodgkin lymphoma, PV polycythemia vera, PTCL peripheral T-cell lymphoma, R rituximab, R/R relapsed/refractory, SLL small lymphocytic lymphoma

In the benzamide group, chidamide, also named CS055 or tucidinostat, inhibits HDAC1, HDAC2, HDAC3, and HDAC10, and has been approved by the China NMPA and EMA to treat R/R PTCL. 674 , 675 For R/R PTCL patients, the ORR of chidamide was 28%, and the median OS was 21.4 months, with good tolerance in clinical trials. 676 In a real-world study, the ORR of chidamide monotherapy was 39.06%, and that of chidamide combined with chemotherapy was 51.18% in R/R PTCL. 677 In addition, there are numerous ongoing clinical trials exploring its efficacy in NHL (mostly T-cell lymphoma), AML, ALL, MM, and hemophagocytic lymphohistiocytosis. 678 In addition to the approved chidamide, other benzamide-based HDAC inhibitors are being explored in clinical trials. Entinostat, also known as MS275, inhibits HDAC1, HDAC3, and HDAC8. Preclinical studies revealed that entinostat relieved the epigenetic silencing of LAT2 caused by AML1/ETO, and inhibited leukemic maintenance. 679 – 681 Entinostat stimulated apoptosis alone and synergized with rituximab in B-cell lymphoma, with BCL2 inhibitors in HL, and with bendamustine in MM. 682 – 684 Various clinical trials are investigating its efficacy in MDS, AML, CMML, and lymphoma. However, bendamustine combined with azacytidine displayed worse ORR and OS in AML and MDS compared with azacytidine treatment alone, indicating antagonism and higher toxicity of the two agents in this setting. 685 , 686 Mocetinostat, also named MGCD0103, inhibits HDAC1, HDAC2, HDAC3, and HDAC11. Mocetinostat triggered H3 and H4 acetylation and exerted significant antitumor effects in various cancer cells. 351 Various clinical trials have explored its effect on R/R lymphoma and AML. Domatinostat, also named 4SC-202, inhibits HDAC1, HDAC2, and HDAC3, and displayed a manageable safety profile with signs of antitumor effects in a phase I trial enrolling patients with advanced hematological malignancies. 687 Tacedinaline, also named CI-994, is a selective HDAC1 inhibitor and has been explored in advanced MM patients.

In the cyclic peptide group, romidepsin, also named FK228 or depsipeptide, inhibits HDAC1 and HDAC2 and was the second HDAC inhibitor approved by the U.S. FDA to treat CTCL and PTCL. Romidepsin inhibited proliferation and angiogenesis and promoted cell cycle arrest and apoptosis in various cancer cells. 688 For previously treated or refractory CTCL patients, romidepsin monotherapy displayed an ORR of 34%. 689 , 690 For R/R PTCL patients, romidepsin monotherapy displayed an ORR of 38%. 691 Numerous ongoing clinical trials are investigating romidepsin combined with anti-PD-1 monoclonal antibody, PIs, PI3K inhibitors, BCL2 inhibitors, IMiDs, and chemotherapy in R/R T-cell NHL.

Dual-target HDAC inhibitors

In addition to the classic HDAC inhibitors, dual-target HDAC inhibitors have also demonstrated favorable antitumor effects in preclinical models. CUDC-101, an HDAC I/receptor tyrosine kinase (RTK) bifunctional inhibitor, inhibits HDAC I, EGFR, and HER2 and has been demonstrated effective in preclinical models of gemcitabine-treated lymphoma, APL, and several solid tumors. 692 , 693 Several clinical trials have investigated its role in solid tumors, while no trials on hematologic malignancies have been conducted. An HDAC6/JAK2 inhibitor was designed based on vorinostat and pacritinib, and showed preclinical efficacy in AML and ALL. 694 CUDC-907, an HDAC/PI3K inhibitor, exerted an ORR of 37% in R/R DLBCL patients, including those with MYC-alterations. 695 HDAC/LSD1 inhibitors and HDAC I/tubulin inhibitors display favorable efficacy in solid tumors, such as colon cancer and breast cancer, but few studies have explored their application to hematologic malignancies. 696 , 697

PROTACs for HDACs

The reversibility of classic small-molecule HDAC inhibitors requires sustainable exposure to a high in vivo drug concentration to maintain sufficient inhibition. However, maintaining a high in vivo drug concentration is sometimes challenging. Proteolysis-targeting chimeras (PROTACs) provide an innovative strategy for degrading HDACs more persistently. A PROTAC is a small bifunctional compound consisting of a ligand for the target protein, an E3 ligase recognition moiety, and a linker. After the ligand binds with the target protein on one side, the E3 ligase on the other side mediates the ubiquitination of the target protein by the ubiquitin-conjugating E2 enzyme. The target protein labeled with ubiquitin is recognized and degraded by proteasomes. The ubiquitination and degradation process are highly efficient and recyclable, making PROTACs a promising strategy to degrade HDACs. Several HDAC-targeted PROTACs have been developed in recent years.

According to the E3 ligase complex, these PROTACs are mainly divided into cereblon (CRBN)-based PROTACs and Von Hippel-Lindau (VHL)-based PROTACs. The first-in-class HDAC6-targeted PROTAC, compound 9c, was developed by conjugating a pan-HDAC nonselective inhibitor to thalidomide as CRBN. The concentration of half-maximal degradation (DC 50 ) for HDAC6 was 34 nM, and HDAC6 was significantly degraded by 9c at a concentration of 80 nM in multiple myeloma MM.1S cells. However, other HDACs were also inhibited by 9c, indicating the need for HDAC6-targeted PROTACs with higher selectivity and specificity. 698 Later, HDAC6-targeted PROTACs with higher selectivity were developed by conjugating a selective HDAC6 inhibitor, nexturastat A, to pomalidomide as CRBN. The degrader, NP8, exerted efficient HDAC6 degradation in MM.1S cells with a DC 50 of 3.8 nM without affecting other types of HDACs. 699 Another degrader, NH2, exerted similarly efficient HDAC6 degradation in MM.1S cells with a DC 50 of 3.2 nM without affecting other types of HDACs. Moreover, the onset of degradation occurred within an hour and peaked at 6–8 h, and HDAC6 rapidly recovered three hours after washout, indicating its efficient and reversible capability to degrade HDAC6. 700

In addition to CRBN-based PROTACs, VHL-based PROTACs targeting HDAC have also been developed. An HDAC6 degrader, compound 3j, was designed by conjugating nexturastat A to VHL, which showed robust HDAC6 degradation with a DC 50 of 7.1 nM in MM.1S cells. Furthermore, the maximal degradation (D max ) of HDAC6 reached up to 90% in MM.1S cells. 701 An HDAC3 degrader, XZ9002, was developed by conjugating a selective HDAC I inhibitor, SR-5228, to VHL. The DC 50 of HDAC3 in breast cancer MDA-MB-468 cells was 42 nM. 702

Combination treatment of HDAC inhibitors with HMAs

Inspired by the encouraging efficacy of HMAs in treating leukemia, numbers of clinical trials have explored the combination treatment of HMAs and HDAC inhibitors in AML and ALL. The majority of clinical trials focused on AML. However, most results were disappointing. A phase I study explored the combination of the HDAC inhibitor AR-42 with decitabine in 13 newly diagnosed or relapsed/refractory AML patients. The ORR was only 23.1% with dose-limiting toxicities occurring at the third dosage. The results were not satisfying, probably due to the small sample size, high-risk baseline clinical features of participants, and the relatively mild HDAC inhibition capability of AR-42. 624 A phase I study investigated decitabine combined with the HDAC inhibitor valproic acid or not in 25 AML patients. The ORR of decitabine monotherapy group was similar to that in combination treatment group. The addition of valproic acid to decitabine showed little treatment effect bonus, but caused encephalopathy. The evident effect of valproic acid on central nervous system, as evidenced by its approved indications as seizures, narrowed its application in combination treatment in AML patients. 703 The addition of valproate to decitabine in AML treatment was proved insignificant again in a phase II trial with larger sample size. 704 Moreover, the combination treatment of decitabine even with the commonly recognized effective HDAC inhibitor vorinostat still exerted limited ORR (23%) in AML patients. 705 In relapsed ALL, combined treatment of vorinostat with decitabine exerted an ORR of 39–46.2%, which was higher than that in AML. However, treatment-related infections were common. 706 , 707 The failure of combination treatment of HDAC inhibitors with HMAs could be attributable to the potential epigenetic antagonism. Several clinical trials are still ongoing in PTCL and DLBCL. Extensive studies are required to thoroughly reveal the exact mechanism and interaction between the two epigenetic therapies.

Combination treatment of HDAC inhibitors with immune treatment

HDACs can regulate both innate and adaptive immune response. In innate immune response, HDACs could promote or inhibit Toll-like receptor (TLR) signaling pathways determined by the types of HDACs and diseases, leading to either an increase or decrease in cytokine and chemokine secretion. Regarding adaptive immune response, HDAC inhibitors could upregulate MHC-I and promote antigen processing, which amplified the antitumor reaction. 708 Panobinostat has been reported to activate Notch pathway and enhance the anti-leukemic influence of human γδT cells in vitro, 709 and could exert synergistic effect with interferon-α in mouse models. 710 Trichostatin A, an HDAC inhibitor, has also been proved to induce dendritic cell differentiation from AML leukemic blasts in vitro. 711 These encouraging preclinical findings indicate the promising application of combination treatment of HDAC inhibitors and immune treatment in hematologic malignancies. The number of clinical trials are investigating the combined treatment of HDAC inhibitors with rituximab in B-cell lymphoma, with lenalidomide in MM, and with brentuximab vedotin in CTCL patients. Various ongoing clinical trials are also exploring the combined treatment of HDAC inhibitors with PD-1 monoclonal antibodies in the treatment of HL, DLBCL, FL, PTCL, CTCL, AITL, ENKT, and HLH secondary to ENKT (Table 4 ). Their results are widely anticipated, and will better reveal the optimal individualized treatment of hematologic malignancies.

Targeting other histone modification agents

Although HDAC inhibitors are one of the most explored and applied epigenetic regimens, agents targeting other histone modification agents are also being developed (Fig. 1 ).

Regarding histone acetylation, agents targeting writers mainly include CBP/P300 inhibitors. CCS1477, a CBP inhibitor, is being explored to treat NHL, MM, AML, and MDS in a phase I/IIa trial ( NCT04068597 ). 712 Agents targeting readers include BET inhibitors. OTX015 inhibited proliferation and stimulated cell cycle arrest and apoptosis in leukemia cells. It also downregulated BRD2, BRD4, and MYC in vitro. 713 In lymphoma, OTX015 stimulated the apoptosis of DLBCL cells with mutations in MYD88, CD79B, or CARD11, and repressed MYC- and E2F1-related expression. 714 OTX015 showed mild efficacy in acute leukemia and lymphoma patients, while no efficacy was found in MM patients. 715 CPI-0610, GSK525762, RO6870810, and FT-1101 are being explored in hematologic malignancies in clinical trials. 716 Apart from the classic BET inhibitors, BET-targeted PROTACs have been reported. ARV-825 was developed by conjugating the BRD4 inhibitor OTX015 to pomalidomide as CRBN. ARV0825 exerted rapid, efficient and sustained degradation of BRD4 and lethal activity compared to BET inhibitors in Burkitt lymphoma cells, mantle cell lymphoma cells, post-MPN secondary AML cells, and T-cell ALL cells. 717 – 721 dBET1 was generated by conjugating the BRD4 inhibitor, JQ1, to phthalimide as CRBN. The efficient and specific degradation of BRD2, BRD3, and BRD4 was accompanied by superior apoptosis induction in AML cells and xenograft models. 722

For histone methylation, agents targeting writers include EZH2 inhibitors and DOT1L inhibitors. EZH2 inhibitors in the clinical stage include tazemetostat, CPI-1205, SHR2554, and PF-06821497. Tazemetostat has been approved by the U.S. FDA to treat metastatic or advanced epithelioid sarcoma. Although most of the EZH2 inhibitor clinical trials focus on solid tumors, several trials are investigating its effect on R/R B-NHL. 723 The DOT1L inhibitor, pinometostat, also named EPZ5676, has been demonstrated to impair H3K79 methylation and moderately effective in treating MLL -rearranged leukemia. 724 Agents targeting histone methylation erasers mainly include LSD1 inhibitors, also named KDM1A inhibitors. ORY-1001, TCP, and GSK2879552 are being investigated in the treatment of R/R AML in clinical trials. INCB059872 and IMG-7289 have been explored in MPN trials. CC-90011 was investigated in R/R NHL. 725

In terms of histone phosphorylation, the JAK2 inhibitors (ruxolitinib, fedratinib, and pacritinib) have been approved by the U.S FDA to treat MPN. 726 Various clinical trials have been investigating their role in CMML, CLL, ALL, and post-MPN AML. 727 , 728 In addition, aurora inhibitors have been developed and have shown synergism with docetaxel in apoptosis stimulation to inhibit lymphoma. 729 , 730

Conclusion

In conclusion, epigenetic regulation plays a fundamental role in hematopoiesis and oncogenesis of hematologic malignancies. Abnormal DNA methylation profiles, including genome-wide hypomethylation and aberrant hypermethylation or hypomethylation of CpG islands, are frequently observed in hematologic malignancies. Upregulation or mutations of DNA methylation writers (DNMT1, DNMT3A, and DNMT3B) are pathogenic in AML. Readers of DNA methylation mainly consist of MBD-containing proteins, methyl-CpG binding zing fingers, and SRA domain-containing proteins, whose upregulation is frequently identified in CML, NHL, and AML, respectively. DNA methylation erasers mainly include the TET family, whose mutations, translocation, and upregulation are relatively common in AML. Correspondingly, HMAs have been developed to target aberrant DNA methylation profiles and have been demonstrated effective to treat MDS, AML, and CMML. Furthermore, histone acetylation and methylation are involved in hematologic oncogenesis. KATs are histone acetylation writers, whose mutations are detected in DLBCL and translocations are identified in AML. HDACs are histone acetylation erasers, whose aberrant expression has been demonstrated in lymphoma. Correspondingly, HDAC inhibitors have been proposed and demonstrated effective in treatment of CTCL, PTCL, and MM. Mutations, translocations, and aberrant expression of histone methylation writers, KMTs, and histone methylation erasers, KDMs, are also found in AML and other hematologic malignancies. Dysregulation of miRNAs and lncRNAs also contributes to hematologic oncogenesis. In addition to DNMT inhibitors and HDAC inhibitors, innovative epigenetic treatment targeting KATs, BETs, KMTs, KDMs, and ncRNAs are emerging and will provide novel treatment strategies in hematologic malignancies.

However, the relationship of cancer epigenetics with interdependent mechanisms like cancer immunology or metabolism should be explored further. In the future, more accurate diagnostic and prognostic information detected by high-throughput genomic technologies can provide more precise and individualized therapeutic options. Moreover, the ncRNA could possibly serve as diagnostic and prognostic molecular biomarkers in the future clinical settings. With the rapid growth of associated scientific research methods and technologies in this academic sector, ncRNA-targeted therapy may soon be a realistic treatment option for patients with hematologic malignancies.

Supplementary information

Supplementary Table 1

These authors contributed equally: Ailin Zhao, Hui Zhou, Jinrong Yang

Supplementary information

The online version contains supplementary material available at 10.1038/s41392-023-01342-6.

Acknowledgements

This work is supported by the National Natural Science Foundation of China (82204490 to A.Z.), the Translational Research Grant of NCRCH (2021WWB03 to T.N.), Achievement Transformation Project (CGZH21001 to T.N.), and 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University (ZYJC21007 to T.N.).

Author contributions

A.Z., H.Z., and J.Y. prepared the manuscript. A.Z., H.Z., J.Y., and M.L. wrote the main parts of the article. M.L., A.Z., and T.N. produced graphics. A.Z. and T.N. performed critical editing to the manuscript. T.N. drafted the final version of the manuscript. All authors have read and approved the article.

Competing interests

The authors declare no competing interests.

References

1. Avery OT Macleod CM McCarty M Studies on the chemical nature of the substance inducing transformation of pneumococcal types: induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III J. Exp. Med. 1944 79 137 158 10.1084/jem.79.2.137 19871359 PMC2135445

2. McCarty M Avery OT Studies on the chemical nature of the substance inducing transformation of pneumococcal types: II. Effect of desoxyribonuclease on the biological activity of the transforming substance J. Exp. Med. 1946 83 89 96 10.1084/jem.83.2.89 21010046

3. Bestor TH Cloning of a mammalian DNA methyltransferase Gene 1988 74 9 12 10.1016/0378-1119(88)90238-7 3248734

4. Gardiner-Garden M Frommer M CpG islands in vertebrate genomes J. Mol. Biol. 1987 196 261 282 10.1016/0022-2836(87)90689-9 3656447

5. Takai D Jones PA Comprehensive analysis of CpG islands in human chromosomes 21 and 22 Proc. Natl Acad. Sci. USA 2002 99 3740 3745 10.1073/pnas.052410099 11891299 PMC122594

6. Maunakea AK Conserved role of intragenic DNA methylation in regulating alternative promoters Nature 2010 466 253 257 10.1038/nature09165 20613842 PMC3998662

7. Bird A Taggart M Frommer M Miller OJ Macleod D A fraction of the mouse genome that is derived from islands of nonmethylated, CpG-rich DNA Cell 1985 40 91 99 10.1016/0092-8674(85)90312-5 2981636

8. Schulz WA Steinhoff C Florl AR Methylation of endogenous human retroelements in health and disease Curr. Top. Microbiol. Immunol. 2006 310 211 250 16909913 10.1007/3-540-31181-5_11

9. Deaton AM Bird A CpG islands and the regulation of transcription Genes Dev. 2011 25 1010 1022 10.1101/gad.2037511 21576262 PMC3093116

10. Saxonov S Berg P Brutlag DL A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters Proc. Natl Acad. Sci. USA 2006 103 1412 1417 10.1073/pnas.0510310103 16432200 PMC1345710

11. Li E Beard C Jaenisch R Role for DNA methylation in genomic imprinting Nature 1993 366 362 365 10.1038/366362a0 8247133

12. Stadler MB DNA-binding factors shape the mouse methylome at distal regulatory regions Nature 2011 480 490 495 10.1038/nature10716 22170606

13. Jones PA Baylin SB The epigenomics of cancer Cell 2007 128 683 692 10.1016/j.cell.2007.01.029 17320506 PMC3894624

14. Karatzas PS Mantzaris GJ Safioleas M Gazouli M DNA methylation profile of genes involved in inflammation and autoimmunity in inflammatory bowel disease Medicine 2014 93 e309 10.1097/MD.0000000000000309 25526479 PMC4603097

15. Easwaran H Tsai HC Baylin SB Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance Mol. Cell 2014 54 716 727 10.1016/j.molcel.2014.05.015 24905005 PMC4103691

16. Kulis M Esteller M DNA methylation and cancer Adv. Genet. 2010 70 27 56 10.1016/B978-0-12-380866-0.60002-2 20920744

17. Baylin SB Jones PA A decade of exploring the cancer epigenome—biological and translational implications Nat. Rev. Cancer 2011 11 726 734 10.1038/nrc3130 21941284 PMC3307543

18. Jones PA Baylin SB The fundamental role of epigenetic events in cancer Nat. Rev. Genet. 2002 3 415 428 10.1038/nrg816 12042769

19. Laird PW Jaenisch R DNA methylation and cancer Hum. Mol. Genet. 1994 3 Spec No 1487 1495 10.1093/hmg/3.suppl_1.1487 7849743

20. Aran D Sabato S Hellman A DNA methylation of distal regulatory sites characterizes dysregulation of cancer genes Genome Biol. 2013 14 R21 10.1186/gb-2013-14-3-r21 23497655 PMC4053839

21. Taberlay PC Three-dimensional disorganization of the cancer genome occurs coincident with long-range genetic and epigenetic alterations Genome Res. 2016 26 719 731 10.1101/gr.201517.115 27053337 PMC4889976

22. Zebardast S The gene expression profile and DNA methylation pattern of cdh1 and DNMT1 genes in acute promyelocytic leukemia (APL) Rep. Biochem. Mol. Biol. 2020 8 454 457 32582805 PMC7275828

23. Rahmani T Patterns of DNMT1 promoter methylation in patients with acute lymphoblastic leukemia Int. J. Hematol. Oncol. Stem Cell Res. 2017 11 172 177 28989582 PMC5625466

24. Zhang YY DNMT3A intragenic hypomethylation is associated with adverse prognosis in acute myeloid leukemia Leuk. Res. 2015 39 1041 1047 10.1016/j.leukres.2015.06.015 26242829

25. Šestáková Š DNA methylation and hydroxymethylation patterns in acute myeloid leukemia patients with mutations in DNMT3A and IDH1/2 and their combinations Cancer Biomark. 2019 25 43 51 10.3233/CBM-182176 30988238 PMC13082415

26. Hajkova H Decreased DNA methylation in acute myeloid leukemia patients with DNMT3A mutations and prognostic implications of DNA methylation Leuk. Res. 2012 36 1128 1133 10.1016/j.leukres.2012.05.012 22749068

27. Yang L DNMT3A loss drives enhancer hypomethylation in FLT3-ITD-associated leukemias Cancer Cell 2016 30 363 365 10.1016/j.ccell.2016.07.015 27505680

28. Yan XJ Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia Nat. Genet. 2011 43 309 315 10.1038/ng.788 21399634

29. Yamazaki J Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia Epigenetics 2012 7 201 207 10.4161/epi.7.2.19015 22395470 PMC3335912

30. Bensberg M TET2 as a tumor suppressor and therapeutic target in T-cell acute lymphoblastic leukemia Proc. Natl Acad. Sci. USA 2021 118 e2110758118 10.1073/pnas.2110758118 34413196 PMC8403940

31. Hayette S High DNA methyltransferase DNMT3B levels: a poor prognostic marker in acute myeloid leukemia PLoS ONE 2012 7 e51527 10.1371/journal.pone.0051527 23251566 PMC3519733

32. Roux B Aberrant DNA methylation impacts HOX genes expression in bone marrow mesenchymal stromal cells of myelodysplastic syndromes and de novo acute myeloid leukemia Cancer Gene Ther. 2022 29 1263 1275 10.1038/s41417-022-00441-w 35194200

33. Kn H Bassal S Tikellis C El-Osta A Expression analysis of the epigenetic methyltransferases and methyl-CpG binding protein families in the normal B-cell and B-cell chronic lymphocytic leukemia (CLL) Cancer Biol. Ther. 2004 3 989 994 10.4161/cbt.3.10.1137 15467427

34. Jiang H DNA methylation markers in the diagnosis and prognosis of common leukemias Signal Transduct. Target Ther. 2020 5 3 10.1038/s41392-019-0090-5 32296024 PMC6959291

35. Okano M Xie S Li E Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases Nat. Genet. 1998 19 219 220 10.1038/890 9662389

36. Ooi SK DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA Nature 2007 448 714 717 10.1038/nature05987 17687327 PMC2650820

37. Okano M Bell DW Haber DA Li E DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development Cell 1999 99 247 257 10.1016/S0092-8674(00)81656-6 10555141

38. Pradhan S Bacolla A Wells RD Roberts RJ Recombinant human DNA (cytosine-5) methyltransferase. I. Expression, purification, and comparison of de novo and maintenance methylation J. Biol. Chem. 1999 274 33002 33010 10.1074/jbc.274.46.33002 10551868

39. Ramsahoye BH Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a Proc. Natl Acad. Sci. USA 2000 97 5237 5242 10.1073/pnas.97.10.5237 10805783 PMC25812

40. Mortusewicz O Schermelleh L Walter J Cardoso MC Leonhardt H Recruitment of DNA methyltransferase I to DNA repair sites Proc. Natl Acad. Sci. USA 2005 102 8905 8909 10.1073/pnas.0501034102 15956212 PMC1157029

41. Jones PA Liang G Rethinking how DNA methylation patterns are maintained Nat. Rev. Genet. 2009 10 805 811 10.1038/nrg2651 19789556 PMC2848124

42. Leonhardt H Page AW Weier HU Bestor TH A targeting sequence directs DNA methyltransferase to sites of DNA replication in mammalian nuclei Cell 1992 71 865 873 10.1016/0092-8674(92)90561-P 1423634

43. Hermann A Goyal R Jeltsch A The Dnmt1 DNA-(cytosine-C5)-methyltransferase methylates DNA processively with high preference for hemimethylated target sites J. Biol. Chem. 2004 279 48350 48359 10.1074/jbc.M403427200 15339928

44. Li E Bestor TH Jaenisch R Targeted mutation of the DNA methyltransferase gene results in embryonic lethality Cell 1992 69 915 926 10.1016/0092-8674(92)90611-F 1606615

45. Challen GA Dnmt3a is essential for hematopoietic stem cell differentiation Nat. Genet. 2011 44 23 31 10.1038/ng.1009 22138693 PMC3637952

46. Hata K Okano M Lei H Li E Dnmt3L cooperates with the Dnmt3 family of de novo DNA methyltransferases to establish maternal imprints in mice Development 2002 129 1983 1993 10.1242/dev.129.8.1983 11934864

47. Suetake I Shinozaki F Miyagawa J Takeshima H Tajima S DNMT3L stimulates the DNA methylation activity of Dnmt3a and Dnmt3b through a direct interaction J. Biol. Chem. 2004 279 27816 27823 10.1074/jbc.M400181200 15105426

48. Jia D Jurkowska RZ Zhang X Jeltsch A Cheng X Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation Nature 2007 449 248 251 10.1038/nature06146 17713477 PMC2712830

49. Mizuno S Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia Blood 2001 97 1172 1179 10.1182/blood.V97.5.1172 11222358

50. Li Y The expression of DNA methyltransferase DNMT1, 3A and 3B in acute leukemia and myelodysplastic syndrome Zhonghua Nei Ke Za Zhi 2003 42 688 691 14633461

51. Li YH Expression and clinical significance of DNMT in patients with chronic myeloid leukemia Zhongguo Shi Yan Xue Ye Xue Za Zhi 2015 23 1547 1550 26708868 10.7534/j.issn.1009-2137.2015.06.003

52. Robaina MC Deregulation of DNMT1, DNMT3B and miR-29s in Burkitt lymphoma suggests novel contribution for disease pathogenesis Exp. Mol. Pathol. 2015 98 200 207 10.1016/j.yexmp.2015.03.006 25746661

53. Amara K DNA methyltransferase DNMT3b protein overexpression as a prognostic factor in patients with diffuse large B-cell lymphomas Cancer Sci. 2010 101 1722 1730 10.1111/j.1349-7006.2010.01569.x 20398054 PMC11159814

54. Zhao H Overexpression of DNA methyltransferase 1 as a negative independent prognostic factor in primary gastrointestinal diffuse large B-cell lymphoma treated with CHOP-like regimen and rituximab Oncol. Lett. 2015 9 2307 2312 10.3892/ol.2015.3038 26137062 PMC4467357

55. Qayum I Ashraf M Increased DNA methyltransferase 1 (DNMT1) gene expression in human lymphomas by fluorescent in situ hybridization J. Ayub Med Coll. Abbottabad 2004 16 1 6 15762053

56. Qayum I Ashraf M Dna methyltransferase 1 (DNMT1) gene activity in human lymphomas correlates with aberrant p53 gene expression J. Ayub Med Coll. Abbottabad 2006 18 1 6 16773959

57. Loo SK DNMT1 is predictive of survival and associated with Ki-67 expression in R-CHOP-treated diffuse large B-cell lymphomas Pathology 2017 49 731 739 10.1016/j.pathol.2017.08.009 29074044

58. Lu QY Zhang ZC Hong XL Expression of DNA methyltransferase in myeloma U266 cells and its significance Zhongguo Shi Yan Xue Ye Xue Za Zhi 2011 19 1429 1431 22169297

59. Trowbridge JJ Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains Genes Dev. 2012 26 344 349 10.1101/gad.184341.111 22345515 PMC3289882

60. Wang XX Zhang H Li Y Preliminary study on the role of miR-148a and DNMT1 in the pathogenesis of acute myeloid leukemia Mol. Med Rep. 2019 19 2943 2952 30720097 10.3892/mmr.2019.9913

61. Haque S Vaiselbuh SR Exosomal DNMT1 mRNA transcript is elevated in acute lymphoblastic leukemia which might reprograms leukemia progression Cancer Genet 2022 260–261 57 64 10.1016/j.cancergen.2021.07.004 34426211

62. Vicente-Duenas C Dnmt1 links BCR-ABLp210 to epigenetic tumor stem cell priming in myeloid leukemia Leukemia 2019 33 249 278 10.1038/s41375-018-0192-z 29955131 PMC6326950

63. Wu K Silencing DNMT1 attenuates the effect of WIF-1 gene promoter methylation on the biological behavior of chronic myeloid leukemia K562 cells Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 29 1768 1774 34893108 10.19746/j.cnki.issn.1009-2137.2021.06.013

64. Peters SL Essential role for Dnmt1 in the prevention and maintenance of MYC-induced T-cell lymphomas Mol. Cell Biol. 2013 33 4321 4333 10.1128/MCB.00776-13 24001767 PMC3811897

65. Poole CJ DNMT3B overexpression contributes to aberrant DNA methylation and MYC-driven tumor maintenance in T-ALL and Burkitt’s lymphoma Oncotarget 2017 8 76898 76920 10.18632/oncotarget.20176 29100357 PMC5652751

66. Loo SK Ab Hamid SS Musa M Wong KK DNMT1 is associated with cell cycle and DNA replication gene sets in diffuse large B-cell lymphoma Pathol. Res. Pr. 2018 214 134 143 10.1016/j.prp.2017.10.005 29137822

67. Wang Z Niu XQ Zhou WW Lu QY Effects of DNMT1 gene silencing on methylation of SOCS-1 gene in myeloma cells Zhongguo Shi Yan Xue Ye Xue Za Zhi 2015 23 713 717 26117023 10.7534/j.issn.1009-2137.2015.03.022

68. Li M Methylation of the promoter region of the tight junction protein-1 by DNMT1 induces EMT-like features in multiple myeloma Mol. Ther. Oncolytics 2020 19 197 207 10.1016/j.omto.2020.10.004 33251332 PMC7666313

69. Kim MS Kim YR Yoo NJ Lee SH Mutational analysis of DNMT3A gene in acute leukemias and common solid cancers APMIS 2013 121 85 94 10.1111/j.1600-0463.2012.02940.x 23031157

70. Li W DNMT3A mutations in Chinese childhood acute myeloid leukemia Medicine 2017 96 e7620 10.1097/MD.0000000000007620 28767575 PMC5626129

71. Liu YN DNMT3A mutation analysis in adult patients with acute lymphoblastic leukemia J. Huazhong Univ. Sci. Technol. Med. Sci. 2015 35 337 342 10.1007/s11596-015-1434-1 26072070

72. El Ghannam D Taalab MM Ghazy HF Eneen AF DNMT3A R882 mutations in patients with cytogenetically normal acute myeloid leukemia and myelodysplastic syndrome Blood Cells Mol. Dis. 2014 53 61 66 10.1016/j.bcmd.2014.01.004 24512939

73. Lin J Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome PLoS ONE 2011 6 e26906 10.1371/journal.pone.0026906 22066015 PMC3204995

74. Jankowska AM Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A Blood 2011 118 3932 3941 10.1182/blood-2010-10-311019 21828135 PMC3193268

75. Grossmann V The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL Genes Chromosomes Cancer 2013 52 410 422 10.1002/gcc.22039 23341344

76. Liang DC Cooperating gene mutations in childhood acute myeloid leukemia with special reference on mutations of ASXL1, TET2, IDH1, IDH2, and DNMT3A Blood 2013 121 2988 2995 10.1182/blood-2012-06-436782 23365461

77. Zhou JF Analysis of DNMT3a mutation in childhood acute myeloid leukemia Zhongguo Shi Yan Xue Ye Xue Za Zhi 2012 20 1297 1301 23257420

78. Ewalt M DNMT3a mutations in high-risk myelodysplastic syndrome parallel those found in acute myeloid leukemia Blood Cancer J. 2011 1 e9 10.1038/bcj.2011.7 22829128 PMC3255278

79. Thol F DNMT3A mutations are rare in childhood acute myeloid leukemia Haematologica 2011 96 1238 1240 10.3324/haematol.2011.046839 21685466 PMC3148921

80. Eckstein OS Mixed-phenotype acute leukemia (MPAL) exhibits frequent mutations in DNMT3A and activated signaling genes Exp. Hematol. 2016 44 740 744 10.1016/j.exphem.2016.05.003 27208809 PMC4956537

81. Sirirat T Mutation analysis of isocitrate dehydrogenase (IDH1/2) and DNA methyltransferase 3A (DNMT3A) in Thai patients with newly diagnosed acute myeloid leukemia Asian Pac. J. Cancer Prev. 2017 18 413 420 28345823 10.22034/APJCP.2017.18.2.413 PMC5454736

82. Sasaki K Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia Cancer 2020 126 765 774 10.1002/cncr.32566 31742675

83. Park DJ Characteristics of DNMT3A mutations in acute myeloid leukemia Blood Res. 2020 55 17 26 10.5045/br.2020.55.1.17 32269971 PMC7106122

84. Lu Q Chen Y Wang H Li Z DNMT3A mutations and clinical features in Chinese patients with acute myeloid leukemia Cancer Cell Int 2013 13 1 10.1186/1475-2867-13-1 23305405 PMC3605177

85. Gou H The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China Tumour Biol. 2016 37 7357 7370 10.1007/s13277-015-4601-x 26676635

86. Pezzi A DNMT3A mutations in patients with acute myeloid leukemia in South Brazil Adv. Hematol. 2012 2012 697691 10.1155/2012/697691 23193409 PMC3502761

87. Gaidzik VI Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG) Blood 2013 121 4769 4777 10.1182/blood-2012-10-461624 23632886

88. El Gammal MM Clinical effect of combined mutations in DNMT3A, FLT3-ITD, and NPM1 among Egyptian acute myeloid leukemia patients Clin. Lymphoma Myeloma Leuk. 2019 19 e281 e290 10.1016/j.clml.2019.02.001 30926392

89. Markova J Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia Eur. J. Haematol. 2012 88 128 135 10.1111/j.1600-0609.2011.01716.x 21967546

90. Ley TJ DNMT3A mutations in acute myeloid leukemia N. Engl. J. Med. 2010 363 2424 2433 10.1056/NEJMoa1005143 21067377 PMC3201818

91. Elrhman H El-Meligui YM Elalawi SM Prognostic impact of concurrent DNMT3A, FLT3 and NPM1 gene mutations in acute myeloid leukemia patients Clin. Lymphoma Myeloma Leuk. 2021 21 e960 e969 10.1016/j.clml.2021.07.011 34376373

92. Chen S Bioinformatics analysis identifies key genes and pathways in acute myeloid leukemia associated with DNMT3A mutation Biomed. Res. Int. 2020 2020 9321630 10.1155/2020/9321630 33299888 PMC7707947

93. Kumar D Mehta A Panigrahi MK Nath S Saikia KK DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations Hematol. Oncol. Stem Cell Ther. 2018 11 82 89 10.1016/j.hemonc.2017.09.004 29079128

94. Zhang Q Wu X Cao J Gao F Huang K Association between increased mutation rates in DNMT3A and FLT3-ITD and poor prognosis of patients with acute myeloid leukemia Exp. Ther. Med. 2019 18 3117 3124 31572552 10.3892/etm.2019.7891 PMC6755468

95. Thol F Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia J. Clin. Oncol. 2011 29 2889 2896 10.1200/JCO.2011.35.4894 21670448

96. Saygin C Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1 Blood Cancer J. 2018 8 4 10.1038/s41408-017-0040-9 29321554 PMC5802549

97. Hou HA DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications Blood 2012 119 559 568 10.1182/blood-2011-07-369934 22077061

98. Loghavi S Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations J. Hematol. Oncol. 2014 7 74 10.1186/s13045-014-0074-4 25281355 PMC4197326

99. Gale RE Simpson’s paradox and the impact of different DNMT3A mutations on outcome in younger adults with acute myeloid leukemia J. Clin. Oncol. 2015 33 2072 2083 10.1200/JCO.2014.59.2022 25964253

100. Bullinger L Döhner K Döhner H Genomics of acute myeloid leukemia diagnosis and pathways J. Clin. Oncol. 2017 35 934 946 10.1200/JCO.2016.71.2208 28297624

101. Patnaik MM DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia Am. J. Hematol. 2017 92 56 61 10.1002/ajh.24581 27733013

102. Bond J DNMT3A mutation is associated with increased age and adverse outcome in adult T-cell acute lymphoblastic leukemia Haematologica 2019 104 1617 1625 10.3324/haematol.2018.197848 30655366 PMC6669163

103. Aref S El Menshawy N El-Ghonemy MS Zeid TA El-Baiomy MA Clinicopathologic effect of DNMT3A mutation in adult T-cell acute lymphoblastic leukemia Clin. Lymphoma Myeloma Leuk. 2016 16 43 48 10.1016/j.clml.2015.11.003 26711182

104. Lin N Biologico-clinical significance of DNMT3A variants expression in acute myeloid leukemia Biochem Biophys. Res. Commun. 2017 494 270 277 10.1016/j.bbrc.2017.10.041 29024628

105. Fried I Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia Haematologica 2012 97 246 250 10.3324/haematol.2011.051581 21993668 PMC3269485

106. Jost E Epimutations mimic genomic mutations of DNMT3A in acute myeloid leukemia Leukemia 2014 28 1227 1234 10.1038/leu.2013.362 24280869 PMC4051212

107. Ibrahem L Mahfouz R Elhelw L Abdsalam EM & Soliman, R. Prognostic significance of DNMT3A mutations in patients with acute myeloid leukemia Blood Cells Mol. Dis. 2015 54 84 89 10.1016/j.bcmd.2014.07.015 25172541

108. Ahmad F Mohota R Sanap S Mandava S Das BR Molecular evaluation of DNMT3A and IDH1/2 gene mutation: frequency, distribution pattern and associations with additional molecular markers in normal karyotype Indian acute myeloid leukemia patients Asian Pac. J. Cancer Prev. 2014 15 1247 1253 10.7314/APJCP.2014.15.3.1247 24606448

109. Marcucci G Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia J. Clin. Oncol. 2012 30 742 750 10.1200/JCO.2011.39.2092 22291079 PMC3295550

110. Wakita S Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia Leukemia 2013 27 1044 1052 10.1038/leu.2012.317 23135354

111. Masuda S DNMT3A mutations in acute myeloid leukemia: impact on low-risk patients with CEBPA mutations J. Clin. Oncol. 2011 29 4592 4593 10.1200/JCO.2011.38.2127 22042957

112. Badar T Atallah E Do histone deacytelase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes? Expert Opin. Investig. Drugs 2021 30 665 673 10.1080/13543784.2021.1915986 33836635

113. Zhang TJ Zhang LC Xu ZJ Zhou JD Expression and prognosis analysis of DNMT family in acute myeloid leukemia Aging 2020 12 14677 14690 10.18632/aging.103520 32597790 PMC7425446

114. Huang X Gene expression profiling of the DNMT3A R882 mutation in acute leukemia Oncol. Lett. 2013 6 268 274 10.3892/ol.2013.1347 23946816 PMC3742503

115. Lauber C Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients Sci. Rep. 2020 10 12761 10.1038/s41598-020-69691-8 32728112 PMC7391693

116. Zhang X Clinical and biological implications of IDH1/2 in acute myeloid leukemia with DNMT3A(mut) Cancer Manag Res. 2018 10 2457 2466 10.2147/CMAR.S157632 30122995 PMC6084071

117. Sehgal AR DNMT3A mutational status affects the results of dose-escalated induction therapy in acute myelogenous leukemia Clin. Cancer Res. 2015 21 1614 1620 10.1158/1078-0432.CCR-14-0327 25609058 PMC4383675

118. Xu Y Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations Am. J. Hematol. 2015 90 992 997 10.1002/ajh.24135 26223865

119. Berenstein R Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemia J. Exp. Clin. Cancer Res. 2015 34 55 10.1186/s13046-015-0173-2 25994761 PMC4443651

120. Gaidzik VI DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia Leukemia 2018 32 30 37 10.1038/leu.2017.200 28643785

121. Sun Y Persistent DNMT3A mutation burden in DNMT3A mutated adult cytogenetically normal acute myeloid leukemia patients in long-term remission Leuk. Res. 2016 49 102 107 10.1016/j.leukres.2016.09.001 27626217

122. Ottone T Longitudinal detection of DNMT3A(R882H) transcripts in patients with acute myeloid leukemia Am. J. Hematol. 2018 93 E120 e123 10.1002/ajh.25061 29417611

123. Ardestani MT FLT3-ITD compared with DNMT3A R882 mutation is a more powerful independent inferior prognostic factor in adult acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation: a retrospective cohort study Turk. J. Haematol. 2018 35 158 167 29786546 10.4274/tjh.2018.0017 PMC6110452

124. Tang SH Effect of FLT3-ITD with DNMT3A R882 double-mutation on the prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation Zhonghua Xue Ye Xue Za Zhi 2018 39 552 557 30122013 10.3760/cma.j.issn.0253-2727.2018.07.005 PMC7342207

125. Ahn JS DNMT3A R882 mutation with FLT3-ITD Positivity is an extremely poor prognostic factor in patients with normal-karyotype acute myeloid leukemia after allogeneic hematopoietic cell transplantation Biol. Blood Marrow Transpl. 2016 22 61 70 10.1016/j.bbmt.2015.07.030 26234722

126. Kim T Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy Leuk. Res. 2017 59 142 148 10.1016/j.leukres.2017.06.009 28667884

127. Ostronoff F Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report Leukemia 2013 27 238 241 10.1038/leu.2012.168 22722750 PMC4457316

128. Couronne L Bastard C Bernard OA TET2 and DNMT3A mutations in human T-cell lymphoma N. Engl. J. Med. 2012 366 95 96 10.1056/NEJMc1111708 22216861

129. Yao WQ Angioimmunoblastic T-cell lymphoma contains multiple clonal T-cell populations derived from a common TET2 mutant progenitor cell J. Pathol. 2020 250 346 357 10.1002/path.5376 31859368 PMC7064999

130. Nicolae A Nodal cytotoxic peripheral T-cell lymphoma occurs frequently in the clinical setting of immunodysregulation and is associated with recurrent epigenetic alterations Mod. Pathol. 2022 35 1126 1136 10.1038/s41379-022-01022-w 35301414

131. Sakata-Yanagimoto M Somatic RHOA mutation in angioimmunoblastic T cell lymphoma Nat. Genet. 2014 46 171 175 10.1038/ng.2872 24413737

132. Odejide O A targeted mutational landscape of angioimmunoblastic T-cell lymphoma Blood 2014 123 1293 1296 10.1182/blood-2013-10-531509 24345752 PMC4260974

133. Lemonnier F Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma Blood Adv. 2021 5 539 548 10.1182/bloodadvances.2020003081 33496747 PMC7839364

134. Mondejar R Molecular basis of targeted therapy in T/NK-cell lymphoma/leukemia: a comprehensive genomic and immunohistochemical analysis of a panel of 33 cell lines PLoS ONE 2017 12 e0177524 10.1371/journal.pone.0177524 28505169 PMC5432176

135. Zhang J Identification of clinical molecular targets for childhood Burkitt lymphoma Transl. Oncol. 2020 13 100855 10.1016/j.tranon.2020.100855 32947237 PMC7502376

136. Beltzung F Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorders: a clinical, pathologic, and molecular study of 60 cases presenting with a single lesion: a multicenter study of the french cutaneous lymphoma study group Am. J. Surg. Pathol. 2020 44 862 872 10.1097/PAS.0000000000001470 32271188

137. Mutzbauer G SYK expression in monomorphic epitheliotropic intestinal T-cell lymphoma Mod. Pathol. 2018 31 505 516 10.1038/modpathol.2017.145 29052597

138. Lee MJ Genome-defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B-cell lymphoma Cancer 2020 126 3493 3503 10.1002/cncr.32866 32469082 PMC7494053

139. Suehara Y Mutations found in cell-free DNAs of patients with malignant lymphoma at remission can derive from clonal hematopoiesis Cancer Sci. 2019 110 3375 3381 10.1111/cas.14176 31436356 PMC6778636

140. Sakata-Yanagimoto M Detection of the circulating tumor DNAs in angioimmunoblastic T- cell lymphoma Ann. Hematol. 2017 96 1471 1475 10.1007/s00277-017-3038-2 28634614

141. Song J The application of NextGen sequencing in the diagnosis of myeloid neoplasms in myeloma patients with cytopenia Clin. Lymphoma Myeloma Leuk. 2022 22 e414 e426 10.1016/j.clml.2021.12.008 34998786

142. Mouhieddine TH Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant Nat. Commun. 2020 11 2996 10.1038/s41467-020-16805-5 32533060 PMC7293239

143. Luzna P Global DNA methylation and increased DNMT3A expression in multiple myeloma patients Biomed. Pap. 2022 10.5507/bp.2022.006 35173353

144. Heuck CJ Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis J. Immunol. 2013 190 2966 2975 10.4049/jimmunol.1202493 23408834 PMC4581585

145. Dai YJ Conditional knockin of Dnmt3a R878H initiates acute myeloid leukemia with mTOR pathway involvement Proc. Natl Acad. Sci. USA 2017 114 5237 5242 10.1073/pnas.1703476114 28461508 PMC5441829

146. Ferreira HJ DNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemia Oncogene 2016 35 3079 3082 10.1038/onc.2015.359 26434589 PMC4705435

147. Lu R Epigenetic perturbations by Arg882-mutated DNMT3A potentiate aberrant stem cell gene-expression program and acute leukemia development Cancer Cell 2016 30 92 107 10.1016/j.ccell.2016.05.008 27344947 PMC4945461

148. Bera R Genetic and epigenetic perturbations by DNMT3A-R882 mutants impaired apoptosis through augmentation of PRDX2 in myeloid leukemia cells Neoplasia 2018 20 1106 1120 10.1016/j.neo.2018.08.013 30245403 PMC6153424

149. Xu J DNMT3A Arg882 mutation drives chronic myelomonocytic leukemia through disturbing gene expression/DNA methylation in hematopoietic cells Proc. Natl Acad. Sci. USA 2014 111 2620 2625 10.1073/pnas.1400150111 24497509 PMC3932885

150. Nguyen TB Identification of cell-type-specific mutations in nodal T-cell lymphomas Blood Cancer J. 2017 7 e516 10.1038/bcj.2016.122 28157189 PMC5301031

151. Ohshima K Miyoshi H Yamada K The microenvironment and immune status of peripheral T-cell lymphoma: focusing on AITL and ATLL Rinsho Ketsueki 2018 59 574 587 29877249 10.11406/rinketsu.59.574

152. Meyer SE DNMT3A haploinsufficiency transforms FLT3ITD myeloproliferative disease into a rapid, spontaneous, and fully penetrant acute myeloid leukemia Cancer Disco. 2016 6 501 515 10.1158/2159-8290.CD-16-0008 PMC4861898 27016502

153. Chang YI Dnmt3a haploinsufficiency cooperates with oncogenic Kras to promote an early-onset T-cell acute lymphoblastic leukemia Am. J. Transl. Res. 2017 9 1326 1334 28386358 PMC5376023

154. Haney SL Promoter hypomethylation and expression is conserved in mouse chronic lymphocytic leukemia induced by decreased or inactivated Dnmt3a Cell Rep. 2016 15 1190 1201 10.1016/j.celrep.2016.04.004 27134162 PMC4864108

155. Haney SL Dnmt3a Is a haploinsufficient tumor suppressor in CD8+ peripheral T cell lymphoma PLoS Genet 2016 12 e1006334 10.1371/journal.pgen.1006334 27690235 PMC5045215

156. Zhang X Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis Blood 2020 135 845 856 10.1182/blood.2019003330 31932841 PMC7068035

157. Lewis NE Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms Blood Adv. 2020 4 2261 2271 10.1182/bloodadvances.2020001636 32442302 PMC7252546

158. Wang C IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma Blood 2015 126 1741 1752 10.1182/blood-2015-05-644591 26268241 PMC4600014

159. Laginestra MA Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified Mod. Pathol. 2020 33 179 187 10.1038/s41379-019-0279-8 31028364 PMC6994417

160. Guryanova OA DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling Nat. Med. 2016 22 1488 1495 10.1038/nm.4210 27841873 PMC5359771

161. Chen YY Mutant DNMT3A clone evading chemotherapy and infiltrating central nervous system in a patient with molecularly good-risk acute myeloid leukemia Ann. Hematol. 2014 93 1441 1442 10.1007/s00277-013-1985-9 24337413

162. Scheller M Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response Nat. Cancer 2021 2 527 544 10.1038/s43018-021-00213-9 35122024

163. Metzeler KH DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia Leukemia 2012 26 1106 1107 10.1038/leu.2011.342 22124213 PMC3696987

164. Rau RE DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia Blood 2016 128 971 981 10.1182/blood-2015-11-684225 27335278 PMC4990856

165. Que Y Study on the immune escape mechanism of acute myeloid leukemia with DNMT3A mutation Front. Immunol. 2021 12 653030 10.3389/fimmu.2021.653030 34093541 PMC8173207

166. Li Y The C46359T polymorphism of DNMT3B promoter gene and pathogenesis of acute leukemia Zhonghua Nei Ke Za Zhi 2005 44 588 591 16194411

167. Niederwieser C Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia Leukemia 2015 29 567 575 10.1038/leu.2014.267 25204569 PMC4351165

168. Zheng Q Association between DNA methyltransferases 3B gene polymorphisms and the susceptibility to acute myeloid leukemia in Chinese Han population PLoS ONE 2013 8 e74626 10.1371/journal.pone.0074626 24069326 PMC3775800

169. Ait Boujmia OK Nadifi S Dehbi H Lamchahab M Quessar A The influence of DNMT3A and DNMT3B gene polymorphisms on acute myeloid leukemia risk in a Moroccan population Curr. Res. Transl. Med. 2020 68 191 195 10.1016/j.retram.2020.08.001 32912818

170. Morscio J Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases Am. J. Surg. Pathol. 2014 38 875 886 10.1097/PAS.0000000000000234 24832164

171. Wang G Synergetic effects of DNA methylation and histone modification during mouse induced pluripotent stem cell generation Sci. Rep. 2017 7 39527 10.1038/srep39527 28155862 PMC5290738

172. Zheng Y Loss of Dnmt3b accelerates MLL-AF9 leukemia progression Leukemia 2016 30 2373 2384 10.1038/leu.2016.112 27133822

173. Tate PH Bird AP Effects of DNA methylation on DNA-binding proteins and gene expression Curr. Opin. Genet. Dev. 1993 3 226 231 10.1016/0959-437X(93)90027-M 8504247

174. Nan X Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex Nature 1998 393 386 389 10.1038/30764 9620804

175. Schubeler D Function and information content of DNA methylation Nature 2015 517 321 326 10.1038/nature14192 25592537

176. Mahmood N Rabbani SA DNA methylation readers and cancer: mechanistic and therapeutic applications Front. Oncol. 2019 9 489 10.3389/fonc.2019.00489 31245293 PMC6579900

177. Meehan RR Lewis JD McKay S Kleiner EL Bird AP Identification of a mammalian protein that binds specifically to DNA containing methylated CpGs Cell 1989 58 499 507 10.1016/0092-8674(89)90430-3 2758464

178. Nan X Meehan RR Bird A Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2 Nucleic Acids Res 1993 21 4886 4892 10.1093/nar/21.21.4886 8177735 PMC311401

179. Hendrich B Bird A Identification and characterization of a family of mammalian methyl-CpG binding proteins Mol. Cell Biol. 1998 18 6538 6547 10.1128/MCB.18.11.6538 9774669 PMC109239

180. Klose RJ DNA binding selectivity of MeCP2 due to a requirement for A/T sequences adjacent to methyl-CpG Mol. Cell 2005 19 667 678 10.1016/j.molcel.2005.07.021 16137622

181. Lopez-Serra L Esteller M Proteins that bind methylated DNA and human cancer: reading the wrong words Br. J. Cancer 2008 98 1881 1885 10.1038/sj.bjc.6604374 18542062 PMC2441952

182. Hashimoto H Recognition and potential mechanisms for replication and erasure of cytosine hydroxymethylation Nucleic Acids Res 2012 40 4841 4849 10.1093/nar/gks155 22362737 PMC3367191

183. Yildirim O Mbd3/NURD complex regulates expression of 5-hydroxymethylcytosine marked genes in embryonic stem cells Cell 2011 147 1498 1510 10.1016/j.cell.2011.11.054 22196727 PMC3252821

184. Laget S The human proteins MBD5 and MBD6 associate with heterochromatin but they do not bind methylated DNA PLoS ONE 2010 5 e11982 10.1371/journal.pone.0011982 20700456 PMC2917364

185. Parry L Clarke AR The roles of the methyl-CpG binding proteins in cancer Genes Cancer 2011 2 618 630 10.1177/1947601911418499 21941618 PMC3174265

186. Schultz DC Ayyanathan K Negorev D Maul GG Rauscher FJ 3rd SETDB1: a novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger proteins Genes Dev. 2002 16 919 932 10.1101/gad.973302 11959841 PMC152359

187. Falandry C CLLD8/KMT1F is a lysine methyltransferase that is important for chromosome segregation J. Biol. Chem. 2010 285 20234 20241 10.1074/jbc.M109.052399 20404330 PMC2888436

188. Li ZY Corrigendum to "the long noncoding RNA MEG3 and its target miR-147 regulate JAK/STAT pathway in advanced chronic myeloid leukemia" EBioMedicine 2018 37 569 10.1016/j.ebiom.2018.10.049 30392744 PMC6286865

189. Li Q Role of one-carbon metabolizing pathway genes and gene-nutrient interaction in the risk of non-Hodgkin lymphoma Cancer Causes Control 2013 24 1875 1884 10.1007/s10552-013-0264-3 23913011 PMC3951097

190. Sharma ND Epigenetic silencing of SOCS5 potentiates JAK-STAT signaling and progression of T-cell acute lymphoblastic leukemia Cancer Sci. 2019 110 1931 1946 10.1111/cas.14021 30974024 PMC6549933

191. Wang Z Zhang J Zhang Y Srivenugopal KS Lim SH SPAN-XB core promoter sequence is regulated in myeloma cells by specific CpG dinucleotides associated with the MeCP2 protein Int. J. Cancer 2006 119 2878 2884 10.1002/ijc.22259 17036333

192. Piazza R Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex Neoplasia 2013 15 511 522 10.1593/neo.121784 23633923 PMC3638354

193. Liang X Xu Y Xu K Liu J Qian X B1, a novel amonafide analogue, overcomes the resistance conferred by Bcl-2 in human promyelocytic leukemia HL60 cells Mol. Cancer Res. 2010 8 1619 1632 10.1158/1541-7786.MCR-10-0341 21076048

194. Dinis J DNA damage response in imatinib resistant chronic myeloid leukemia K562 cells Leuk. Lymphoma 2012 53 2004 2014 10.3109/10428194.2012.681654 22475343

195. Hudson NO Buck-Koehntop BA Zinc finger readers of methylated DNA Molecules 2018 23 2555 10.3390/molecules23102555 30301273 PMC6222495

196. Prokhortchouk A The p120 catenin partner Kaiso is a DNA methylation-dependent transcriptional repressor Genes Dev. 2001 15 1613 1618 10.1101/gad.198501 11445535 PMC312733

197. Filion GJ A family of human zinc finger proteins that bind methylated DNA and repress transcription Mol. Cell Biol. 2006 26 169 181 10.1128/MCB.26.1.169-181.2006 16354688 PMC1317629

198. Daniel JM Reynolds AB The catenin p120(ctn) interacts with Kaiso, a novel BTB/POZ domain zinc finger transcription factor Mol. Cell Biol. 1999 19 3614 3623 10.1128/MCB.19.5.3614 10207085 PMC84161

199. Daniel JM Spring CM Crawford HC Reynolds AB Baig A The p120(ctn)-binding partner Kaiso is a bi-modal DNA-binding protein that recognizes both a sequence-specific consensus and methylated CpG dinucleotides Nucleic Acids Res 2002 30 2911 2919 10.1093/nar/gkf398 12087177 PMC117053

200. Cofre J Menezes JR Pizzatti L Abdelhay E Knock-down of Kaiso induces proliferation and blocks granulocytic differentiation in blast crisis of chronic myeloid leukemia Cancer Cell Int 2012 12 28 10.1186/1475-2867-12-28 22709531 PMC3461418

201. Xue X Zhang J Lan H Xu Y Wang H Kaiso protects human umbilical vein endothelial cells against apoptosis by differentially regulating the expression of B-cell CLL/lymphoma 2 family members Sci. Rep. 2017 7 7116 10.1038/s41598-017-07559-0 28769046 PMC5540925

202. Gu C Identification of berberine as a novel drug for the treatment of multiple myeloma via targeting UHRF1 BMC Biol. 2020 18 33 10.1186/s12915-020-00766-8 32213189 PMC7098108

203. Arita K Ariyoshi M Tochio H Nakamura Y Shirakawa M Recognition of hemi-methylated DNA by the SRA protein UHRF1 by a base-flipping mechanism Nature 2008 455 818 821 10.1038/nature07249 18772891

204. Avvakumov GV Structural basis for recognition of hemi-methylated DNA by the SRA domain of human UHRF1 Nature 2008 455 822 825 10.1038/nature07273 18772889

205. Bostick M UHRF1 plays a role in maintaining DNA methylation in mammalian cells Science 2007 317 1760 1764 10.1126/science.1147939 17673620

206. Sharif J The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNA Nature 2007 450 908 912 10.1038/nature06397 17994007

207. Mori T Li Y Hata H Ono K Kochi H NIRF, a novel RING finger protein, is involved in cell-cycle regulation Biochem Biophys. Res. Commun. 2002 296 530 536 10.1016/S0006-291X(02)00890-2 12176013

208. Simonetti G Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery Cancer 2019 125 712 725 10.1002/cncr.31837 30480765 PMC6587451

209. Kim KB H3K9 methyltransferase G9a negatively regulates UHRF1 transcription during leukemia cell differentiation Nucleic Acids Res 2015 43 3509 3523 10.1093/nar/gkv183 25765655 PMC4402520

210. Yao J Luo Y Zeng C He H Zhang X UHRF1 regulates the transcriptional repressor HBP1 through MIF in T acute lymphoblastic leukemia Oncol. Rep. 2021 46 131 10.3892/or.2021.8082 34013373

211. Alhosin M Thymoquinone and difluoromethylornithine (DFMO) Synergistically induce apoptosis of human acute T lymphoblastic leukemia Jurkat cells through the modulation of epigenetic pathways Technol. Cancer Res. Treat. 2020 19 1533033820947489 10.1177/1533033820947489 32912061 PMC7488875

212. Alhosin M Induction of apoptosis by thymoquinone in lymphoblastic leukemia Jurkat cells is mediated by a p73-dependent pathway which targets the epigenetic integrator UHRF1 Biochem. Pharm. 2010 79 1251 1260 10.1016/j.bcp.2009.12.015 20026309

213. Guan D Factor D Liu Y Wang Z Kao HY The epigenetic regulator UHRF1 promotes ubiquitination-mediated degradation of the tumor-suppressor protein promyelocytic leukemia protein Oncogene 2013 32 3819 3828 10.1038/onc.2012.406 22945642 PMC3578017

214. Mayer W Niveleau A Walter J Fundele R Haaf T Demethylation of the zygotic paternal genome Nature 2000 403 501 502 10.1038/35000656 10676950

215. Oswald J Active demethylation of the paternal genome in the mouse zygote Curr. Biol. 2000 10 475 478 10.1016/S0960-9822(00)00448-6 10801417

216. Paroush Z Keshet I Yisraeli J Cedar H Dynamics of demethylation and activation of the alpha-actin gene in myoblasts Cell 1990 63 1229 1237 10.1016/0092-8674(90)90418-E 2261641

217. Zhang F Pomerantz JH Sen G Palermo AT Blau HM Active tissue-specific DNA demethylation conferred by somatic cell nuclei in stable heterokaryons Proc. Natl Acad. Sci. USA 2007 104 4395 4400 10.1073/pnas.0700181104 17360535 PMC1838613

218. Bhutani N Reprogramming towards pluripotency requires AID-dependent DNA demethylation Nature 2010 463 1042 1047 10.1038/nature08752 20027182 PMC2906123

219. Inoue A Zhang Y Replication-dependent loss of 5-hydroxymethylcytosine in mouse preimplantation embryos Science 2011 334 194 10.1126/science.1212483 21940858 PMC3799877

220. Iqbal K Jin SG Pfeifer GP Szabó PE Reprogramming of the paternal genome upon fertilization involves genome-wide oxidation of 5-methylcytosine Proc. Natl Acad. Sci. USA 2011 108 3642 3647 10.1073/pnas.1014033108 21321204 PMC3048122

221. Moore LD Le T Fan G DNA methylation and its basic function Neuropsychopharmacology 2013 38 23 38 10.1038/npp.2012.112 22781841 PMC3521964

222. Huang H TET1 plays an essential oncogenic role in MLL-rearranged leukemia Proc. Natl Acad. Sci. USA 2013 110 11994 11999 10.1073/pnas.1310656110 23818607 PMC3718141

223. Zhang T Zhao Y Zhao Y Zhou J Expression and prognosis analysis of TET family in acute myeloid leukemia Aging 2020 12 5031 5047 10.18632/aging.102928 32209730 PMC7138570

224. Huang Y Comprehensively analyze the expression and prognostic role for ten-eleven translocations (TETs) in acute myeloid leukemia Transl. Cancer Res. 2020 9 7259 7283 10.21037/tcr-20-3149 35117329 PMC8798779

225. Vitkeviciene A Skliute G Zucenka A Borutinskaite V Navakauskiene R Potential Prognostic Markers for Relapsed/Refractory vs. Responsive Acute Myeloid Leukemia Cancers 2022 14 2752 10.3390/cancers14112752 35681732 PMC9179343

226. Wang J High expression of TET1 predicts poor survival in cytogenetically normal acute myeloid leukemia from two cohorts EBioMedicine 2018 28 90 96 10.1016/j.ebiom.2018.01.031 29402726 PMC5835576

227. Van Damme M Characterization of TET and IDH gene expression in chronic lymphocytic leukemia: comparison with normal B cells and prognostic significance Clin. Epigenet. 2016 8 132 10.1186/s13148-016-0298-y PMC5141649 27980696

228. Yeh CH Erratum to: ‘Mutation of epigenetic regulators TET2 and MLL3 in patients with HTLV-I-induced acute adult T-cell leukemia Mol. Cancer 2016 15 20 10.1186/s12943-016-0504-8 26936184 PMC4774154

229. Dolnik A Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing Blood 2012 120 e83 e92 10.1182/blood-2011-12-401471 22976956

230. Kalender Atak Z High accuracy mutation detection in leukemia on a selected panel of cancer genes PLoS ONE 2012 7 e38463 10.1371/journal.pone.0038463 22675565 PMC3366948

231. Bamezai S TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition Leukemia 2021 35 389 403 10.1038/s41375-020-0864-3 32409690

232. Wang J Analysis of TET2 and EZH2 gene functions in chromosome instability in acute myeloid leukemia Sci. Rep. 2020 10 2706 10.1038/s41598-020-59365-w 32066746 PMC7026035

233. Yamazaki J Hypomethylation of TET2 target genes identifies a curable subset of acute myeloid leukemia J. Natl Cancer Inst. 2015 108 djv323 26568194 10.1093/jnci/djv323 PMC4862435

234. Damm F TET2 mutations in cytogenetically normal acute myeloid leukemia: clinical implications and evolutionary patterns Genes Chromosomes Cancer 2014 53 824 832 10.1002/gcc.22191 24898826

235. Metzeler KH TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a cancer and leukemia group B study J. Clin. Oncol. 2011 29 1373 1381 10.1200/JCO.2010.32.7742 21343549 PMC3084003

236. Tian X TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutations Int J. Hematol. 2014 100 96 104 10.1007/s12185-014-1595-x 24859829

237. Gaidzik VI TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group J. Clin. Oncol. 2012 30 1350 1357 10.1200/JCO.2011.39.2886 22430270

238. Weissmann S Landscape of TET2 mutations in acute myeloid leukemia Leukemia 2012 26 934 942 10.1038/leu.2011.326 22116554

239. Ponciano-Gomez A Mutations in TET2 and DNMT3A genes are associated with changes in global and gene-specific methylation in acute myeloid leukemia Tumour Biol. 2017 39 1010428317732181 10.1177/1010428317732181 28992762

240. Shaikh ARK TET2 mutations in acute myeloid leukemia: a comprehensive study in patients of Sindh, Pakistan PeerJ 2021 9 e10678 10.7717/peerj.10678 33643703 PMC7901355

241. Wei JF The incidence of TET2 gene mutation and its clinical significance in acute myeloid leukemia patients Zhonghua Xue Ye Xue Za Zhi 2011 32 304 307 21729597

242. Ohgami RS Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations Mod. Pathol. 2015 28 706 714 10.1038/modpathol.2014.160 25412851 PMC5436901

243. Nibourel O Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission Blood 2010 116 1132 1135 10.1182/blood-2009-07-234484 20489055

244. Chehreghani Z Detection of TET2 mutation in patients with de novo acute myeloid leukemia: a mutation analysis of 51 Iranian patients Asian Pac. J. Cancer Prev. 2022 23 803 806 10.31557/APJCP.2022.23.3.803 35345350 PMC9360970

245. Ahn JS Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype Haematologica 2015 100 e351 e353 10.3324/haematol.2015.126227 26045292 PMC4800711

246. Chou WC TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics Blood 2011 118 3803 3810 10.1182/blood-2011-02-339747 21828143

247. Shimoda K TET2 mutation in adult T-cell leukemia/lymphoma J. Clin. Exp. Hematop 2015 55 145 149 10.3960/jslrt.55.145 26763362

248. Marçais A Adult T cell leukemia aggressivenness correlates with loss of both 5-hydroxymethylcytosine and TET2 expression Oncotarget 2017 8 52256 52268 10.18632/oncotarget.13665 28881727 PMC5581026

249. Olson TL Frequent somatic TET2 mutations in chronic NK-LGL leukemia with distinct patterns of cytopenias Blood 2021 138 662 673 10.1182/blood.2020005831 33786584 PMC8394905

250. Makishima H CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia Blood 2011 117 e198 e206 10.1182/blood-2010-06-292433 21346257 PMC3110035

251. Hamed NA Elhalawani NA Kassem HS Ayad MW Dammag EA The prognostic significance of TET2 single nucleotide polymorphism in Egyptian chronic myeloid leukemia Mediterr. J. Hematol. Infect. Dis. 2020 12 e2020004 10.4084/mjhid.2020.004 31934314 PMC6951353

252. Kosmider O TET2 mutations in secondary acute myeloid leukemias: a French retrospective study Haematologica 2011 96 1059 1063 10.3324/haematol.2011.040840 21508122 PMC3128227

253. Konstandin N Genomic 5-hydroxymethylcytosine levels correlate with TET2 mutations and a distinct global gene expression pattern in secondary acute myeloid leukemia Leukemia 2011 25 1649 1652 10.1038/leu.2011.134 21625234

254. Patnaik MM Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia Blood Cancer J. 2016 6 e385 10.1038/bcj.2015.113 26771811 PMC4742630

255. Coltro G Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients Leukemia 2020 34 1407 1421 10.1038/s41375-019-0690-7 31836856

256. Cui Y Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia Exp. Hematol. Oncol. 2015 4 14 10.1186/s40164-015-0009-y 26019984 PMC4445804

257. Perez C TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia PLoS ONE 2012 7 e31605 10.1371/journal.pone.0031605 22328940 PMC3273467

258. Zhao W The prognostic value of the interaction between ASXL1 and TET2 gene mutations in patients with chronic myelomonocytic leukemia: a meta-analysis Hematology 2022 27 367 378 10.1080/16078454.2021.1958486 35306971

259. Patnaik MM Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance Blood Cancer J. 2016 6 e472 10.1038/bcj.2016.82 27662201 PMC5056973

260. Grossmann V Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance Leukemia 2011 25 877 879 10.1038/leu.2011.10 21339759

261. Cui Y TET2 mutations were predictive of inferior prognosis in the presence of ASXL1 mutations in patients with chronic myelomonocytic leukemia Stem Cell Investig. 2016 3 50 10.21037/sci.2016.09.04 27777939 PMC5067368

262. Kosmider O TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia Haematologica 2009 94 1676 1681 10.3324/haematol.2009.011205 19797729 PMC2791942

263. Yang YC Clinical significance of truncated mutant ΔJBP of TET2 gene in patients with acute myeloid leukemia Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 29 1011 1018 34362476 10.19746/j.cnki.issn.1009-2137.2021.04.001

264. Li YW Analysis of clinical significance and prognostic impact of TET2 single nucleotide polymorphism I1762V in patients with acute myeloid leukemia Zhonghua Xue Ye Xue Za Zhi 2022 43 241 246 35405783 10.3760/cma.j.issn.0253-2727.2022.03.010 PMC9072067

265. Wang X Correlation of TET2 SNP rs2454206 with improved survival in children with acute myeloid leukemia featuring intermediate-risk cytogenetics Genes Chromosomes Cancer 2018 57 379 386 10.1002/gcc.22540 29664232

266. Mohamed AM TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML Leuk. Res. 2017 56 21 28 10.1016/j.leukres.2017.01.012 28167452

267. Itzykson R Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias Leukemia 2011 25 1147 1152 10.1038/leu.2011.71 21494260

268. Cull AH Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia Leuk. Res. 2018 65 5 13 10.1016/j.leukres.2017.12.003 29227812

269. Hernández-Sánchez M TET2 overexpression in chronic lymphocytic leukemia is unrelated to the presence of TET2 variations Biomed. Res. Int. 2014 2014 814294 10.1155/2014/814294 24693539 PMC3947698

270. Zhang TJ TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia J. Cell Physiol. 2018 233 5838 5846 10.1002/jcp.26373 29219176

271. Zhu Z Clinical significance of TET2 gene expression in 157 adult acute myeloid leukemia patients with normal cytogenetics Zhonghua Xue Ye Xue Za Zhi 2014 35 802 807 25246247 10.3760/cma.j.issn.0253-2727.2014.09.004

272. Musialik E Bujko M Wypych A Matysiak M Siedlecki JA TET2 promoter DNA methylation and expression analysis in pediatric B-cell acute lymphoblastic leukemia Hematol. Rep. 2014 6 5333 10.4081/hr.2014.5333 24711921 PMC3977158

273. Zhang P Low expression of TET2 gene in pediatric acute lymphoblastic leukemia is associated with poor clinical outcome Int. J. Lab Hematol. 2019 41 702 709 10.1111/ijlh.13099 31441600

274. Hill HA Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis Blood Adv. 2020 4 2927 2938 10.1182/bloodadvances.2019001350 32598477 PMC7362354

275. Kubuki Y TET2 mutation in diffuse large B-cell lymphoma J. Clin. Exp. Hematop 2017 56 145 149 10.3960/jslrt.56.145 28331128 PMC6144178

276. Au-Yeung RKH Molecular features of non-anaplastic peripheral T-cell lymphoma in children and adolescents Pediatr. Blood Cancer 2021 68 e29285 10.1002/pbc.29285 34390161

277. Schwartz FH TET2 mutations in B cells of patients affected by angioimmunoblastic T-cell lymphoma J. Pathol. 2017 242 129 133 10.1002/path.4898 28337768

278. Asmar F Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma Haematologica 2013 98 1912 1920 10.3324/haematol.2013.088740 23831920 PMC3856967

279. Ramis-Zaldivar JE MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma Haematologica 2021 106 2682 2693 10.3324/haematol.2020.271957 33951889 PMC8485662

280. Ye Y Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas Exp. Hematol. Oncol. 2021 10 9 10.1186/s40164-021-00200-x 33546774 PMC7866778

281. Lemonnier F Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters Blood 2012 120 1466 1469 10.1182/blood-2012-02-408542 22760778

282. Wu F Thyroid MALT lymphoma: self-harm to gain potential T-cell help Leukemia 2021 35 3497 3508 10.1038/s41375-021-01289-z 34021249 PMC8632687

283. Guo YM Angioimmunoblastic T-cell lymphoma: histopathological grading and prognosis Zhonghua Bing. Li Xue Za Zhi 2019 48 784 790 31594043 10.3760/cma.j.issn.0529-5807.2019.10.007

284. Stremenova Spegarova J Germline TET2 loss of function causes childhood immunodeficiency and lymphoma Blood 2020 136 1055 1066 10.1182/blood.2020005844 32518946

285. Elliott EK Epigenetic regulation of miR-92a and TET2 and their association in non-Hodgkin lymphoma Front. Genet. 2021 12 768913 10.3389/fgene.2021.768913 34899857 PMC8661906

286. Maia C Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma Blood 2020 135 2375 2387 10.1182/blood.2019003382 32299093

287. Hoang PH An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics Blood Cancer J. 2020 10 101 10.1038/s41408-020-00367-2 33057009 PMC7560599

288. Ryland GL Novel genomic findings in multiple myeloma identified through routine diagnostic sequencing J. Clin. Pathol. 2018 71 895 899 10.1136/jclinpath-2018-205195 29760015

289. Cimmino L Restoration of TET2 function blocks aberrant self-renewal and leukemia progression Cell 2017 170 1079 1095 e1020 10.1016/j.cell.2017.07.032 28823558 PMC5755977

290. Yao H TET2 and MEG3 promoter methylation is associated with acute myeloid leukemia in a Hainan population Oncotarget 2017 8 18337 18347 10.18632/oncotarget.15440 28407691 PMC5392332

291. Yamazaki J TET2 mutations affect non-CpG island DNA methylation at enhancers and transcription factor-binding sites in chronic myelomonocytic leukemia Cancer Res 2015 75 2833 2843 10.1158/0008-5472.CAN-14-0739 25972343 PMC4506197

292. Bahari G Hashemi M Naderi M Taheri M TET2 promoter DNA methylation and expression in childhood acute lymphoblastic leukemia Asian Pac. J. Cancer Prev. 2016 17 3959 3962 27644645

293. Wei Y Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia Leukemia 2022 36 2097 2107 10.1038/s41375-022-01605-1 35697791

294. Nguyen PN Clinicopathological implications of RHOA mutations in angioimmunoblastic T-cell lymphoma: a meta-analysis: RHOA mutations in AITL Clin. Lymphoma Myeloma Leuk. 2021 21 431 438 10.1016/j.clml.2021.03.002 33849798

295. Jiao J AID and TET2 co-operation modulates FANCA expression by active demethylation in diffuse large B cell lymphoma Clin. Exp. Immunol. 2019 195 190 201 10.1111/cei.13227 30357811 PMC6330643

296. Muto H Reduced TET2 function leads to T-cell lymphoma with follicular helper T-cell-like features in mice Blood Cancer J. 2014 4 e264 10.1038/bcj.2014.83 25501021 PMC4315889

297. Sun D Epigenomic profiling of young and aged HSCs reveals concerted changes during aging that reinforce self-renewal Cell Stem Cell 2014 14 673 688 10.1016/j.stem.2014.03.002 24792119 PMC4070311

298. Truong TP Age-dependent decrease of DNA hydroxymethylation in human T cells J. Clin. Exp. Hematop 2015 55 1 6 10.3960/jslrt.55.1 26105999

299. Togasaki E Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia Blood Cancer J. 2017 7 e559 10.1038/bcj.2017.36 28452984 PMC5436079

300. Conticello SG Thomas CJ Petersen-Mahrt SK Neuberger MS Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases Mol. Biol. Evol. 2005 22 367 377 10.1093/molbev/msi026 15496550

301. Harris RS Liddament MT Retroviral restriction by APOBEC proteins Nat. Rev. Immunol. 2004 4 868 877 10.1038/nri1489 15516966

302. Muto T Muramatsu M Taniwaki M Kinoshita K Honjo T Isolation, tissue distribution, and chromosomal localization of the human activation-induced cytidine deaminase (AID) gene Genomics 2000 68 85 88 10.1006/geno.2000.6268 10950930

303. Reaves SK Regulation of intestinal apolipoprotein B mRNA editing levels by a zinc-deficient diet and cDNA cloning of editing protein in hamsters J. Nutr. 2000 130 2166 2173 10.1093/jn/130.9.2166 10958808

304. Liao W APOBEC-2, a cardiac- and skeletal muscle-specific member of the cytidine deaminase supergene family Biochem Biophys. Res. Commun. 1999 260 398 404 10.1006/bbrc.1999.0925 10403781

305. Jarmuz A An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22 Genomics 2002 79 285 296 10.1006/geno.2002.6718 11863358

306. Rogozin IB Basu MK Jordan IK Pavlov YI Koonin EV APOBEC4, a new member of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases predicted by computational analysis Cell Cycle 2005 4 1281 1285 10.4161/cc.4.9.1994 16082223

307. Conticello SG The AID/APOBEC family of nucleic acid mutators Genome Biol. 2008 9 229 10.1186/gb-2008-9-6-229 18598372 PMC2481415

308. Ferreira PG Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia Genome Res 2014 24 212 226 10.1101/gr.152132.112 24265505 PMC3912412

309. Antic Z Unravelling the sequential interplay of mutational mechanisms during clonal evolution in relapsed pediatric acute lymphoblastic leukemia Genes 2021 12 214 10.3390/genes12020214 33540666 PMC7913080

310. Cifola I Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns Oncotarget 2015 6 17543 17558 10.18632/oncotarget.4028 26046463 PMC4627327

311. Cheng S Zhang W Inghirami G Tam W Mutation analysis links angioimmunoblastic T-cell lymphoma to clonal hematopoiesis and smoking eLife 2021 10 e66395 10.7554/eLife.66395 34581268 PMC8480981

312. Ren W Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma Blood 2018 131 2670 2681 10.1182/blood-2017-11-817601 29545328 PMC6063049

313. Bustoros M Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression J. Clin. Oncol. 2020 38 2380 2389 10.1200/JCO.20.00437 32442065 PMC7367550

314. Oben B Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities Nat. Commun. 2021 12 1861 10.1038/s41467-021-22140-0 33767199 PMC7994386

315. Bolli N Genomic patterns of progression in smoldering multiple myeloma Nat. Commun. 2018 9 3363 10.1038/s41467-018-05058-y 30135448 PMC6105687

316. Rustad EH Timing the initiation of multiple myeloma Nat. Commun. 2020 11 1917 10.1038/s41467-020-15740-9 32317634 PMC7174344

317. Hoang PH Cornish AJ Dobbins SE Kaiser M Houlston RS Mutational processes contributing to the development of multiple myeloma Blood Cancer J. 2019 9 60 10.1038/s41408-019-0221-9 31387987 PMC6684612

318. Samur MK Genome-wide somatic alterations in multiple myeloma reveal a superior outcome group J. Clin. Oncol. 2020 38 3107 3118 10.1200/JCO.20.00461 32687451 PMC7499613

319. Walker BA APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma Nat. Commun. 2015 6 6997 10.1038/ncomms7997 25904160 PMC4568299

320. Maura F Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines Leukemia 2018 32 1044 1048 10.1038/leu.2017.345 29209044 PMC5886048

321. Talluri S Dysregulated APOBEC3G causes DNA damage and promotes genomic instability in multiple myeloma Blood Cancer J. 2021 11 166 10.1038/s41408-021-00554-9 34625538 PMC8501035

322. Yamazaki H Endogenous APOBEC3B overexpression constitutively generates DNA substitutions and deletions in myeloma cells Sci. Rep. 2019 9 7122 10.1038/s41598-019-43575-y 31073151 PMC6509214

323. Cortazar D Embryonic lethal phenotype reveals a function of TDG in maintaining epigenetic stability Nature 2011 470 419 423 10.1038/nature09672 21278727

324. Peng B Hurt EM Hodge DR Thomas SB Farrar WL DNA hypermethylation and partial gene silencing of human thymine- DNA glycosylase in multiple myeloma cell lines Epigenetics 2006 1 138 145 10.4161/epi.1.3.2938 17965616

325. Takahashi H Hatakeyama S Saitoh H Nakayama KI Noncovalent SUMO-1 binding activity of thymine DNA glycosylase (TDG) is required for its SUMO-1 modification and colocalization with the promyelocytic leukemia protein J. Biol. Chem. 2005 280 5611 5621 10.1074/jbc.M408130200 15569683

326. Xu W Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases Cancer Cell 2011 19 17 30 10.1016/j.ccr.2010.12.014 21251613 PMC3229304

327. Patel JP Prognostic relevance of integrated genetic profiling in acute myeloid leukemia N. Engl. J. Med 2012 366 1079 1089 10.1056/NEJMoa1112304 22417203 PMC3545649

328. Abbas S Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value Blood 2010 116 2122 2126 10.1182/blood-2009-11-250878 20538800

329. Chotirat S Thongnoppakhun W Promsuwicha O Boonthimat C Auewarakul CU Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients J. Hematol. Oncol. 2012 5 5 10.1186/1756-8722-5-5 22397365 PMC3320529

330. Chou WC Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation Blood 2010 115 2749 2754 10.1182/blood-2009-11-253070 20097881

331. Marcucci G IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study J. Clin. Oncol. 2010 28 2348 2355 10.1200/JCO.2009.27.3730 20368543 PMC2881719

332. Mardis ER Recurring mutations found by sequencing an acute myeloid leukemia genome N. Engl. J. Med. 2009 361 1058 1066 10.1056/NEJMoa0903840 19657110 PMC3201812

333. Paschka P IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication J. Clin. Oncol. 2010 28 3636 3643 10.1200/JCO.2010.28.3762 20567020

334. Chou WC The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia Leukemia 2011 25 246 253 10.1038/leu.2010.267 21079611

335. Gruber E Inhibition of mutant IDH1 promotes cycling of acute myeloid leukemia stem cells Cell Rep. 2022 40 111182 10.1016/j.celrep.2022.111182 35977494

336. Choe S Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML Blood Adv. 2020 4 1894 1905 10.1182/bloodadvances.2020001503 32380538 PMC7218420

337. Amatangelo MD Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response Blood 2017 130 732 741 10.1182/blood-2017-04-779447 28588019 PMC5553578

338. Goldberg L Mutant Idh2 cooperates with a NUP98-HOXD13 fusion to induce early immature thymocyte precursor ALL Cancer Res 2021 81 5033 5046 10.1158/0008-5472.CAN-21-1027 34321240 PMC8487989

339. Riva M IDH2(R172) mutation in angioimmunoblastic T-cell lymphoma: a retrospective multicenter case series Eur. J. Haematol. 2022 110 217 220 10.1111/ejh.13885 36264618

340. Steinhilber J The pathological features of angioimmunoblastic T-cell lymphomas with IDH2(R172) mutations Mod. Pathol. 2019 32 1123 1134 10.1038/s41379-019-0254-4 30952970

341. Leclaire Alirkilicarslan A Expression of TFH markers and detection of RHOA p.G17V and IDH2 p.R172K/S mutations in cutaneous localizations of angioimmunoblastic T-cell lymphomas Am. J. Surg. Pathol. 2017 41 1581 1592 10.1097/PAS.0000000000000956 28945625

342. Cairns RA IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma Blood 2012 119 1901 1903 10.1182/blood-2011-11-391748 22215888 PMC3293643

343. Hayashida M Combination of multicolor flow cytometry for circulating lymphoma cells and tests for the RHOA(G17V) and IDH2(R172) hot-spot mutations in plasma cell-free DNA as liquid biopsy for the diagnosis of angioimmunoblastic T-cell lymphoma Leuk. Lymphoma 2020 61 2389 2398 10.1080/10428194.2020.1768382 32476550

344. Lemonnier F The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development Proc. Natl Acad. Sci. USA 2016 113 15084 15089 10.1073/pnas.1617929114 27956631 PMC5206549

345. Song S IDH2 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in multiple myeloma Oncogene 2021 40 5393 5402 10.1038/s41388-021-01939-7 34274946

346. Bergaggio E IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies Blood 2019 133 156 167 10.1182/blood-2018-05-850826 30455381

347. Li CC Pre-configuring chromatin architecture with histone modifications guides hematopoietic stem cell formation in mouse embryos Nat. Commun. 2022 13 346 10.1038/s41467-022-28018-z 35039499 PMC8764075

348. Jeong J BAP1 shapes the bone marrow niche for lymphopoiesis by fine-tuning epigenetic profiles in endosteal mesenchymal stromal cells Cell Death Differ. 2022 29 2151 2162 10.1038/s41418-022-01006-y 35473985 PMC9613645

349. Dey A Loss of the tumor suppressor BAP1 causes myeloid transformation Science 2012 337 1541 1546 10.1126/science.1221711 22878500 PMC5201002

350. Heintzman ND Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome Nat. Genet. 2007 39 311 318 10.1038/ng1966 17277777

351. Ruzic D Targeting histone deacetylases: opportunities for cancer treatment and chemoprevention Pharmaceutics 2022 14 209 10.3390/pharmaceutics14010209 35057104 PMC8778744

352. Rice KL Hormaeche I Licht JD Epigenetic regulation of normal and malignant hematopoiesis Oncogene 2007 26 6697 6714 10.1038/sj.onc.1210755 17934479

353. Ji MM Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified Haematologica 2018 103 679 687 10.3324/haematol.2017.182444 29305415 PMC5865443

354. Huang S Brandt SJ mSin3A regulates murine erythroleukemia cell differentiation through association with the TAL1 (or SCL) transcription factor Mol. Cell Biol. 2000 20 2248 2259 10.1128/MCB.20.6.2248-2259.2000 10688671 PMC110841

355. Dawson MA Kouzarides T Cancer epigenetics: from mechanism to therapy Cell 2012 150 12 27 10.1016/j.cell.2012.06.013 22770212

356. Zhu Y Oncogenic mutations and tumor microenvironment alterations of older patients with diffuse large B-cell lymphoma Front. Immunol. 2022 13 842439 10.3389/fimmu.2022.842439 35401516 PMC8990904

357. Brown JA Patent spotlight: small-molecule lysine acetyltransferase inhibitors (KATi) Pharm. Pat. Anal. 2020 9 17 28 10.4155/ppa-2019-0025 32008421

358. Bannister AJ Kouzarides T The CBP co-activator is a histone acetyltransferase Nature 1996 384 641 643 10.1038/384641a0 8967953

359. Schmitz R Genetics and pathogenesis of diffuse large B-cell lymphoma N. Engl. J. Med. 2018 378 1396 1407 10.1056/NEJMoa1801445 29641966 PMC6010183

360. Mareschal S Identification of somatic mutations in primary cutaneous diffuse large B-cell lymphoma, leg type by massive parallel sequencing J. Investig. Dermatol 2017 137 1984 1994 10.1016/j.jid.2017.04.010 28479318

361. García-Ramírez I Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice Blood 2017 129 2645 2656 10.1182/blood-2016-08-733469 28288979 PMC5428458

362. Wang J Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease EMBO J. 2005 24 368 381 10.1038/sj.emboj.7600521 15635450 PMC545811

363. Pasqualucci L Inactivating mutations of acetyltransferase genes in B-cell lymphoma Nature 2011 471 189 195 10.1038/nature09730 21390126 PMC3271441

364. Kasper LH A transcription-factor-binding surface of coactivator p300 is required for haematopoiesis Nature 2002 419 738 743 10.1038/nature01062 12384703

365. Huang YH CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis Signal Transduct. Target Ther. 2021 6 10 10.1038/s41392-020-00437-8 33431788 PMC7801454

366. Iyer NG Ozdag H Caldas C p300/CBP and cancer Oncogene 2004 23 4225 4231 10.1038/sj.onc.1207118 15156177

367. Zhuravleva J MOZ/TIF2-induced acute myeloid leukaemia in transgenic fish Br. J. Haematol. 2008 143 378 382 10.1111/j.1365-2141.2008.07362.x 18729850

368. Yang Y The histone lysine acetyltransferase HBO1 (KAT7) regulates hematopoietic stem cell quiescence and self-renewal Blood 2022 139 845 858 10.1182/blood.2021013954 34724565

369. Yan J Diaz J Jiao J Wang R You J Perturbation of BRD4 protein function by BRD4-NUT protein abrogates cellular differentiation in NUT midline carcinoma J. Biol. Chem. 2011 286 27663 27675 10.1074/jbc.M111.246975 21652721 PMC3149357

370. Chaidos A Caputo V Karadimitris A Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence Ther. Adv. Hematol. 2015 6 128 141 10.1177/2040620715576662 26137204 PMC4480520

371. French CA BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells Oncogene 2008 27 2237 2242 10.1038/sj.onc.1210852 17934517

372. Esteller M Epigenetics in cancer N. Engl. J. Med. 2008 358 1148 1159 10.1056/NEJMra072067 18337604

373. Marquard L Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas Histopathology 2009 54 688 698 10.1111/j.1365-2559.2009.03290.x 19438744

374. Pillonel V Histone deacetylase 1 plays a predominant pro-oncogenic role in Eμ-myc driven B cell lymphoma Sci. Rep. 2016 6 37772 10.1038/srep37772 27886239 PMC5122906

375. Min SK Expression of HAT1 and HDAC1, 2, 3 in diffuse large B-cell lymphomas, peripheral T-cell lymphomas, and NK/T-cell lymphomas Korean J. Pathol. 2012 46 142 150 10.4132/KoreanJPathol.2012.46.2.142 23109994 PMC3479788

376. Jiang Y CREBBP Inactivation promotes the development of HDAC3-dependent lymphomas Cancer Disco. 2017 7 38 53 10.1158/2159-8290.CD-16-0975 PMC5300005 27733359

377. Lemercier C Class II histone deacetylases are directly recruited by BCL6 transcriptional repressor J. Biol. Chem. 2002 277 22045 22052 10.1074/jbc.M201736200 11929873

378. Lee SH Expression of histone deacetylases in diffuse large B-cell lymphoma and its clinical significance Int. J. Med. Sci. 2014 11 994 1000 10.7150/ijms.8522 25076845 PMC4115238

379. Pérez-Salvia M In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma Haematologica 2018 103 e537 e540 10.3324/haematol.2018.189241 29880608 PMC6278978

380. Maharaj K HDAC6 inhibition alleviates CLL-induced T-cell dysfunction and enhances immune checkpoint blockade efficacy in the Eμ-TCL1 model Front. Immunol. 2020 11 590072 10.3389/fimmu.2020.590072 33329575 PMC7719839

381. Bae J Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors Leukemia 2018 32 1932 1947 10.1038/s41375-018-0062-8 29487385 PMC6537609

382. Azagra A In vivo conditional deletion of HDAC7 reveals its requirement to establish proper B lymphocyte identity and development J. Exp. Med. 2016 213 2591 2601 10.1084/jem.20150821 27810920 PMC5110011

383. Barneda-Zahonero B The transcriptional repressor HDAC7 promotes apoptosis and c-Myc downregulation in particular types of leukemia and lymphoma Cell Death Dis. 2015 6 e1635 10.1038/cddis.2014.594 25675295 PMC4669785

384. Kasler HG Histone deacetylase 7 regulates cell survival and TCR signaling in CD4/CD8 double-positive thymocytes J. Immunol. 2011 186 4782 4793 10.4049/jimmunol.1001179 21398603

385. Wang Z SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells Oncogene 2013 32 589 598 10.1038/onc.2012.83 22410779 PMC3376246

386. Ojaimi MA Disorders of histone methylation: molecular basis and clinical syndromes Clin. Genet. 2022 102 169 181 10.1111/cge.14181 35713103

387. Barski A High-resolution profiling of histone methylations in the human genome Cell 2007 129 823 837 10.1016/j.cell.2007.05.009 17512414

388. Liu MK Methylation alterations and advance of treatment in lymphoma Front. Biosci. 2021 26 602 613 10.52586/4970 34590470

389. Xia ZB Anderson M Diaz MO Zeleznik-Le NJ MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein Proc. Natl Acad. Sci. USA 2003 100 8342 8347 10.1073/pnas.1436338100 12829790 PMC166231

390. Castiglioni S KMT2A: umbrella gene for multiple diseases Genes 2022 13 514 10.3390/genes13030514 35328068 PMC8949091

391. Morin RD Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma Nature 2011 476 298 303 10.1038/nature10351 21796119 PMC3210554

392. Leeman-Neill RJ Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas Haematologica 2022 107 201 210 10.3324/haematol.2020.267294 33297669 PMC8719101

393. Zhang J Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis Nat. Med. 2015 21 1190 1198 10.1038/nm.3940 26366712 PMC5145002

394. Green MR Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma Blood 2013 121 1604 1611 10.1182/blood-2012-09-457283 23297126 PMC3587323

395. Ayton PM Cleary ML Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9 Genes Dev. 2003 17 2298 2307 10.1101/gad.1111603 12952893 PMC196466

396. Sun QY Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD) Leukemia 2017 31 1 10 10.1038/leu.2016.160 27389053 PMC5214979

397. Yap DB Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation Blood 2011 117 2451 2459 10.1182/blood-2010-11-321208 21190999 PMC3062411

398. Papakonstantinou N The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia Oncotarget 2016 7 35946 35959 10.18632/oncotarget.9371 27191993 PMC5094974

399. Yan J EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity Blood 2013 121 4512 4520 10.1182/blood-2012-08-450494 23529930

400. Zhang J The genetic basis of early T-cell precursor acute lymphoblastic leukaemia Nature 2012 481 157 163 10.1038/nature10725 22237106 PMC3267575

401. Nikoloski G Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes Nat. Genet. 2010 42 665 667 10.1038/ng.620 20601954

402. Ernst T Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders Nat. Genet. 2010 42 722 726 10.1038/ng.621 20601953

403. Hollink IH NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern Blood 2011 118 3645 3656 10.1182/blood-2011-04-346643 21813447

404. Struski S NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis Leukemia 2017 31 565 572 10.1038/leu.2016.267 27694926

405. Shiba N NUP98-NSD1 gene fusion and its related gene expression signature are strongly associated with a poor prognosis in pediatric acute myeloid leukemia Genes Chromosomes Cancer 2013 52 683 693 23630019 10.1002/gcc.22064

406. Mohanty S Targeted inhibition of the NUP98-NSD1 fusion oncogene in acute myeloid leukemia Cancers 2020 12 2766 10.3390/cancers12102766 32993115 PMC7600396

407. Crescenzi B NUP98/11p15 translocations affect CD34+ cells in myeloid and T lymphoid leukemias Leuk. Res. 2015 39 769 772 10.1016/j.leukres.2015.04.014 26004809

408. Avet-Loiseau H Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p) J. Clin. Oncol. 2010 28 4630 4634 10.1200/JCO.2010.28.3945 20644101

409. Gertz MA Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy Blood 2005 106 2837 2840 10.1182/blood-2005-04-1411 15976175 PMC1895302

410. Taketani T NUP98-NSD3 fusion gene in radiation-associated myelodysplastic syndrome with t(8;11)(p11;p15) and expression pattern of NSD family genes Cancer Genet. Cytogenet. 2009 190 108 112 10.1016/j.cancergencyto.2008.12.008 19380029

411. Rosati R NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15) Blood 2002 99 3857 3860 10.1182/blood.V99.10.3857 11986249

412. Greenblatt SM CARM1 is essential for myeloid leukemogenesis but dispensable for normal hematopoiesis Cancer Cell 2018 33 1111 1127.e1115 10.1016/j.ccell.2018.05.007 29894694 PMC6191185

413. Chevillard-Briet M Trouche D Vandel L Control of CBP co-activating activity by arginine methylation EMBO J. 2002 21 5457 5466 10.1093/emboj/cdf548 12374746 PMC129080

414. Jin Y Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia J. Clin. Investig. 2016 126 3961 3980 10.1172/JCI85239 27643437 PMC5096815

415. Liu C Loss of PRMT7 reprograms glycine metabolism to selectively eradicate leukemia stem cells in CML Cell Metab. 2022 34 818 835.e817 10.1016/j.cmet.2022.04.004 35508169

416. Wang GG Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger Nature 2009 459 847 851 10.1038/nature08036 19430464 PMC2697266

417. Dialynas GK Vitalini MW Wallrath LL Linking heterochromatin protein 1 (HP1) to cancer progression Mutat. Res. 2008 647 13 20 10.1016/j.mrfmmm.2008.09.007 18926834 PMC2637788

418. Coles AH Jones SN The ING gene Fam. Regul. Cell growth tumorigenesis. J. Cell Physiol. 2009 218 45 57 10.1002/jcp.21583 PMC2872195 18780289

419. Garcia-Bassets I Histone methylation-dependent mechanisms impose ligand dependency for gene activation by nuclear receptors Cell 2007 128 505 518 10.1016/j.cell.2006.12.038 17289570 PMC1994663

420. Metzger E LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription Nature 2005 437 436 439 10.1038/nature04020 16079795

421. Cowger JJ Zhao Q Isovic M Torchia J Biochemical characterization of the zinc-finger protein 217 transcriptional repressor complex: identification of a ZNF217 consensus recognition sequence Oncogene 2007 26 3378 3386 10.1038/sj.onc.1210126 17130829

422. Lee MG Functional interplay between histone demethylase and deacetylase enzymes Mol. Cell Biol. 2006 26 6395 6402 10.1128/MCB.00723-06 16914725 PMC1592851

423. Forneris F A highly specific mechanism of histone H3-K4 recognition by histone demethylase LSD1 J. Biol. Chem. 2006 281 35289 35295 10.1074/jbc.M607411200 16987819

424. Kohrogi K LSD1 defines erythroleukemia metabolism by controlling the lineage-specific transcription factors GATA1 and C/EBPα Blood Adv. 2021 5 2305 2318 10.1182/bloodadvances.2020003521 33929501 PMC8114557

425. Hu X LSD1-mediated epigenetic modification is required for TAL1 function and hematopoiesis Proc. Natl Acad. Sci. USA 2009 106 10141 10146 10.1073/pnas.0900437106 19497860 PMC2700898

426. Tatsumi G LSD1-mediated repression of GFI1 super-enhancer plays an essential role in erythroleukemia Leukemia 2020 34 746 758 10.1038/s41375-019-0614-6 31676828

427. Zhang S Liu M Yao Y Yu B Liu H Targeting LSD1 for acute myeloid leukemia (AML) treatment Pharm. Res. 2021 164 105335 10.1016/j.phrs.2020.105335 33285227

428. Noort S The clinical and biological characteristics of NUP98-KDM5A in pediatric acute myeloid leukemia Haematologica 2021 106 630 634 10.3324/haematol.2019.236745 32381579 PMC7849578

429. Shokri G Doudi S Fathi-Roudsari M Kouhkan F Sanati MH Targeting histone demethylases KDM5A and KDM5B in AML cancer cells: a comparative view Leuk. Res. 2018 68 105 111 10.1016/j.leukres.2018.02.003 29602065

430. Xu S KDM5A suppresses PML-RARα target gene expression and APL differentiation through repressing H3K4me2 Blood Adv. 2021 5 3241 3253 10.1182/bloodadvances.2020002819 34448811 PMC8525237

431. Xue S Histone lysine demethylase KDM5B maintains chronic myeloid leukemia via multiple epigenetic actions Exp. Hematol. 2020 82 53 65 10.1016/j.exphem.2020.01.006 32007477

432. Sera Y UTX maintains the functional integrity of the murine hematopoietic system by globally regulating aging-associated genes Blood 2021 137 908 922 10.1182/blood.2019001044 33174606 PMC7918186

433. Tian L Kdm6a deficiency restricted to mouse hematopoietic cells causes an age- and sex-dependent myelodysplastic syndrome-like phenotype PLoS ONE 2021 16 e0255706 10.1371/journal.pone.0255706 34780480 PMC8592440

434. Stief SM Loss of KDM6A confers drug resistance in acute myeloid leukemia Leukemia 2020 34 50 62 10.1038/s41375-019-0497-6 31201358 PMC7214274

435. Zheng L Utx loss causes myeloid transformation Leukemia 2018 32 1458 1465 10.1038/s41375-018-0011-6 29479066

436. Gozdecka M UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs Nat. Genet. 2018 50 883 894 10.1038/s41588-018-0114-z 29736013 PMC6029661

437. Rocha-Viegas L Role of UTX in retinoic acid receptor-mediated gene regulation in leukemia Mol. Cell Biol. 2014 34 3765 3775 10.1128/MCB.00839-14 25071154 PMC4187727

438. Benyoucef A UTX inhibition as selective epigenetic therapy against TAL1-driven T-cell acute lymphoblastic leukemia Genes Dev. 2016 30 508 521 10.1101/gad.276790.115 26944678 PMC4782046

439. Montalban-Bravo G DiNardo CD The role of IDH mutations in acute myeloid leukemia Future Oncol. 2018 14 979 993 10.2217/fon-2017-0523 29543066

440. Drennan AC Rui L HiJAKing the epigenome in leukemia and lymphoma Leuk. Lymphoma 2017 58 2540 2547 10.1080/10428194.2017.1312370 28402164 PMC5764090

441. Rui L Cooperative epigenetic modulation by cancer amplicon genes Cancer Cell 2010 18 590 605 10.1016/j.ccr.2010.11.013 21156283 PMC3049192

442. Rosenwald A Staudt LM Gene expression profiling of diffuse large B-cell lymphoma Leuk. Lymphoma 2003 44 Suppl 3 S41 S47 10.1080/10428190310001623775 15202524

443. Rui L Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma Proc. Natl Acad. Sci. USA 2016 113 E7260 e7267 10.1073/pnas.1610970113 27799566 PMC5135360

444. Wu XP Resveratrol induces apoptosis of human chronic myelogenous leukemia cells in vitro through p38 and JNK-regulated H2AX phosphorylation Acta Pharm. Sin. 2015 36 353 361 10.1038/aps.2014.132 PMC4349923 25619392

445. Dong Y H2AX phosphorylation regulated by p38 is involved in Bim expression and apoptosis in chronic myelogenous leukemia cells induced by imatinib Apoptosis 2014 19 1281 1292 10.1007/s10495-014-0997-9 24830786

446. Zhang YJ Imatinib induces H2AX phosphorylation and apoptosis in chronic myelogenous leukemia cells in vitro via caspase-3/Mst1 pathway Acta Pharm. Sin. Sin. 2012 33 551 557 10.1038/aps.2012.9 PMC4003371 22388075

447. Eddy SR Non-coding RNA genes and the modern RNA world Nat. Rev. Genet. 2001 2 919 929 10.1038/35103511 11733745

448. Mattick JS Non-coding RNAs: the architects of eukaryotic complexity EMBO Rep. 2001 2 986 991 10.1093/embo-reports/kve230 11713189 PMC1084129

449. Lander ES Initial sequencing and analysis of the human genome Nature 2001 409 860 921 10.1038/35057062 11237011

450. Venter JC The sequence of the human genome Science 2001 291 1304 1351 10.1126/science.1058040 11181995

451. Djebali S Landscape of transcription in human cells Nature 2012 489 101 108 10.1038/nature11233 22955620 PMC3684276

452. Birney E Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project Nature 2007 447 799 816 10.1038/nature05874 17571346 PMC2212820

453. Kapranov P Willingham AT Gingeras TR Genome-wide transcription and the implications for genomic organization Nat. Rev. Genet. 2007 8 413 423 10.1038/nrg2083 17486121

454. Dragomir MP FuncPEP: A database of functional peptides encoded by non-coding RNAs Noncoding RNA 2020 6 41 10.3390/ncrna6040041 32977531 PMC7712257

455. Calin GA Croce CM MicroRNA-cancer connection: the beginning of a new tale Cancer Res 2006 66 7390 7394 10.1158/0008-5472.CAN-06-0800 16885332

456. Schmitt AM Chang HY Long noncoding RNAs in cancer pathways Cancer Cell 2016 29 452 463 10.1016/j.ccell.2016.03.010 27070700 PMC4831138

457. Calin GA Croce CM MicroRNA signatures in human cancers Nat. Rev. Cancer 2006 6 857 866 10.1038/nrc1997 17060945

458. Calin GA Croce CM Investigation of microRNA alterations in leukemias and lymphomas Methods Enzymol. 2007 427 193 213 17720486 10.1016/S0076-6879(07)27011-9

459. Bartel DP MicroRNAs: genomics, biogenesis, mechanism, and function Cell 2004 116 281 297 10.1016/S0092-8674(04)00045-5 14744438

460. Lee RC Feinbaum RL Ambros V The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 Cell 1993 75 843 854 10.1016/0092-8674(93)90529-Y 8252621

461. Wightman B Ha I Ruvkun G Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans Cell 1993 75 855 862 10.1016/0092-8674(93)90530-4 8252622

462. He L Hannon GJ MicroRNAs: small RNAs with a big role in gene regulation Nat. Rev. Genet. 2004 5 522 531 10.1038/nrg1379 15211354

463. Bartel DP Metazoan microRNAs Cell 2018 173 20 51 10.1016/j.cell.2018.03.006 29570994 PMC6091663

464. Rigoutsos I New tricks for animal microRNAS: targeting of amino acid coding regions at conserved and nonconserved sites Cancer Res 2009 69 3245 3248 10.1158/0008-5472.CAN-09-0352 19351814

465. Tay Y Zhang J Thomson AM Lim B Rigoutsos I MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation Nature 2008 455 1124 1128 10.1038/nature07299 18806776

466. Schnall-Levin M Unusually effective microRNA targeting within repeat-rich coding regions of mammalian mRNAs Genome Res 2011 21 1395 1403 10.1101/gr.121210.111 21685129 PMC3166825

467. Zhou H Rigoutsos I MiR-103a-3p targets the 5' UTR of GPRC5A in pancreatic cells Rna 2014 20 1431 1439 10.1261/rna.045757.114 24984703 PMC4138326

468. Zisoulis DG Comprehensive discovery of endogenous Argonaute binding sites in Caenorhabditis elegans Nat. Struct. Mol. Biol. 2010 17 173 179 10.1038/nsmb.1745 20062054 PMC2834287

469. Leung AK Genome-wide identification of Ago2 binding sites from mouse embryonic stem cells with and without mature microRNAs Nat. Struct. Mol. Biol. 2011 18 237 244 10.1038/nsmb.1991 21258322 PMC3078052

470. Chi SW Zang JB Mele A Darnell RB Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps Nature 2009 460 479 486 10.1038/nature08170 19536157 PMC2733940

471. Cesana M A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA Cell 2011 147 358 369 10.1016/j.cell.2011.09.028 22000014 PMC3234495

472. Anastasiadou E Faggioni A Trivedi P Slack FJ The nefarious nexus of noncoding RNAs in cancer Int. J. Mol. Sci. 2018 19 2072 10.3390/ijms19072072 30018188 PMC6073630

473. Dragomir MP Knutsen E Calin GA Classical and noncanonical functions of miRNAs in cancers Trends Genet 2022 38 379 394 10.1016/j.tig.2021.10.002 34728089

474. Kozomara A Birgaoanu M Griffiths-Jones S miRBase: from microRNA sequences to function Nucleic Acids Res 2019 47 D155 d162 10.1093/nar/gky1141 30423142 PMC6323917

475. Calin GA Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia Proc. Natl Acad. Sci. USA 2002 99 15524 15529 10.1073/pnas.242606799 12434020 PMC137750

476. Cimmino A miR-15 and miR-16 induce apoptosis by targeting BCL2 Proc. Natl Acad. Sci. USA 2005 102 13944 13949 10.1073/pnas.0506654102 16166262 PMC1236577

477. Rassenti LZ MicroRNA dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia Proc. Natl Acad. Sci. USA 2017 114 10731 10736 10.1073/pnas.1708264114 28923920 PMC5635897

478. Volinia S A microRNA expression signature of human solid tumors defines cancer gene targets Proc. Natl Acad. Sci. USA 2006 103 2257 2261 10.1073/pnas.0510565103 16461460 PMC1413718

479. Lu J MicroRNA expression profiles classify human cancers Nature 2005 435 834 838 10.1038/nature03702 15944708

480. Ramkissoon SH Hematopoietic-specific microRNA expression in human cells Leuk. Res. 2006 30 643 647 10.1016/j.leukres.2005.09.001 16226311

481. Fabbri M MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications Leukemia 2008 22 1095 1105 10.1038/leu.2008.30 18323801

482. Slack FJ Chinnaiyan AM The role of non-coding RNAs in oncology Cell 2019 179 1033 1055 10.1016/j.cell.2019.10.017 31730848 PMC7347159

483. Costinean S Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice Proc. Natl Acad. Sci. USA 2006 103 7024 7029 10.1073/pnas.0602266103 16641092 PMC1459012

484. Eis PS Accumulation of miR-155 and BIC RNA in human B cell lymphomas Proc. Natl Acad. Sci. USA 2005 102 3627 3632 10.1073/pnas.0500613102 15738415 PMC552785

485. O'Connell RM Chaudhuri AA Rao DS Baltimore D Inositol phosphatase SHIP1 is a primary target of miR-155 Proc. Natl Acad. Sci. USA 2009 106 7113 7118 10.1073/pnas.0902636106 19359473 PMC2678424

486. Cheng CJ MicroRNA silencing for cancer therapy targeted to the tumour microenvironment Nature 2015 518 107 110 10.1038/nature13905 25409146 PMC4367962

487. Si ML miR-21-mediated tumor growth Oncogene 2007 26 2799 2803 10.1038/sj.onc.1210083 17072344

488. Chan JA Krichevsky AM Kosik KS MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells Cancer Res 2005 65 6029 6033 10.1158/0008-5472.CAN-05-0137 16024602

489. Schetter AJ MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma J. Am. Med. Assoc. 2008 299 425 436 10.1001/jama.299.4.425 PMC2614237 18230780

490. Fulci V Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia Blood 2007 109 4944 4951 10.1182/blood-2006-12-062398 17327404

491. Lawrie CH MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma Int. J. Cancer 2007 121 1156 1161 10.1002/ijc.22800 17487835

492. Jongen-Lavrencic M Sun SM Dijkstra MK Valk PJ Löwenberg B MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia Blood 2008 111 5078 5085 10.1182/blood-2008-01-133355 18337557

493. Navarro A MicroRNA expression profiling in classic Hodgkin lymphoma Blood 2008 111 2825 2832 10.1182/blood-2007-06-096784 18089852

494. Medina PP Nolde M Slack FJ OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma Nature 2010 467 86 90 10.1038/nature09284 20693987

495. Mendell JT miRiad roles for the miR-17-92 cluster in development and disease Cell 2008 133 217 222 10.1016/j.cell.2008.04.001 18423194 PMC2732113

496. Ota A Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma Cancer Res 2004 64 3087 3095 10.1158/0008-5472.CAN-03-3773 15126345

497. He L A microRNA polycistron as a potential human oncogene Nature 2005 435 828 833 10.1038/nature03552 15944707 PMC4599349

498. O'Donnell KA Wentzel EA Zeller KI Dang CV Mendell JT c-Myc-regulated microRNAs modulate E2F1 expression Nature 2005 435 839 843 10.1038/nature03677 15944709

499. Sun R Therapeutic targeting miR130b counteracts diffuse large B-cell lymphoma progression via OX40/OX40L-mediated interaction with Th17 cells Signal Transduct. Target Ther. 2022 7 80 10.1038/s41392-022-00895-2 35301282 PMC8931122

500. Döhner H Genomic aberrations and survival in chronic lymphocytic leukemia N. Engl. J. Med. 2000 343 1910 1916 10.1056/NEJM200012283432602 11136261

501. Baskar S Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia Clin. Cancer Res. 2008 14 396 404 10.1158/1078-0432.CCR-07-1823 18223214

502. Broome HE Rassenti LZ Wang HY Meyer LM Kipps TJ ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia Leuk. Res. 2011 35 1390 1394 10.1016/j.leukres.2011.06.021 21813176 PMC3163753

503. Cui B High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia Blood 2016 128 2931 2940 10.1182/blood-2016-04-712562 27815263 PMC5179332

504. Fukuda T Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a Proc. Natl Acad. Sci. USA 2008 105 3047 3052 10.1073/pnas.0712148105 18287027 PMC2268582

505. Widhopf GF 2nd ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice Proc. Natl Acad. Sci. USA 2014 111 793 798 10.1073/pnas.1308374111 24379361 PMC3896194

506. Choi MY Phase I trial: cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia Cell Stem Cell 2018 22 951 959.e953 10.1016/j.stem.2018.05.018 29859176 PMC7001723

507. Chen Y Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia Blood 2019 134 1084 1094 10.1182/blood.2019001366 31409670 PMC6764264

508. Pekarsky Y Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181 Cancer Res 2006 66 11590 11593 10.1158/0008-5472.CAN-06-3613 17178851

509. Santanam U Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression Proc. Natl Acad. Sci. USA 2010 107 12210 12215 10.1073/pnas.1007186107 20566844 PMC2901490

510. Guttman M Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals Nature 2009 458 223 227 10.1038/nature07672 19182780 PMC2754849

511. Mattick JS Rinn JL Discovery and annotation of long noncoding RNAs Nat. Struct. Mol. Biol. 2015 22 5 7 10.1038/nsmb.2942 25565026

512. Statello L Guo CJ Chen LL Huarte M Gene regulation by long non-coding RNAs and its biological functions Nat. Rev. Mol. Cell Biol. 2021 22 96 118 10.1038/s41580-020-00315-9 33353982 PMC7754182

513. Cabili MN Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses Genes Dev. 2011 25 1915 1927 10.1101/gad.17446611 21890647 PMC3185964

514. Derrien T The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression Genome Res 2012 22 1775 1789 10.1101/gr.132159.111 22955988 PMC3431493

515. Iyer MK The landscape of long noncoding RNAs in the human transcriptome Nat. Genet. 2015 47 199 208 10.1038/ng.3192 25599403 PMC4417758

516. Guo CJ Distinct Processing of lncRNAs Contributes to Non-conserved Functions in Stem Cells Cell 2020 181 621 636.e622 10.1016/j.cell.2020.03.006 32259487

517. Quinn JJ Rapid evolutionary turnover underlies conserved lncRNA-genome interactions Genes Dev. 2016 30 191 207 10.1101/gad.272187.115 26773003 PMC4719309

518. Melé M Chromatin environment, transcriptional regulation, and splicing distinguish lincRNAs and mRNAs Genome Res 2017 27 27 37 10.1101/gr.214205.116 27927715 PMC5204342

519. Lagarde J High-throughput annotation of full-length long noncoding RNAs with capture long-read sequencing Nat. Genet. 2017 49 1731 1740 10.1038/ng.3988 29106417 PMC5709232

520. Zuckerman B Ulitsky I Predictive models of subcellular localization of long RNAs Rna 2019 25 557 572 10.1261/rna.068288.118 30745363 PMC6467007

521. Zuckerman B Ron M Mikl M Segal E Ulitsky I Gene architecture and sequence composition underpin selective dependency of nuclear export of long RNAs on NXF1 and the TREX complex Mol. Cell 2020 79 251 267.e256 10.1016/j.molcel.2020.05.013 32504555

522. Anastasiadou E Jacob LS Slack FJ Non-coding RNA networks in cancer Nat. Rev. Cancer 2018 18 5 18 10.1038/nrc.2017.99 29170536 PMC6337726

523. Kopp F Mendell JT Functional classification and experimental dissection of long noncoding RNAs Cell 2018 172 393 407 10.1016/j.cell.2018.01.011 29373828 PMC5978744

524. Yap KL Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a Mol. Cell 2010 38 662 674 10.1016/j.molcel.2010.03.021 20541999 PMC2886305

525. Csorba T Questa JI Sun Q Dean C Antisense COOLAIR mediates the coordinated switching of chromatin states at FLC during vernalization Proc. Natl Acad. Sci. USA 2014 111 16160 16165 10.1073/pnas.1419030111 25349421 PMC4234544

526. Rosa S Duncan S Dean C Mutually exclusive sense-antisense transcription at FLC facilitates environmentally induced gene repression Nat. Commun. 2016 7 13031 10.1038/ncomms13031 27713408 PMC5059766

527. Jain AK LncPRESS1 is a p53-regulated lncRNA that safeguards pluripotency by disrupting SIRT6-mediated de-acetylation of histone H3K56 Mol. Cell 2016 64 967 981 10.1016/j.molcel.2016.10.039 27912097 PMC5137794

528. Postepska-Igielska A LncRNA Khps1 regulates expression of the proto-oncogene SPHK1 via triplex-mediated changes in chromatin structure Mol. Cell 2015 60 626 636 10.1016/j.molcel.2015.10.001 26590717

529. Blank-Giwojna A Postepska-Igielska A Grummt I lncRNA KHPS1 activates a poised enhancer by triplex-dependent recruitment of epigenomic regulators Cell Rep. 2019 26 2904 2915.e2904 10.1016/j.celrep.2019.02.059 30865882

530. Boque-Sastre R Head-to-head antisense transcription and R-loop formation promotes transcriptional activation Proc. Natl Acad. Sci. USA 2015 112 5785 5790 10.1073/pnas.1421197112 25902512 PMC4426458

531. Arab K GADD45A binds R-loops and recruits TET1 to CpG island promoters Nat. Genet. 2019 51 217 223 10.1038/s41588-018-0306-6 30617255 PMC6420098

532. Ariel F R-loop mediated trans action of the APOLO long noncoding RNA Mol. Cell 2020 77 1055 1065.e1054 10.1016/j.molcel.2019.12.015 31952990

533. Niehrs C Luke B Regulatory R-loops as facilitators of gene expression and genome stability Nat. Rev. Mol. Cell Biol. 2020 21 167 178 10.1038/s41580-019-0206-3 32005969 PMC7116639

534. Beckedorff FC The intronic long noncoding RNA ANRASSF1 recruits PRC2 to the RASSF1A promoter, reducing the expression of RASSF1A and increasing cell proliferation PLoS Genet 2013 9 e1003705 10.1371/journal.pgen.1003705 23990798 PMC3749938

535. Latos PA Airn transcriptional overlap, but not its lncRNA products, induces imprinted Igf2r silencing Science 2012 338 1469 1472 10.1126/science.1228110 23239737

536. Stojic L Transcriptional silencing of long noncoding RNA GNG12-AS1 uncouples its transcriptional and product-related functions Nat. Commun. 2016 7 10406 10.1038/ncomms10406 26832224 PMC4740813

537. Thebault P Transcription regulation by the noncoding RNA SRG1 requires Spt2-dependent chromatin deposition in the wake of RNA polymerase II Mol. Cell Biol. 2011 31 1288 1300 10.1128/MCB.01083-10 21220514 PMC3067896

538. Rom A Regulation of CHD2 expression by the Chaserr long noncoding RNA gene is essential for viability Nat. Commun. 2019 10 5092 10.1038/s41467-019-13075-8 31704914 PMC6841665

539. Andersson R An atlas of active enhancers across human cell types and tissues Nature 2014 507 455 461 10.1038/nature12787 24670763 PMC5215096

540. Hon CC An atlas of human long non-coding RNAs with accurate 5' ends Nature 2017 543 199 204 10.1038/nature21374 28241135 PMC6857182

541. Melo CA eRNAs are required for p53-dependent enhancer activity and gene transcription Mol. Cell 2013 49 524 535 10.1016/j.molcel.2012.11.021 23273978

542. Grossi E A lncRNA-SWI/SNF complex crosstalk controls transcriptional activation at specific promoter regions Nat. Commun. 2020 11 936 10.1038/s41467-020-14623-3 32071317 PMC7028943

543. Isoda T Non-coding transcription instructs chromatin folding and compartmentalization to dictate enhancer-promoter communication and T cell fate Cell 2017 171 103 119.e118 10.1016/j.cell.2017.09.001 28938112 PMC5621651

544. Cai Z RIC-seq for global in situ profiling of RNA-RNA spatial interactions Nature 2020 582 432 437 10.1038/s41586-020-2249-1 32499643

545. Xiang JF Human colorectal cancer-specific CCAT1-L lncRNA regulates long-range chromatin interactions at the MYC locus Cell Res 2014 24 513 531 10.1038/cr.2014.35 24662484 PMC4011346

546. Anderson KM Transcription of the non-coding RNA upperhand controls Hand2 expression and heart development Nature 2016 539 433 436 10.1038/nature20128 27783597 PMC5261552

547. Dao LTM Genome-wide characterization of mammalian promoters with distal enhancer functions Nat. Genet. 2017 49 1073 1081 10.1038/ng.3884 28581502

548. Engreitz JM Local regulation of gene expression by lncRNA promoters, transcription and splicing Nature 2016 539 452 455 10.1038/nature20149 27783602 PMC6853796

549. Yap K A short tandem repeat-enriched RNA assembles a nuclear compartment to control alternative splicing and promote cell survival Mol. Cell 2018 72 525 540.e513 10.1016/j.molcel.2018.08.041 30318443 PMC6224606

550. Wu H Unusual Processing generates SPA lncRNAs that sequester multiple RNA binding proteins Mol. Cell 2016 64 534 548 10.1016/j.molcel.2016.10.007 27871485

551. Lee S Noncoding RNA NORAD regulates genomic stability by sequestering PUMILIO proteins Cell 2016 164 69 80 10.1016/j.cell.2015.12.017 26724866 PMC4715682

552. Tichon A Perry RB Stojic L Ulitsky I SAM68 is required for regulation of Pumilio by the NORAD long noncoding RNA Genes Dev. 2018 32 70 78 10.1101/gad.309138.117 29386330 PMC5828396

553. Liu B A cytoplasmic NF-κB interacting long noncoding RNA blocks IκB phosphorylation and suppresses breast cancer metastasis Cancer Cell 2015 27 370 381 10.1016/j.ccell.2015.02.004 25759022

554. Kretz M Control of somatic tissue differentiation by the long non-coding RNA TINCR Nature 2013 493 231 235 10.1038/nature11661 23201690 PMC3674581

555. Gong C Maquat L E. lncRNAs transactivate STAU1-mediated mRNA decay by duplexing with 3' UTRs via Alu elements Nature 2011 470 284 288 10.1038/nature09701 21307942 PMC3073508

556. Wang J Gong C Maquat LE Control of myogenesis by rodent SINE-containing lncRNAs Genes Dev. 2013 27 793 804 10.1101/gad.212639.112 23558772 PMC3639419

557. Salmena L Poliseno L Tay Y Kats L Pandolfi PP A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell 2011 146 353 358 10.1016/j.cell.2011.07.014 21802130 PMC3235919

558. Clemson CM An architectural role for a nuclear noncoding RNA: NEAT1 RNA is essential for the structure of paraspeckles Mol. Cell 2009 33 717 726 10.1016/j.molcel.2009.01.026 19217333 PMC2696186

559. Tripathi V The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation Mol. Cell 2010 39 925 938 10.1016/j.molcel.2010.08.011 20797886 PMC4158944

560. Yamazaki T Functional domains of NEAT1 architectural lncRNA induce paraspeckle assembly through phase separation Mol. Cell 2018 70 1038 1053.e1037 10.1016/j.molcel.2018.05.019 29932899

561. Lin Y Schmidt BF Bruchez MP McManus CJ Structural analyses of NEAT1 lncRNAs suggest long-range RNA interactions that may contribute to paraspeckle architecture Nucleic Acids Res 2018 46 3742 3752 10.1093/nar/gky046 29394378 PMC5909464

562. Huarte M The emerging role of lncRNAs in cancer Nat. Med. 2015 21 1253 1261 10.1038/nm.3981 26540387

563. Huarte M A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response Cell 2010 142 409 419 10.1016/j.cell.2010.06.040 20673990 PMC2956184

564. Trimarchi T Genome-wide mapping and characterization of Notch-regulated long noncoding RNAs in acute leukemia Cell 2014 158 593 606 10.1016/j.cell.2014.05.049 25083870 PMC4131209

565. Bill M Expression and functional relevance of long non-coding RNAs in acute myeloid leukemia stem cells Leukemia 2019 33 2169 2182 10.1038/s41375-019-0429-5 30858548

566. Zhao P A novel lncRNA TCLlnc1 promotes peripheral T cell lymphoma progression through acting as a modular scaffold of HNRNPD and YBX1 complexes Cell Death Dis. 2021 12 321 10.1038/s41419-021-03594-y 33767152 PMC7994313

567. Lyu Y Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and -independent pathways Leukemia 2017 31 2543 2551 10.1038/leu.2017.116 28400619 PMC5729340

568. Guo G A long noncoding RNA critically regulates Bcr-Abl-mediated cellular transformation by acting as a competitive endogenous RNA Oncogene 2015 34 1768 1779 10.1038/onc.2014.131 24837367

569. Raj K Mufti GJ Azacytidine (Vidaza(R)) in the treatment of myelodysplastic syndromes Ther. Clin. Risk Manag 2006 2 377 388 10.2147/tcrm.2006.2.4.377 18360650 PMC1936359

570. Santos FP Kantarjian H Garcia-Manero G Issa JP Ravandi F Decitabine in the treatment of myelodysplastic syndromes Expert Rev. Anticancer Ther. 2010 10 9 22 10.1586/era.09.164 20014881

571. Kaminskas E Farrell AT Wang YC Sridhara R Pazdur R FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension Oncologist 2005 10 176 182 10.1634/theoncologist.10-3-176 15793220

572. Hollenbach PW A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines PLoS ONE 2010 5 e9001 10.1371/journal.pone.0009001 20126405 PMC2814859

573. Chilakala S Tracking decitabine incorporation into malignant myeloid cell DNA in vitro and in vivo by LC-MS/MS with enzymatic digestion Sci. Rep. 2019 9 4558 10.1038/s41598-019-41070-y 30872721 PMC6418203

574. Chen J Odenike O Rowley JD Leukaemogenesis: more than mutant genes Nat. Rev. Cancer 2010 10 23 36 10.1038/nrc2765 20029422 PMC2972637

575. Chabot GG Bouchard J Momparler RL Kinetics of deamination of 5-aza-2'-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside Biochem Pharm. 1983 32 1327 1328 10.1016/0006-2952(83)90293-9 6189497

576. Dhillon S Decitabine/cedazuridine: first approval Drugs 2020 80 1373 1378 10.1007/s40265-020-01389-7 32860582 PMC7708383

577. Griffiths EA SGI-110: DNA methyltransferase inhibitor oncolytic Drugs Future 2013 38 535 543 26190889 PMC4503259

578. Issa JJ Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study Lancet Oncol. 2015 16 1099 1110 10.1016/S1470-2045(15)00038-8 26296954 PMC5557041

579. Kamachi K Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia Cancer Lett. 2022 526 273 283 10.1016/j.canlet.2021.11.032 34875342

580. Watanabe T Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100 Blood 2020 136 871 884 10.1182/blood.2019003084 32391874

581. Silverman LR Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B J. Clin. Oncol. 2002 20 2429 2440 10.1200/JCO.2002.04.117 12011120

582. Fenaux P Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study Lancet Oncol. 2009 10 223 232 10.1016/S1470-2045(09)70003-8 19230772 PMC4086808

583. Wu D Decitabine for treatment of myelodysplastic syndromes in Chinese patients: an open-label, phase-3b study Adv. Ther. 2015 32 1140 1159 10.1007/s12325-015-0263-8 26568466 PMC4662721

584. Cheng JC Inhibition of DNA methylation and reactivation of silenced genes by zebularine J. Natl Cancer Inst. 2003 95 399 409 10.1093/jnci/95.5.399 12618505

585. Andrade AF Zebularine induces chemosensitization to methotrexate and efficiently decreases AhR gene methylation in childhood acute lymphoblastic leukemia cells Anticancer Drugs 2014 25 72 81 10.1097/CAD.0000000000000028 24052107

586. Holleran JL Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine Clin. Cancer Res. 2005 11 3862 3868 10.1158/1078-0432.CCR-04-2406 15897587

587. Pappalardi MB Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia Nat. Cancer 2021 2 1002 1017 10.1038/s43018-021-00249-x 34790902 PMC8594913

588. Vitkeviciene A Baksiene S Borutinskaite V Navakauskiene R Epigallocatechin-3-gallate and BIX-01294 have different impact on epigenetics and senescence modulation in acute and chronic myeloid leukemia cells Eur. J. Pharm. 2018 838 32 40 10.1016/j.ejphar.2018.09.005 30194939

589. Shi X Gao HY Yan W He XW Yang W Effects of EGCG on proliferation, cell cycle and DAPK1 gene methylation of acute promyelocytic leukemia NB4 cell line Zhongguo Shi Yan Xue Ye Xue Za Zhi 2018 26 1288 1293 30295240 10.7534/j.issn.1009-2137.2018.05.006

590. Wu M Epigallocatechin gallate induces CHD5 gene demethylation to promote acute myeloid leukemia cell apoptosis in vitro by regulating p19(Arf)-p53-p21(Cip1) signaling pathway Nan Fang. Yi Ke Da Xue Xue Bao 2020 40 1230 1238 32990229 10.12122/j.issn.1673-4254.2020.09.02 PMC7544577

591. Borutinskaite V Virksaite A Gudelyte G Navakauskiene R Green tea polyphenol EGCG causes anti-cancerous epigenetic modulations in acute promyelocytic leukemia cells Leuk. Lymphoma 2018 59 469 478 10.1080/10428194.2017.1339881 28641467

592. Fan LP Effect of epigallocatechin-3-galate on human acute monocytic leukemia cell line U937 and its relevant mechanism Zhongguo Shi Yan Xue Ye Xue Za Zhi 2010 18 286 290 20416153

593. Yu AF Shen JZ Chen ZZ Fan LP Lin FA Demethylation and transcription of p16 gene in malignant lymphoma cell line CA46 induced by EGCG Zhongguo Shi Yan Xue Ye Xue Za Zhi 2008 16 1073 1078 18928598

594. Pang J Thymoquinone exerts potent growth-suppressive activity on leukemia through DNA hypermethylation reversal in leukemia cells Oncotarget 2017 8 34453 34467 10.18632/oncotarget.16431 28415607 PMC5470982

595. Al-Rawashde FA Thymoquinone inhibits growth of acute myeloid leukemia cells through reversal SHP-1 and SOCS-3 hypermethylation: in vitro and in silico evaluation Pharmaceuticals 2021 14 1287 10.3390/ph14121287 34959687 PMC8703481

596. Alvarez MC Maso V Torello CO Ferro KP Saad STO The polyphenol quercetin induces cell death in leukemia by targeting epigenetic regulators of pro-apoptotic genes Clin. Epigenet. 2018 10 139 10.1186/s13148-018-0563-3 PMC6225654 30409182

597. Oodi A Norouzi H Amirizadeh N Nikougoftar M Vafaie Z Harmine, a novel DNA methyltransferase 1 inhibitor in the leukemia cell line Indian J. Hematol. Blood Transfus. 2017 33 509 515 10.1007/s12288-016-0770-z 29075061 PMC5640528

598. Yu J Curcumin down-regulates DNA methyltransferase 1 and plays an anti-leukemic role in acute myeloid leukemia PLoS ONE 2013 8 e55934 10.1371/journal.pone.0055934 23457487 PMC3572185

599. Sun D Novel curcumin liposome modified with hyaluronan targeting CD44 plays an anti-leukemic role in acute myeloid leukemia in vitro and in vivo ACS Appl. Mater. Interfaces 2017 9 16857 16868 10.1021/acsami.7b02863 28489348

600. Kowolik CM Lin M Xie J Overman LE Horne DA NT1721, a novel epidithiodiketopiperazine, exhibits potent in vitro and in vivo efficacy against acute myeloid leukemia Oncotarget 2016 7 86186 86197 10.18632/oncotarget.13364 27863389 PMC5349906

601. Karam L Anticancer activities of parthenolide in primary effusion lymphoma preclinical models Mol. Carcinog. 2021 60 567 581 10.1002/mc.23324 34101920

602. Liao M Oridonin inhibits DNMT3A R882 mutation-driven clonal hematopoiesis and leukemia by inducing apoptosis and necroptosis Cell Death Disco. 2021 7 297 10.1038/s41420-021-00697-5 PMC8523644 34663800

603. Brueckner B Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases Cancer Res 2005 65 6305 6311 10.1158/0008-5472.CAN-04-2957 16024632

604. Lin Y Chen W Wang Z Cai P Emodin promotes the arrest of human lymphoma Raji cell proliferation through the UHRF1-DNMT3A-∆Np73 pathways Mol. Med. Rep. 2017 16 6544 6551 10.3892/mmr.2017.7423 28901428 PMC5865823

605. Qing Y Berberine induces apoptosis in human multiple myeloma cell line U266 through hypomethylation of p53 promoter Cell Biol. Int. 2014 38 563 570 10.1002/cbin.10206 24843889

606. Klisovic RB A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia Clin. Cancer Res. 2008 14 2444 2449 10.1158/1078-0432.CCR-07-1320 18413836

607. Abaza Y Zeidan AM Immune checkpoint inhibition in acute myeloid leukemia and myelodysplastic syndromes Cells 2022 11 2249 10.3390/cells11142249 35883692 PMC9318025

608. Majeti R CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells Cell 2009 138 286 299 10.1016/j.cell.2009.05.045 19632179 PMC2726837

609. Sallman DA The first-in-class anti-CD47 antibody magrolimab (5F9) in combination with azacitidine is effective in MDS and AML patients: ongoing phase 1b results Blood 2019 134 569 10.1182/blood-2019-126271

610. Zeidan AM A multi-center phase I trial of ipilimumab in patients with myelodysplastic syndromes following hypomethylating agent failure Clin. Cancer Res. 2018 24 3519 3527 10.1158/1078-0432.CCR-17-3763 29716921 PMC6680246

611. Daver N Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in relapsed/refractory acute myeloid leukemia: a non-randomized, prospective, phase 2 study Blood 2019 134 830 830 10.1182/blood-2019-131494

612. Chien KS Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome Br. J. Haematol. 2021 195 378 387 10.1111/bjh.17689 34340254

613. Nie J Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed/refractory classical Hodgkin lymphoma J. Clin. Oncol. 2019 37 1479 1489 10.1200/JCO.18.02151 31039052

614. Gourd E New treatment for relapsed or refractory Hodgkin’s lymphoma Lancet Oncol. 2019 20 e298 10.1016/S1470-2045(19)30289-X 31085049

615. DiNardo CD Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML N. Engl. J. Med. 2018 378 2386 2398 10.1056/NEJMoa1716984 29860938

616. Watts JM Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial Lancet Haematol. 2022 10 e46 e58 10.1016/S2352-3026(22)00292-7 36370742 PMC12250719

617. Stein EM Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia Blood 2017 130 722 731 10.1182/blood-2017-04-779405 28588020 PMC5572791

618. DiNardo CD Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia J. Clin. Oncol. 2021 39 57 65 10.1200/JCO.20.01632 33119479 PMC7771719

619. Montesinos P Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia N. Engl. J. Med. 2022 386 1519 1531 10.1056/NEJMoa2117344 35443108

620. Shanmugam G Rakshit S Sarkar K HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseases Transl. Oncol. 2022 16 101312 10.1016/j.tranon.2021.101312 34922087 PMC8688863

621. Guzman ML Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia Mol. Cancer Ther. 2014 13 1979 1990 10.1158/1535-7163.MCT-13-0963 24934933 PMC4383047

622. Canella A HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide Oncotarget 2015 6 31134 31150 10.18632/oncotarget.5290 26429859 PMC4741593

623. Zhang S The novel histone deacetylase inhibitor, AR-42, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells Int. J. Cancer 2011 129 204 213 10.1002/ijc.25660 20824695 PMC4201584

624. Liva SG Phase I study of AR-42 and decitabine in acute myeloid leukemia Leuk. Lymphoma 2020 61 1484 1492 10.1080/10428194.2020.1719095 32037935 PMC7375689

625. Sborov DW A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas Leuk. Lymphoma 2017 58 2310 2318 10.1080/10428194.2017.1298751 28270022 PMC5489371

626. Olsen EA Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma J. Clin. Oncol. 2007 25 3109 3115 10.1200/JCO.2006.10.2434 17577020

627. Duvic M Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) Blood 2007 109 31 39 10.1182/blood-2006-06-025999 16960145 PMC1785068

628. O'Connor OA Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study J. Clin. Oncol. 2015 33 2492 2499 10.1200/JCO.2014.59.2782 26101246 PMC5087312

629. San-Miguel JF Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial Lancet Haematol. 2016 3 e506 e515 10.1016/S2352-3026(16)30147-8 27751707

630. San-Miguel JF Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial Lancet Oncol. 2014 15 1195 1206 10.1016/S1470-2045(14)70440-1 25242045

631. Richardson PG PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma Blood 2013 122 2331 2337 10.1182/blood-2013-01-481325 23950178

632. Popat R Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial Lancet Haematol. 2016 3 e572 e580 10.1016/S2352-3026(16)30165-X 27843120

633. Amaru Calzada A Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2(V617F) myeloproliferative neoplasm patients Exp. Hematol. 2013 41 253 260.e252 10.1016/j.exphem.2012.10.013 23111067

634. Amaru Calzada A The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells Exp. Hematol. 2012 40 634 645.e610 10.1016/j.exphem.2012.04.007 22579713

635. Yao C Potent induction of apoptosis by givinostat in BCR-ABL1-positive and BCR-ABL1-negative precursor B-cell acute lymphoblastic leukemia cell lines Leuk. Res. 2017 60 129 134 10.1016/j.leukres.2017.08.003 28818808

636. Savino AM The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL Leukemia 2017 31 2365 2375 10.1038/leu.2017.93 28331226

637. Pinazza M An immediate transcriptional signature associated with response to the histone deacetylase inhibitor Givinostat in T acute lymphoblastic leukemia xenografts Cell Death Dis. 2016 6 e2047 10.1038/cddis.2015.394 26764573 PMC4816177

638. Rambaldi A Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program Blood Cancer J. 2021 11 53 10.1038/s41408-021-00445-z 33677466 PMC7936975

639. Rambaldi A Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study Leukemia 2020 34 2234 2237 10.1038/s41375-020-0735-y 32047238 PMC7387307

640. Finazzi G A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy Br. J. Haematol. 2013 161 688 694 10.1111/bjh.12332 23573950

641. Stühmer T Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585 Br. J. Haematol. 2010 149 529 536 10.1111/j.1365-2141.2010.08126.x 20331455

642. Deleu S The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models Leukemia 2009 23 1894 1903 10.1038/leu.2009.121 19494837

643. Deleu S Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma Cancer Res 2009 69 5307 5311 10.1158/0008-5472.CAN-08-4472 19531653

644. Moreau P Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma Leuk. Lymphoma 2016 57 1546 1559 10.3109/10428194.2015.1117611 26758913

645. Child F Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome Br. J. Dermatol 2016 175 80 88 10.1111/bjd.14427 26836950

646. Zabkiewicz J The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias Oncotarget 2016 7 16650 16662 10.18632/oncotarget.7692 26934551 PMC4941341

647. Ossenkoppele GJ A phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies Br. J. Haematol. 2013 162 191 201 10.1111/bjh.12359 23647373

648. Mandl-Weber S The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells Br. J. Haematol. 2010 149 518 528 10.1111/j.1365-2141.2010.08124.x 20201941

649. Karagianni F Combination of resminostat with ruxolitinib exerts antitumor effects in the chick embryo chorioallantoic membrane model for cutaneous T cell lymphoma Cancers 2022 14 1070 10.3390/cancers14041070 35205818 PMC8870185

650. Walewski J Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study Leuk. Lymphoma 2019 60 675 684 10.1080/10428194.2018.1492122 30160566

651. Markozashvili D Histone deacetylase inhibitor abexinostat affects chromatin organization and gene transcription in normal B cells and in mantle cell lymphoma Gene 2016 580 134 143 10.1016/j.gene.2016.01.017 26774800

652. Bhalla S PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells Clin. Cancer Res. 2009 15 3354 3365 10.1158/1078-0432.CCR-08-2365 19417023 PMC2704489

653. Evens AM A phase I/II multicenter, open-label study of the oral histone deacetylase inhibitor abexinostat in relapsed/refractory lymphoma Clin. Cancer Res. 2016 22 1059 1066 10.1158/1078-0432.CCR-15-0624 26482040

654. Kim SJ Kim S Choi YJ Kim UJ Kang KW CKD-581 downregulates Wnt/β-catenin pathway by DACT3 induction in hematologic malignancy Biomol. Ther. 2022 30 435 446 10.4062/biomolther.2022.022 PMC9424334 35794797

655. Kim SJ Kim UJ Yoo HY Choi YJ Kang KW Anti-cancer effects of CKD-581, a potent histone deacetylase inhibitor against diffuse large B-Cell lymphoma Int. J. Mol. Sci. 2020 21 4377 10.3390/ijms21124377 32575557 PMC7352247

656. Cho H Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy Invest. N. Drugs 2018 36 877 885 10.1007/s10637-018-0582-0 29520651

657. North BJ Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor PLoS ONE 2017 12 e0173507 10.1371/journal.pone.0173507 28264055 PMC5338861

658. Kilgour JM Phase II open-label, single-arm trial to investigate the efficacy and safety of topical remetinostat gel in patients with basal cell carcinoma Clin. Cancer Res. 2021 27 4717 4725 10.1158/1078-0432.CCR-21-0560 34362809 PMC8416931

659. Rauzan M Chuah CT Ko TK Ong ST The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia PLoS ONE 2017 12 e0174107 10.1371/journal.pone.0174107 28301600 PMC5354438

660. Novotny-Diermayr V The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML Blood Cancer J. 2012 2 e69 10.1038/bcj.2012.14 22829971 PMC3366067

661. Yalniz FF A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy Br. J. Haematol. 2020 188 404 412 10.1111/bjh.16173 31468521

662. Bose P A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis Leuk. Lymphoma 2019 60 1767 1774 10.1080/10428194.2018.1543876 30632841 PMC6594864

663. Garcia-Manero G Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes Cancer 2017 123 994 1002 10.1002/cncr.30533 28094841 PMC5432122

664. Quintás-Cardama A Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis Leuk. Res. 2012 36 1124 1127 10.1016/j.leukres.2012.03.003 22475363 PMC4152772

665. Santo L Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma Blood 2012 119 2579 2589 10.1182/blood-2011-10-387365 22262760 PMC3337713

666. García-Guerrero E Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab Leukemia 2021 35 201 214 10.1038/s41375-020-0840-y 32350373 PMC8318885

667. Amengual JE Dual targeting of protein degradation pathways with the selective HDAC6 inhibitor ACY-1215 and bortezomib is synergistic in lymphoma Clin. Cancer Res. 2015 21 4663 4675 10.1158/1078-0432.CCR-14-3068 26116270 PMC4609274

668. Vekaria PH Functional cooperativity of p97 and histone deacetylase 6 in mediating DNA repair in mantle cell lymphoma cells Leukemia 2019 33 1675 1686 10.1038/s41375-018-0355-y 30664664 PMC6730676

669. Lee DH Kim GW Kwon SH The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma Mol. Carcinog. 2019 58 944 956 10.1002/mc.22983 30693983

670. Vogl DT Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma Clin. Cancer Res. 2017 23 3307 3315 10.1158/1078-0432.CCR-16-2526 28053023 PMC5496796

671. Yee AJ Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial Lancet Oncol. 2016 17 1569 1578 10.1016/S1470-2045(16)30375-8 27646843

672. Zhu Z Therapeutic efficacy of an injectable formulation of purinostat mesylate in SU-DHL-6 tumour model Ann. Med. 2022 54 743 753 10.1080/07853890.2022.2045347 35243950 PMC8903780

673. Yang L Purinostat Mesylate is a uniquely potent and selective inhibitor of HDACs for the treatment of BCR-ABL-induced B-cell acute lymphoblastic leukemia Clin. Cancer Res. 2019 25 7527 7539 10.1158/1078-0432.CCR-19-0516 31439580

674. Lu X Ning Z Li Z Cao H Wang X Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China Intractable Rare Dis. Res 2016 5 185 191 10.5582/irdr.2016.01024 27672541 PMC4995415

675. Ning ZQ Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity Cancer Chemother. Pharm. 2012 69 901 909 10.1007/s00280-011-1766-x 22080169

676. Shi Y Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma Ann. Oncol. 2015 26 1766 1771 10.1093/annonc/mdv237 26105599

677. Shi Y Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China J. Hematol. Oncol. 2017 10 69 10.1186/s13045-017-0439-6 28298231 PMC5351273

678. Zhang MC Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma Clin. Epigenet. 2020 12 160 10.1186/s13148-020-00948-9 PMC7585299 33097085

679. Zhou L HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML Leukemia 2013 27 1358 1368 10.1038/leu.2012.366 23247046 PMC3892989

680. Ramsey JM Entinostat prevents leukemia maintenance in a collaborating oncogene-dependent model of cytogenetically normal acute myeloid leukemia Stem Cells 2013 31 1434 1445 10.1002/stem.1398 23592435

681. Duque-Afonso J The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO Oncogene 2011 30 3062 3072 10.1038/onc.2011.32 21577204

682. Frys S Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents Br. J. Haematol. 2015 169 506 519 10.1111/bjh.13318 25712263 PMC5802357

683. Cai B Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response Cancer Lett. 2013 335 343 350 10.1016/j.canlet.2013.02.046 23459296 PMC4174452

684. Jóna A The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors Exp. Hematol. 2011 39 1007 1017.e1001 10.1016/j.exphem.2011.07.002 21767511 PMC3177003

685. Prebet T Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study Br. J. Haematol. 2016 172 384 391 10.1111/bjh.13832 26577691 PMC4794257

686. Prebet T Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905 J. Clin. Oncol. 2014 32 1242 1248 10.1200/JCO.2013.50.3102 24663049 PMC3986386

687. von Tresckow B Phase I study of domatinostat (4SC-202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies Eur. J. Haematol. 2019 102 163 173 10.1111/ejh.13188 30347469

688. Smolewski P Robak T The discovery and development of romidepsin for the treatment of T-cell lymphoma Expert Opin. Drug Discov. 2017 12 859 873 28641053 10.1080/17460441.2017.1341487

689. Whittaker SJ Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma J. Clin. Oncol. 2010 28 4485 4491 10.1200/JCO.2010.28.9066 20697094

690. Piekarz RL Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma J. Clin. Oncol. 2009 27 5410 5417 10.1200/JCO.2008.21.6150 19826128 PMC2773225

691. Piekarz RL Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma Blood 2011 117 5827 5834 10.1182/blood-2010-10-312603 21355097 PMC3112033

692. Li H Cui R Ji M Jin SY CUDC-101 enhances the chemosensitivity of gemcitabine-treated lymphoma cells Leuk. Res. 2021 106 106575 10.1016/j.leukres.2021.106575 33878513

693. Zhang T CUDC-101 overcomes arsenic trioxide resistance via caspase-dependent promyelocytic leukemia-retinoic acid receptor alpha degradation in acute promyelocytic leukemia Anticancer Drugs 2020 31 158 168 10.1097/CAD.0000000000000847 31584454

694. Yang EG Design and synthesis of Janus kinase 2 (JAK2) and histone deacetlyase (HDAC) bispecific inhibitors based on pacritinib and evidence of dual pathway inhibition in hematological cell Lines J. Med Chem. 2016 59 8233 8262 10.1021/acs.jmedchem.6b00157 27541357

695. Oki Y CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial Haematologica 2017 102 1923 1930 10.3324/haematol.2017.172882 28860342 PMC5664396

696. Duan YC Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment Eur. J. Med. Chem. 2017 140 392 402 10.1016/j.ejmech.2017.09.038 28987602

697. Zhang X Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors Eur. J. Med. Chem. 2015 95 127 135 10.1016/j.ejmech.2015.03.035 25805446

698. Yang K Development of the first small molecule histone deacetylase 6 (HDAC6) degraders Bioorg. Med. Chem. Lett. 2018 28 2493 2497 10.1016/j.bmcl.2018.05.057 29871848

699. An Z Lv W Su S Wu W Rao Y Developing potent PROTACs tools for selective degradation of HDAC6 protein Protein Cell 2019 10 606 609 10.1007/s13238-018-0602-z 30603959 PMC6626596

700. Yang H Plasticity in designing PROTACs for selective and potent degradation of HDAC6 Chem. Commun. 2019 55 14848 14851 10.1039/C9CC08509B 31769449

701. Yang K Development of selective histone deacetylase 6 (HDAC6) degraders recruiting Von Hippel-Lindau (VHL) E3 ubiquitin ligase ACS Med Chem. Lett. 2020 11 575 581 10.1021/acsmedchemlett.0c00046 32292566 PMC7153272

702. Xiao Y Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs Chem. Commun. 2020 56 9866 9869 10.1039/D0CC03243C PMC7654701 32840532

703. Blum W Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia J. Clin. Oncol. 2007 25 3884 3891 10.1200/JCO.2006.09.4169 17679729

704. Lübbert M Valproate and retinoic acid in combination with decitabine in elderly nonfit patients with acute myeloid leukemia: results of a multicenter, randomized, 2 × 2, phase II trial J. Clin. Oncol. 2020 38 257 270 10.1200/JCO.19.01053 31794324

705. How J A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia Leuk. Lymphoma 2015 56 2793 2802 10.3109/10428194.2015.1018248 25682963 PMC4688006

706. Burke MJ Decitabine and vorinostat with chemotherapy in relapsed pediatric acute lymphoblastic leukemia: a TACL pilot study Clin. Cancer Res. 2020 26 2297 2307 10.1158/1078-0432.CCR-19-1251 31969338 PMC7477726

707. Burke MJ A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia Am. J. Hematol. 2014 89 889 895 10.1002/ajh.23778 24891274 PMC4134715

708. Borcoman E HDAC inhibition to prime immune checkpoint inhibitors Cancers 2021 14 66 10.3390/cancers14010066 35008230 PMC8750966

709. He Y HDAC inhibitor LBH589 suppresses the proliferation but enhances the antileukemic effect of human γδT cells Mol. Ther. Oncolytics 2020 18 623 630 10.1016/j.omto.2020.08.003 33005729 PMC7515977

710. Salmon JM Epigenetic activation of plasmacytoid DCs drives IFNAR-dependent therapeutic differentiation of AML Cancer Discov. 2022 12 1560 1579 10.1158/2159-8290.CD-20-1145 35311997 PMC9355625

711. Moldenhauer A Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins J. Leukoc. Biol. 2004 76 623 633 10.1189/jlb.1103581 15197237

712. He ZX Current development of CBP/p300 inhibitors in the last decade Eur. J. Med. Chem. 2021 209 112861 10.1016/j.ejmech.2020.112861 33045661

713. Coudé MM BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells Oncotarget 2015 6 17698 17712 10.18632/oncotarget.4131 25989842 PMC4627339

714. Boi M The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs Clin. Cancer Res. 2015 21 1628 1638 10.1158/1078-0432.CCR-14-1561 25623213

715. Amorim S Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study Lancet Haematol. 2016 3 e196 e204 10.1016/S2352-3026(16)00021-1 27063978

716. Stathis A Bertoni F BET proteins as targets for anticancer treatment Cancer Disco. 2018 8 24 36 10.1158/2159-8290.CD-17-0605 29263030

717. Wu S BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes Cancer Cell Int 2021 21 230 10.1186/s12935-021-01908-w 33888130 PMC8061034

718. Saenz DT Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML Leukemia 2019 33 1373 1386 10.1038/s41375-018-0334-3 30575820

719. Sun B BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells Leukemia 2018 32 343 352 10.1038/leu.2017.207 28663582 PMC12856936

720. Saenz DT Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells Leukemia 2017 31 1951 1961 10.1038/leu.2016.393 28042144 PMC5537055

721. Lu J Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chemistry Biol 2015 22 755 763 10.1016/j.chembiol.2015.05.009 PMC4475452 26051217

722. Winter GE DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation Science 2015 348 1376 1381 10.1126/science.aab1433 25999370 PMC4937790

723. Duan R Du W Guo W EZH2: a novel target for cancer treatment J. Hematol. Oncol. 2020 13 104 10.1186/s13045-020-00937-8 32723346 PMC7385862

724. Stein EM The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia Blood 2018 131 2661 2669 10.1182/blood-2017-12-818948 29724899 PMC6265654

725. Fang Y Liao G Yu B LSD1/KDM1A inhibitors in clinical trials: advances and prospects J. Hematol. Oncol. 2019 12 129 10.1186/s13045-019-0811-9 31801559 PMC6894138

726. Pandey G Kuykendall AT Reuther GW JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation. Blood Cancer J. 2022 12 13 10.1038/s41408-022-00609-5 PMC8792018 35082276

727. Dao KT Efficacy of ruxolitinib in patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia J. Clin. Oncol. 2020 38 1006 1018 10.1200/JCO.19.00895 31880950 PMC7106977

728. Bose P A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia Leukemia 2020 34 2489 2492 10.1038/s41375-020-0778-0 32099037 PMC12136008

729. Qi W AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas Int. J. Cancer 2012 130 2997 3005 10.1002/ijc.26324 21796626

730. Qi W Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma Biochem. Pharm. 2011 81 881 890 10.1016/j.bcp.2011.01.017 21291867 PMC3792566

731. Metzler M Wilda M Busch K Viehmann S Borkhardt A High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma Genes Chromosomes Cancer 2004 39 167 169 10.1002/gcc.10316 14695998

732. Kluiver J BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas J. Pathol. 2005 207 243 249 10.1002/path.1825 16041695

733. Calin GA MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias Proc. Natl Acad. Sci. USA 2004 101 11755 11760 10.1073/pnas.0404432101 15284443 PMC511048

734. Kluiver J Lack of BIC and microRNA miR-155 expression in primary cases of Burkitt lymphoma Genes Chromosomes Cancer 2006 45 147 153 10.1002/gcc.20273 16235244

735. Gerloff D NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia Leukemia 2015 29 535 547 10.1038/leu.2014.231 25092144 PMC4490787

736. Wallace JA miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response Blood 2017 129 3074 3086 10.1182/blood-2016-09-740209 28432220 PMC5465836

737. Wang M miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression J. Pathol. 2008 215 13 20 10.1002/path.2333 18348159

738. Hussein K Significant inverse correlation of microRNA-150/MYB and microRNA-222/p27 in myelodysplastic syndrome Leuk. Res. 2010 34 328 334 10.1016/j.leukres.2009.06.014 19615744

739. Jiang X Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia Cancer Cell 2012 22 524 535 10.1016/j.ccr.2012.08.028 23079661 PMC3480215

740. Felli N MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation Proc. Natl Acad. Sci. USA 2005 102 18081 18086 10.1073/pnas.0506216102 16330772 PMC1312381

741. Herling M TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state Leukemia 2006 20 280 285 10.1038/sj.leu.2404017 16341048

742. Calin GA A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia N. Engl. J. Med. 2005 353 1793 1801 10.1056/NEJMoa050995 16251535

743. Debernardi S MicroRNA miR-181a correlates with morphological sub-class of acute myeloid leukaemia and the expression of its target genes in global genome-wide analysis Leukemia 2007 21 912 916 10.1038/sj.leu.2404605 17330104

744. Kitada S Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses Blood 1998 91 3379 3389 10.1182/blood.V91.9.3379 9558396

745. Naguibneva I The microRNA miR-181 targets the homeobox protein Hox-A11 during mammalian myoblast differentiation Nat. Cell Biol. 2006 8 278 284 10.1038/ncb1373 16489342

746. Roccaro AM MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma Blood 2009 113 6669 6680 10.1182/blood-2009-01-198408 19401561 PMC2710922

747. Akao Y Nakagawa Y Kitade Y Kinoshita T Naoe T Downregulation of microRNAs-143 and -145 in B-cell malignancies Cancer Sci. 2007 98 1914 1920 10.1111/j.1349-7006.2007.00618.x 17892514 PMC11158757

748. Mets E MicroRNA-193b-3p acts as a tumor suppressor by targeting the MYB oncogene in T-cell acute lymphoblastic leukemia Leukemia 2015 29 798 806 10.1038/leu.2014.276 25231743 PMC4890642

749. Boldrin E MicroRNA-497/195 is tumor suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia Blood 2021 138 1953 1965 10.1182/blood.2020007591 34098582

750. Jiang X miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia Nat. Commun. 2016 7 11452 10.1038/ncomms11452 27116251 PMC5477496

751. Shen C The PU.1-modulated microRNA-22 Is a regulator of monocyte/macrophage differentiation and acute myeloid leukemia PLoS Genet 2016 12 e1006259 10.1371/journal.pgen.1006259 27617961 PMC5019412

752. Chen P miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia Proc. Natl Acad. Sci. USA 2013 110 11511 11516 10.1073/pnas.1310144110 23798388 PMC3710804

753. Senyuk V Critical role of miR-9 in myelopoiesis and EVI1-induced leukemogenesis Proc. Natl Acad. Sci. USA 2013 110 5594 5599 10.1073/pnas.1302645110 23509296 PMC3619279

754. Emmrich S miR-9 is a tumor suppressor in pediatric AML with t(8;21) Leukemia 2014 28 1022 1032 10.1038/leu.2013.357 24270738

755. Mi S Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia Proc. Natl Acad. Sci. USA 2010 107 3710 3715 10.1073/pnas.0914900107 20133587 PMC2840429

756. Wong P The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression Cancer Res. 2010 70 3833 3842 10.1158/0008-5472.CAN-09-3268 20406979 PMC2862107

757. Starczynowski DT Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype Nat. Med. 2010 16 49 58 10.1038/nm.2054 19898489

758. Zhao JL NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies Proc. Natl Acad. Sci. USA 2011 108 9184 9189 10.1073/pnas.1105398108 21576471 PMC3107319

759. Boldin MP miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice J. Exp. Med. 2011 208 1189 1201 10.1084/jem.20101823 21555486 PMC3173243

760. Su YL Myeloid cell-targeted miR-146a mimic inhibits NF-κB-driven inflammation and leukemia progression in vivo Blood 2020 135 167 180 10.1182/blood.2019002045 31805184 PMC6966933

761. Bousquet M Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation J. Exp. Med 2008 205 2499 2506 10.1084/jem.20080285 18936236 PMC2571925

762. So AY Dual mechanisms by which miR-125b represses IRF4 to induce myeloid and B-cell leukemias Blood 2014 124 1502 1512 10.1182/blood-2014-02-553842 25006123 PMC4148772

763. Li Z Overexpression and knockout of miR-126 both promote leukemogenesis Blood 2015 126 2005 2015 10.1182/blood-2015-04-639062 26361793 PMC4616234

764. de Leeuw DC Attenuation of microRNA-126 expression that drives CD34+38- stem/progenitor cells in acute myeloid leukemia leads to tumor eradication Cancer Res. 2014 74 2094 2105 10.1158/0008-5472.CAN-13-1733 24477595

765. Lechman ER miR-126 regulates distinct self-renewal outcomes in normal and malignant hematopoietic stem cells Cancer Cell. 2016 29 214 228 10.1016/j.ccell.2015.12.011 26832662 PMC4749543

766. Gao XN MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia Oncogene 2011 30 3416 3428 10.1038/onc.2011.62 21399664

767. Li Y Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway Blood 2013 121 499 509 10.1182/blood-2012-07-444729 23223432

768. Popovic R Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization Blood 2009 113 3314 3322 10.1182/blood-2008-04-154310 19188669 PMC2665896

769. Li Z miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia Nat. Commun. 2012 3 688 10.1038/ncomms1681 22353710 PMC3514459

770. Bhayadia R Endogenous tumor suppressor microRNA-193b: therapeutic and prognostic value in acute myeloid leukemia J. Clin. Oncol. 2018 36 1007 1016 10.1200/JCO.2017.75.2204 29432078

771. Fazi F Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein Cancer Cell 2007 12 457 466 10.1016/j.ccr.2007.09.020 17996649

772. Pulikkan JA Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia Blood 2010 115 1768 1778 10.1182/blood-2009-08-240101 20029046 PMC2832809

773. Jiang X MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia Proc. Natl Acad. Sci. USA 2012 109 19397 19402 10.1073/pnas.1217519109 23132946 PMC3511140

774. Zhao JJ miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway Cancer Res. 2014 74 1801 1813 10.1158/0008-5472.CAN-13-3311-T 24599134 PMC3959627

775. Yang Y miR-137 and miR-197 induce apoptosis and suppress tumorigenicity by targeting MCL-1 in multiple myeloma Clin. Cancer Res. 2015 21 2399 2411 10.1158/1078-0432.CCR-14-1437 25724519

776. Misiewicz-Krzeminska I Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication Haematologica 2013 98 640 648 10.3324/haematol.2012.070011 23100276 PMC3659997

777. Hu Y Targeting of CD38 by the tumor suppressor miR-26a serves as a novel potential therapeutic agent in multiple myeloma Cancer Res. 2020 80 2031 2044 10.1158/0008-5472.CAN-19-1077 32193289 PMC7231653

778. Zhu G HOXBLINC long non-coding RNA activation promotes leukemogenesis in NPM1-mutant acute myeloid leukemia Nat. Commun. 2021 12 1956 10.1038/s41467-021-22095-2 33782403 PMC8007823

779. Papaioannou D The long non-coding RNA HOXB-AS3 regulates ribosomal RNA transcription in NPM1-mutated acute myeloid leukemia Nat. Commun. 2019 10 5351 10.1038/s41467-019-13259-2 31767858 PMC6877618

780. Fragliasso V The novel lncRNA BlackMamba controls the neoplastic phenotype of ALK(-) anaplastic large cell lymphoma by regulating the DNA helicase HELLS Leukemia 2020 34 2964 2980 10.1038/s41375-020-0754-8 32123306

781. Yang J The identification of long non-coding RNA H19 target and its function in chronic myeloid leukemia Mol. Ther. Nucleic Acids 2020 19 1368 1378 10.1016/j.omtn.2020.01.021 32160707 PMC7044501

782. Taiana E Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma Leukemia 2020 34 234 244 10.1038/s41375-019-0542-5 31427718

783. David A The long non-coding RNA CRNDE regulates growth of multiple myeloma cells via an effect on IL6 signalling Leukemia 2021 35 1710 1721 10.1038/s41375-020-01034-y 32879426 PMC8179846

784. Hu Y Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma Leukemia 2018 32 2250 2262 10.1038/s41375-018-0104-2 29632340 PMC6151178